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ABSTRACT
THE ROLE OF OBESITY IN MACROPHAGE-MEDIATED MECHANISMS
PROMOTING EARLY-ONSET COLON CANCER

Katharina Marietta Scheurlen
March 31st, 2022

Early-onset colon cancer (EOCC) is a leading cause of cancer death among
people younger than 50 years of age in the United States and is associated with
metabolic dysfunction and obesity. Anti-inflammatory tumor-associated
macrophages (TAM) and low Peroxisome Proliferator Activated Receptor
Gamma (PPARγ) gene expression in colon cancer (CC) tissue promote tumor
progression and decreased patient survival. Obesity-related hormones, such as
leptin and adiponectin, have the potential to affect gene expression in TAM to
promote CC progression and thereby link obesity and EOCC. The aim of this
project was to identify target genes in human CC and to investigate the effects of
leptin, adiponectin and the inflammatory macrophage metabolite itaconate on
age- and obesity-related gene expression.

v

These studies have provided the following results:

1. M2-like macrophages created using our 14-day cell line model represent a
distinct anti-inflammatory macrophage phenotype. Marker gene
expression, protein expression and cell surface marker analyses revealed
an M2-like expression profile similar to gene expression patterns
described in human primary monocyte-derived macrophages with tumorassociated marker expression. This model provides a basis for in vitro
investigation of anti-inflammatory mechanisms in cancer development.
2. The macrophage-specific enzyme is responsible for production of
carcinogenic itaconate is encoded by Immune-Responsive Gene 1 (IRG1),
which expressed in CC and is associated with decreased patient survival.
As a macrophage metabolite affecting inflammation, itaconate may have a
particular immunotherapeutic role in patients with CC and obesity,
specifically with EOCC.
3. In M2-like anti-inflammatory macrophages, Itaconate downregulates
PPARγ as a tumor suppressing factor and upregulates anti-inflammatory
cytokines. Itaconate provides a link between obesity and CC and may
thereby be a key regulator in EOCC.
4. M0 macrophages show limited responses to leptin and itaconate
compared to M2-like cells, suggesting that the investigated mechanisms
play a role in tumor progression rather than cancer onset.

vi

5. Leptin and adiponectin mediate tumor-promoting mechanisms through
macrophages, altering gene expression of the NOTCH4-GATA4-IRG1
axis. Upregulation of the genes GATA-binding factor 4 (GATA4), Delta
Like Canonical Notch Ligand 4 (DLL4), Hes Related Family BHLH
Transcription Factor With YRPW (HEY1), Notch Receptor 4 (NOTCH4),
Serpin Family E Member 1 (SERPINE1) and Vascular Endothelial Growth
Factor A (VEGFA) in CC is age-dependent, increased in the young and
associated with decreased patient survival.
6. Upregulation of ATP Binding Cassette Subfamily G Member 5 (ABCG5)
and GATA5 was obesity-dependent in CC, increased in the obese and
associated with decreased patient survival.

Our data provide evidence that the obesity-related hormones leptin and
adiponectin as well as the macrophage-specific metabolite itaconate can exert
tumor promoting effects through metabolic reprogramming of macrophages by
altering gene expression of the NOTCH4-GATA4-IRG1 axis.
Future studies investigating the function of this axis in macrophages and CC cells
in the surgical patient are required. The NOTCH4-GATA4-IRG1 axis may provide
a specific treatment target for young patients with EOCC.
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CHAPTER I

INTRODUCTION

Colorectal cancer (CRC) is one of the most common causes of cancer-related
death in the USA (1). The rising incidence of obesity and metabolic dysfunction is
accompanied by an increasing number of patients that are diagnosed with earlyonset CRC (EOCRC) (2-5). EOCRC is generally defined as CRC occurring in
individuals <50 years of age. Incidence rates in the United States increased by
22% from 2000 to 2013 and mortality increased by 13% (6). Regular screening
for CRC has been recommended by the U.S. Preventive Services Task Force
(USPSTF) beginning at age 50, which changed in the year 2021 (7). Due to the
large-scale screening programs in these patients >50 years of age with removal
of precancerous polyps during colonoscopy and earlier detection of CRC, the
incidence and mortality of CRC has declined (8, 9). The increasing number of
colon cancer (CC) cases among younger adults has, however, led to the
recommendation of an earlier start of regular screening by the American Cancer
Society (ACS) in 2018 and the USPSTF in 2021, beginning at age 45 (10, 11).
The parallel increase in the incidence of obesity in the young and EOCRC
suggests that obesity-related inflammatory mechanisms may play a greater role
in the development of CRC than assumed.
1

Most cases of CRC are either sporadic in etiology, based on a somatic mutation
involving adenomatous polyposis coli gene (APC) function, or less often
hereditary, as in hereditary nonpolyposis CRC (HNPCC) or familial adenomatous
polyposis (FAP) (12, 13). HNPCC is the most common cause of hereditary CRC
(14). While the proportion of other hereditary cancer syndromes in patients with
EOCRC is widely unknown, HNPCC represents 4%-13.5% of cancers in patients
with EOCRC (14). More than 80% of patients with EOCRC, however, are
diagnosed with sporadic cancers (14).
Only a small percentage of CRC is actually associated with inflammatory bowel
disease such as ulcerative colitis or Crohn's disease (15, 16). Compared to 0.4%
of patients with a late onset of CRC, young patients with CRC showed an
increased prevalence of inflammatory bowel disease in 3% of cases (17). This
suggests that inflammatory processes may have a greater role in the onset and
development of CRC than previously assumed. A systemic proinflammatory state
and local immune mechanisms on a tissue level may link obesity to early cancer
onset and tumor progression in EOCRC (18).
As essential components of the immune inflammatory response, macrophages
are able to orchestrate inflammatory mechanisms and therefore tumorigenesis.
The tumor microenvironment (TME) is a dynamic environment surrounding the
tumor and a critical part of these regulatory processes. Tumor cells, immune cells
and the blood and lymphatic vascular networks interact with stromal cells and
their extracellular matrix, coordinating cancer establishment, tumor growth and
metastasis (19). Current evidence shows that tumor-associated macrophages
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(TAMs) play a central role in the dynamic processes within the TME, contributing
to tumor promoting effects as well as contributing to tumor suppressing
mechanisms in CRC (19). Various functions require dynamic switching between
different TAM phenotypes. These phenotypes depend upon specific metabolic
pathways within TAMs, which provide a source for functional metabolites and
phenotype-specific cytokine expression, mediating inflammatory activities during
cancer development (20, 21). The impact of TAM-mediated effects within the
TME on cancer progression and a patient's outcome is poorly understood.
The purpose of this work is to develop a coculture model of TAM and CC cells
and to investigate the effects of obesity-related inflammatory signaling pathways.
A specific focus is the anti-inflammatory mediator itaconate, a macrophagespecific metabolite involved in cancer progression.
To give an overview of the various genes and macrophage markers discussed in
this work, Table 1 provides a list of abbreviations.
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Table 1
List of abbreviations
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ABCG

ATP Binding Cassette Subfamily G Member

LPS

Lipopolysaccharide

ACOD1

Cis-Aconitate Decarboxylase

Ly6C

Lymphocyte antigen 6 Complex

ACS

American Cancer Society

MAPK

Mitogen-Activated Protein Kinase

ADAMTS1

ADAM Metallopeptidase With Thrombospondin Type 1
Motif 1

MGLL

Monoacylglycerol Lipase

ADIPOR

Adiponectin Receptor

MHC

Major Histocompatibility Complex

AKT

AKT Serine/Threonine Kinase

MMP

Matrix Metalloproteinase

AMPK

AMP-activated Protein Kinase

MMR

DNA Mismatch Repair

AP-1

Activating Protein-1

mTOR

Mechanistic Target Of Rapamycin kinase

APC

Adenomatous Polyposis Coli

NASH

Non-alcoholic Steatohepatitis

ARG1

Arginase 1

NFLD

Non-alcoholic Fatty Liver Disease

ATP

Adenosine Thiotriphosphate

NFκB

Nuclear Factor Kappa B

BMI

Body Mass Index

NICD

Notch Intracellular Domain

B-Raf

B-Raf Proto-Oncogene

NOTCH

Notch receptor

CC

Colon Cancer

NRF

Nuclear factor erythroid 2-related Factor 2

CCL

CC chemokine Ligand

NSAID

Nonsteroidal Anti-inflammatory Drugs

CCR

CC chemokine Receptor

OXPHOS

Oxidative Phosphorylation

CD

Cluster of Differentiation

P53

Tumor protein p53

CMS

Consensus Molecular Subtype

PBP

(PPAR)-binding protein

COX

Cyclooxygenase

PDGF

Platelet-derived Growth Factor

CRC

Colorectal Cancer

PFKFB3

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3

CSF

Colony Stimulating Factor

PI3K

Phosphoinositide Kinase-3

CSL

CBF1, Suppressor of Hairless, Lag-1

PMA

Phorbol 12-Myristate-13-Acetate

CXCL

C-X-C motif Chemokine Ligand

PPARγ

Peroxisome Proliferator Activated Receptor Gamma
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CXCR

C-X-C motif Chemokine Receptors

RNA-seq

RNA sequencing

DLL4

Delta Like Canonical Notch Ligand 4

RNI

reactive nitrogen intermediates

EMT

Epithelial-Mesenchymal Transition

ROI

Reactive Oxygen Intermediates

EOCC

Early-Onset Colon Cancer

ROS

Reactive Oxygen Species

EOCRC

Early-Onset Colorectal Cancer

SERPINE1

FAP

Familial Adenomatous Polyposis

SIGN

GATA

GATA-binding protein

STAT3

Serpin Family E Member 1
Specific Intercellular adhesion molecule-grabbing
Nonintegrin
Signal Transducer and Activator of Transcription 3

GLP

Glucagon-Like Peptide

TAM

Tumor-associated macrophage

HES

Hairy and Enhancer of split

TCA cycle

Tricarboxylic Acid cycle

HEY

Hes Related Family BHLH Transcription Factor With
YRPW

TGF

Transforming Growth Factor

HIF1α

Hypoxia Inducible Factor 1 Subunit Alpha

TIMP

Tissue Inhibitor of Metalloproteinase

HNPCC

Hereditary Non-polyposis Colorectal Cancer

TLR

Toll Like Receptor

IFN

Interferon

TME

Tumor Microenvironment

IL

Interleukin

TNF

Tumor-Necrosis Factor

IL-1Ra

Interleukin-1 Receptor Antagonist

USPSTF

U.S. Preventive Services Task Force

IRF

Interferon-Regulatory Factor

VEGF

vascular endothelial growth factor

IRG1

Immune-Responsive Gene 1

WHO

World Health Organization

JAK

Janus kinase

WNT

WNT family member

K-Ras

KRAS Proto-Oncogene

CHAPTER II

SIGNIFICANCE OF OBESITY-RELATED INFLAMMATION IN
EARLY-ONSET COLON CANCER

a.

Background

Overweight and obesity are defined as an abnormal fat accumulation with a
respective Body Mass Index (BMI) of ≥25 kg/m² and ≥30 kg/m² by the World
Health Organization (WHO) (22). Obesity is an established risk factor for type 2
diabetes mellitus and its associated complications (23). The underlying metabolic
dysfunction is due to chronic systemic inflammation that can lead to insulinresistance (24). During the last three decades, epidemiological data and several
cohort and case-control studies have shown an association between obesity and
CRC (25-27). The simultaneously rising incidence of obesity and CRC in patients
younger than 50 years of age indicates a particular contributing role of metabolic
dysfunction in the development EOCRC (4). Liu et al. prospectively analyzed a
patient cohort of more than 85,000 women aged 25 to 42 years, that were part of
the The Nurses’ Health Study II (4). An association between obesity and EOCRC
was found among this patient collective. The recent analysis of Hussan et al.
showed an increasing trend in CRC among young patients with obesity, that
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could not be demonstrated in other types of gastrointestinal cancer (28).
Focusing on the age of diagnosis in patients with CRC, an increased cancer
riskwas shown after a diagnosis of type 2 diabetes, especially in men younger
than 55 years (29).
A recent study on the molecular characteristics of EOCRC showed that
inflammatory mechanisms, such as deregulated redox homeostasis as one of the
hallmarks of CRC in young patients, play a distinct role (30). The major pathways
that are involved in these mechanisms are altered nuclear factor erythroid 2related factor 2 (NRF)-mediated oxidative stress response, glutathione
metabolism, and the chemokine (C-X-C motif) ligand 12 - C-X-C motif chemokine
receptor 4 (CXCL12-CXCR4) signaling axis (30). These findings suggest that
metabolic dysfunction and obesity represent an important contributing factor in
CRC development in young patients.
A chronic inflammatory environment is caused by the proinflammatory
endocrine activity of adipose tissue, affecting energy homeostasis and glucose
metabolism (31). Inflammatory macrophages can accumulate within adipose
tissue in obese patients and trigger inflammation, which leads to systemic
metabolic dysfunction, including insulin resistance (32). The presence of
macrophages is a hallmark of proinflammatory adipose tissue. They form crownlike structures in subcutaneous and visceral fat deposits (32). Furthermore,
adipose tissue-derived inflammatory mediators have been shown to induce
macrophage polarization towards a proinflammatory phenotype in an in vitro
model (33). In other obesity-related comorbidities, such as non-alcoholic fatty
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liver disease (NFLD) or steatohepatitis (NASH), inflamed adipose tissue has
been associated with activation of liver macrophages as a determinant for liver
fibrosis (34). Proinflammatory macrophage polarization in tissue macrophages
can provide a link between the proinflammatory systemic state in obesity and a
chronic inflammatory environment in colon tissue, which in turn can trigger
carcinogenic mechanisms in colon epithelium through inflammatory stress.
Itaconate is a macrophage-specific metabolite, which is produced in
proinflammatory macrophages, and which is known to have tumor promoting
effects (35). TAMs in tumor-bearing mice as well as monocytes isolated form
patients with ovarian cancer showed increased itaconate production (35).
Identifying the role of macrophage metabolism and itaconate in a chronic
inflammatory state due to metabolic dysfunction and obesity could lead to
innovative approaches to screening diagnosis and treatment of CRC.

b.

Role of chronic inflammation in colorectal cancer

Chronic inflammation is closely linked to two systems of the human body that
have major roles for survival: the immune system with the ability to fight infection
and the metabolic system that can provide stored energy during a period of low
nutrition (24). Immunity and metabolism are therefore in a continuous state of
interplay through inflammatory pathways. Both systems share several
mediators, including hormones, cytokines, transcription factors, signaling proteins
and lipids. A chronic inflammatory state functions as a stressor and promotes
tissue damage that can lead to neoplasia. Once a genetic mutation leads to
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oncogene activation, inflammation will contribute to cell proliferation, tumor
establishment, growth and metastasis. CRC is a cancer type known to be closely
associated with chronic inflammation. Even though less than 2% of CRC is
colitis-associated, sporadic CRC shows similar mutations in genes and signaling
pathways, such as the Wnt/β-catenin pathway, K-Ras or B-Raf activation,
adenomatous polyposis coli (APC) inactivation, transforming growth factor(TGF)β, tumor protein p53 (P53), and the DNA mismatch repair (MMR) proteins (3639). The pathogenesis of both CRC types differs in the histological sequence that
is followed during development of neoplasia and the initiation of cancer
formation.
Numerous clinical and epidemiological studies have shown that the use of
aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a
reduced risk of CRC or recurrent adenomatous polyps as well as decreased
CRC mortality (40-45). Furthermore, low-dose aspirin therapy seems to slow
progression of a tumor that is already established. A recent cohort study of more
than 300,000 patients in the United Kingdom demonstrated that new use of low
dose aspirin was associated with a reduced risk of advanced stage CRC (Duke’s
B-D) at diagnosis (43). In 2015, the USPSTF started recommending low-dose
aspirin for chemoprevention of CRC in patients with increased cardiovascular risk
aged 50-59 years (46).
Independent of its pathogenesis, CRC is infiltrated by immune cells such
as macrophages, neutrophils or lymphocytes, that induce and maintain cancerrelated inflammation (47). In colon adenomas, the precursor lesions of sporadic
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CRC, TAMs with low major histocompatibility complex class 2 (MHC II)
expression were observed, and the density of these macrophages correlates with
tumor progression (48). This suggests that mechanisms within the TME lead to
macrophage polarization towards an anti-inflammatory phenotype during the
development of cancer. Furthermore, high-grade adenomas have been shown to
consist of a higher fraction of anti-inflammatory macrophages than low-grade
adenomas (49). This leads to the conclusion that macrophages of an antiinflammatory type seem to have a role in malignant transformation of colorectal
adenomas towards CRC.
The link between immunity and cancer through inflammation was
observed as early as the 19th century by the German pathologist Rudolf Virchow,
when he described white blood cells as part of the tumor mass. In 1986, the
American pathologist Harold Dvorak investigated angiogenesis within tumors,
considered these mechanisms similar to those in wounds and depicted tumors as
‘wounds that do not heal’ (50). Inflammatory tissue injury causes chemotactic
signaling that attracts immune cells to repair damage, and TAMs are the major
cell type orchestrating the pathways within the TME, to either promote or
suppress tumor development in CRC (51). These opposing functions of TAMs
are characterized by a respective dominating metabolic pathway of the
macrophage that can be affected by extracellular signals within the tumor
environment. This polarization into different functional subsets can be affected by
proinflammatory cytokines (52, 53), leading to the conclusion, that there is a
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direct connection between metabolism, inflammation and macrophage
differentiation affecting tumor behavior.
Itaconate is a metabolite within inflammatory macrophages, and a
regulator of cellular metabolism as well. It regulates glycolysis and leads to
succinate accumulation through inhibition of succinate dehydrogenase (54). This
can lead to decreased production of reactive oxygen species (ROS) and altered
activation of numerous transcription factors, such as nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB), hypoxia-inducible factor 1α (HIF1α),
signal transducer and activator of transcription 3 (STAT3), and activator protein 1
(AP-1) (35, 54). NRF2 is a superordinate regulator of these anti-inflammatory
functions, that is affected by itaconate (54). In anti-inflammatory macrophages,
itaconate can further boost anti-inflammatory functions (54). Since antiinflammatory macrophages play a role in tumor progression in CRC, this
suggests that itaconate affects CRC growth.

c.

Tumor-associated macrophages in colorectal cancer

The ability of macrophages to adapt to various environments and to provide a
wide variety of functions in tissue is due to dynamic adjustments of their cellular
metabolism. These metabolic pathways can be affected by the particular TME
inducing the metabolic reprogramming, which in turn leads to different cell
phenotypes.
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i.

Cellular metabolism and different phenotypes of tumor
associated macrophages

Metabolic reprogramming can occur as a result of different stimuli on TAMs, e.g.
mediators secreted by cancer cells, signals from cells within the tumor
microenvironment, self-secretion or indirect stimuli such as hypoxia. Although
switching between phenotypes is a continuous transition with intermediate types
present, two main macrophage phenotypes have been described: an M1-subtype
with primarily inflammatory functions and an M2-subtype, with predominantly
anti-inflammatory and immunosuppressive activity (Figure 1). This simplified
classification is an attempt to distinguish between subsets of macrophages that
have a primarily - but not exclusively - inflammatory or anti-inflammatory function.
The ‘waterfall model’ illustrates specific characteristics of TAMs during their
development from a monocyte to an anti-inflammatory macrophage subtype (55).
During this process, monocytes that initially present markers C-C chemokine
receptor type 2 (CCR2) and lymphocyte antigen 6 complex (Ly6C), undergo
functional and therefore phenotypical changes, losing Ly6C and gaining MHC II
expression (55). This demonstrates the continuous transition of monocytes and
macrophages with overlapping cell surface markers during all stages of
development.
Depending upon their phenotype, macrophages prefer specific metabolic
pathways for their energy homeostasis. The characteristic metabolic profiles of
inflammatory and anti-inflammatory macrophages lead to distinct phenotypes
with respect to cellular metabolism, which can be studied instead of targeting cell
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surface markers (Table 2). While aerobic glycolysis is the main pathway in
proinflammatory macrophages receiving M1 stimuli, anti-inflammatory M2
macrophages are characterized by slower rates of aerobic glycolysis and
primarily fatty acid oxidation (56, 57). The classically activated inflammatory M1
macrophages show induction of glycolysis through the AKT/mTOR/HIF pathway
(35). Aerobic glycolysis is an inefficient pathway with a high rate of glucose
consumption, but it is essential for rapid energy production and biosynthesis. M1
macrophages utilize this pathway for host-defense against pathogens, including
the production of ROS to kill bacteria or tumor cells. A slower rate of aerobic
glycolysis within M2 macrophages is necessary for the production of cytokines
(57). In contrast to M1 macrophages, the M2 subset macrophages show
increased oxidative phosphorylation (OXPHOS) (35). As shown in hepatocellular
carcinoma, cancer cells can promote glycolysis in M2 macrophages through
soluble mediators, increasing the gene expression of the glycolytic enzyme 6phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) (58). Therefore,
glycolysis plays a role in both macrophage phenotypes, but the respective
energy production focuses on different glycolysis-associated pathways.

13

Figure 1. Metabolic pathways in proinflammatory and anti-inflammatory
phenotypes of TAMs.

Simplified model showing the dominating metabolic pathways in both extremes of
phenotypes in TAMs. As macrophages can switch between proinflammatory and
anti-inflammatory phenotypes continuously by changing their cell metabolism,
metabolic pathways can overlap between both types. Proinflammatory
macrophages focus on aerobic glycolysis, truncated tricarboxylic acid cycle (TCA
cycle) and fatty acid synthesis for energy homeostasis of the cell. Anti
inflammatory macrophages use the TCA cycle, oxidative phosphorylation and β
oxidation as their major energy sources.

ROS = reactive oxygen species; TCA cycle = tricarboxylic acid cycle.
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Table 2

Human macrophage characteristics and marker expression depending on their
metabolic phenotype (inflammatory versus anti-inflammatory)

Phenotype

Cell surface markers
Factors inducing
differentiation

Proinflammatory

Anti-inflammatory

(M1-like subtype)

(M2-like subtype)

CD11c, CD16, CD80,

CD163, CD206,

CD86, MHC II

CD209

IFN-γ, TNF, LPS, ATP

IL-4, IL-10, IL-13,
TGF-β

aerobic glycolysis,
Metabolic pathways

truncated TCA cycle

β-oxidation,

(Itaconate production),

oxidative TCA cycle

fatty acid synthesis

Secreted factors

IL-1β, IL-6, IL-8, IL-12,

IL-10, IL-13, IL-1RA,

IL-23, IL-27, TNF-α,

TGF-β, CCL17,

CXCL1, CXCL9, CXCL10,

CCL18, CCL22,

CXCL11, CCL2, CCL5,

CCL24, Arg1, COX1,

RNI, ROI, COX2

VEGF, PDGF

The listed cell surface markers, factors and metabolic pathways are not
exclusively present in only one of these macrophage phenotypes. Since
macrophages can switch between phenotypes showing continuous transitions,
these characteristics might overlap. However, the characteristics that are shown
in this table are more likely to be present in the respective phenotype.

CD = cluster of differentiation; MHC II = major histocompatibility complex class 2;
IFN = interferon; TNF = tumor-necrosis factor; LPS = lipopolysaccharides; ATP =
adenosine thiotriphosphate; IL = interleukin; IL-1RA = Interleukin-1 receptor
antagonist; TCA cycle = tricarboxylic acid cycle; CXCL = chemokine (C-X-C
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motif) ligand; TGF = transforming growth factor; CCL = CC-chemokine ligand;
RNI = reactive nitrogen intermediates; ROI = reactive oxygen intermediates;
COX = cyclooxygenase; Arg1 = arginase 1; VEGF = vascular endothelial growth
factor; PDGF = platelet-derived growth factor.

ii.

The dual role of tumor-associated macrophages in
colorectal cancer

In contrast to other solid human cancers, TAMs in CRC seem to have the ability
to both support and suppress tumor growth. Tumor-promoting mechanisms are
known to result from an interplay between cancer cells, the tumor
microenvironment and TAMs. It is hypothesized, that tumor initiation is fostered
by mutagenic mechanisms from a chronic inflammatory environment in the
subepithelial stroma (59). Proinflammatory M1 macrophages that produce
reactive oxygen and nitrogen species, are able to potentiate this effect, triggering
oncogenic mutations in the adjacent epithelial layer (Figure 2). Once neoplasia is
initiated, the tumor recruits additional bone marrow-derived monocytes from the
bloodstream and stimulates myelopoiesis by releasing growth factors and
chemotactic signals such as CC-chemokine ligands 2 and 5 (CCL2, CCL5),
vascular endothelial growth factor (VEGF) and TGF-β (59-61). In adipose tissue,
a similar mechanism is described, where CCL2 expression leads to increased
macrophage infiltration and inflammation, which in turn is associated with insulin
resistance (62). Macrophage colony stimulating factor-1 (M-CSF or CSF-1) has
been shown to be produced by CC cells in order to attract and ‘re-educate’
macrophages (61). During the early stages of tumor development, neoplastic
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cells seem to first attract monocytes and ensure their maturation to macrophages
within the TME. After their differentiation to TAMs, cancer cells take these
macrophages hostage by manipulating their metabolism through multiple
signaling pathways and use these TAMs to support further tumor growth and
progression. Overexpression of the chemoattractant CCL2 has been associated
with advanced tumor stages, metastatic disease and poor prognosis in CRC (63,
64). Furthermore, CRC cells produce lactic acid as a by-product of predominantly
aerobic glycolysis (65). Proliferating cancer cells switch their metabolism towards
aerobic glycolysis, which is known as the ‘Warburg effect’. Irrespective of the
availability of oxygen, they metabolize glucose to lactate, which is also secreted
to induce VEGF and arginase 1 (ARG1) expression in TAMs (65). VEGF
expression in macrophages was shown to be upregulated by a pathway
described in hypoxia, even under normoxic conditions (65). This mechanism
leads to macrophage recruitment and polarization towards the tumor promoting
M2 macrophage phenotype and is therefore associated with metabolic
reprogramming in TAMs. Another key mechanism for the alternative activation of
tissue macrophages is the peroxisome proliferator activated receptor-γ (PPARγ)
pathway (66). In animal studies, the disruption of this pathway also was
associated with diet-induced obesity, insulin resistance, and glucose intolerance
(66). PPARγ deficiency can also lead to increased itaconate production, which
suggests that itaconate acts as an alternative regulator of M2-like polarization
(54).
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Furthermore, STAT3 activation leads to M2 polarization of macrophages (67).
This pathway can be induced by glucagon-like peptide 1 (GLP-1), a
postprandially secreted hormone that improves insulin resistance (67). TAMs
also promote tumor development by inducing interleukin 10 (IL-10) production in
CRC cells through a STAT3 pathway (68, 69) and produce cytokines such as
VEGF to induce tumor angiogenesis and tumor growth (70).
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Figure 2. TAMs in chronic inflammation and CRC development.
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A Tissue-resident macrophages with a proinflammatory phenotype might be able to trigger the onset of CRC in the
presence of a mutagenic activation of oncogenes in colon epithelial cells due to inflammatory stress and itaconate
production. B During early cancer development CC cells produce chemokines (CCL2) to attract bone narrow-derived
monocytes and induce macrophage differentiation releasing cytokines and growth factors such as IL-6, IL-10, TGF-β and
M-CSF (CSF-1). C CC cells release mediators such as lactate to induce TAM polarization into an anti-inflammatory
phenotype. Reprogrammed macrophages show an increased expression of vascular endothelial growth factor (VEGF)
and Arginase 1 (Arg 1), promoting angiogenesis and tumor growth. Furthermore, anti-inflammatory TAMs promote tumor
development by inducing IL-10 production in CC cells.

ROS = reactive oxygen species; IL = interleukin; TGF = transforming growth factor; M-CSF = Macrophage colonystimulating factor.

iii.

Macrophage phenotypes as prognosticators in
colorectal cancer

The density of recruited macrophages and their metabolic phenotype were found
to be associated with different clinical outcomes in CRC patients. Despite the
heterogeneity among study methods used to investigate the degree of TAM
infiltration, a high TAM density within the primary tumor is associated with an
improved prognosis in CRC patients (71). In other solid tumors, such as gastric,
urogenital and head and neck cancers, a high TAM density is accompanied by
worse overall survival (71). A higher degree of infiltrating macrophages in the
invasive front of CRC, in particular those with an M1 phenotype, is associated
with a better prognosis in a stage-dependent manner (72, 73). Furthermore, it is
inversely correlated to lymph node and liver metastases (74, 75). While M2
macrophages seem to be more prevalent in stage II CRC, M1 macrophages are
predominant in less invasive T1 tumors (76). This indicates that M1
macrophages are primarily responsible for tumor initiation because of
inflammatory mechanisms increasing oncogenic potential. Further in the course
of the tumor, cancer cells recruit additional bone marrow-derived blood
monocytes and reprogram their metabolism to induce M2-polarization (59).
Investigating the different functions and phenotypes of TAMs during tumor
development, which in turn promote and suppress tumor growth, is the basis for
developing new diagnostic and therapeutic targets, especially in EOCRC. The
specific role of itaconate, that can regulate macrophage polarization in tumors, is
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currently unknown in CRC. Table 3 provides an overview of current studies
investigating TAM phenotypes and therefore indirectly TAM metabolism in CRC.
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Table 3

Studies on CRC investigating cancer-related mechanisms related to the phenotype and metabolism of TAMs

Year

Study Model

2014

Murine/
murine cell
line

Deng et al. (77)

2010

Murine

Edin et al. (72)

2012

Human tissue

22

Colegio et al. (65)

Aims & Objectives
• Identification of tumor
signals that lead to functional
polarization of macrophages
• Lactic acid levels in cell line
media
• The effect of lactic acid on
macrophage polarization
towards an anti-inflammatory
M2-like phenotype using
syngeneic LLC tumors
• M2-marker expression by
macrophages induced by
lactic acid
• Effect of blocking STAT3mediated signaling in
macrophages in a transgenic
mouse line
• Tumor development in
inflamed colon & cecum in
STAT3 knockout mice & the
effect of microflora on these
processes

• Identification of
macrophage phenotypes in
CRC in relation to prognosis

Results
• Tumor cells induce VEGF
& Arginase1 expression in
macrophages via HIF1α
• Comparison of intracellular
metabolites of M1-line & M2like macrophages revealed
that lactate & pyruvate levels
were most different
• Lactic acid induced FIZZ1,
MGL1 & MGL2 in bonemarrow derived macrophages
• 20% of STAT3 knockout
mice showed pronounced
colitis at 8 weeks of age; the
rate further increased in older
mice. Macrophage density
increased in the colon of
these mice
• The inflamed colon
developed visible polyps with
associated carcinoma
• A higher density of intestinal
microflora was found in the
stool of STAT3 knockout mice
compared to controls
• The amount of iNOS
positive and CD163 positive

Conclusions Regarding
TAM Metabolism
• Tumor cell-derived lactic
acid had an important
signaling role in
macrophage polarization &
therefore tumor growth
• Lactic acid induced
expression of genes that
are defined as markers of
M2-like anti-inflammatory
macrophages (VEGF,
Arginase 1, FIZZ1, MGL1 &
MGL2)
• STAT3 knockout
promotes tissue
inflammation in the colon of
this transgenic mouse line,
suggesting a role in
macrophage polarization
towards an M1-like
proinflammatory subtype
• Abnormal immunity in the
bowel mucosa might induce
changes in the microflora

• A higher density of iNOS
positive cells (M1 subtype,
proinflammatory) is

in CRC in general & in
subgroups defined by
microsatellite instability (MSI)
screening status & CpG
island methylator phenotype
(CIMP)

2019

Human tissue

• Macrophage density &
proportion of CD206 positive
macrophages as
prognostic/predictive
biomarkers in stage II CC

Herbeuval et al.
(68)

2004

Human cell
lines

• Interactions between
macrophages & tumor cells
including IL-6, IL-10 & STAT3
activation

23

Feng et al. (78)

cells both correlated inversely
with tumor stage
• A higher amount of iNOS
positive cells associated with
better prognosis, independent
of MSI & CIMP status
• No significant survival
associations found in groups
of CRC with different
iNOS/CD163 ratios
• A high CD206/CD68 ratio
was associated with poor
disease-free survival & poor
overall survival
• CD206/CD68 ratio had a
better prognostic efficacy
than density of macrophages
(CD68 positive cells), or of
CD206 positive macrophages
or other clinicopathologic
high-risk factors
• Disease-free survival &
overall survival were
improved in patients with a
high CD206/CD68 ratio
receiving adjuvant
chemotherapy, but not in
patients with a low
CD206/CD68 ratio receiving
adjuvant chemotherapy
• Media of cultured
macrophages can stimulate
IL-10 production in several
human colon
adenocarcinoma cell lines
through a mechanism
involving IL-6
• Recombinant IL-6 (but not
recombinant IL-10), TNF-α

accompanied by a higher
amount of CD163 positive
cells (M2-like subtype, antiinflammatory) & correlated
with better prognosis in a
stage dependent manner

• In stage II CC, a higher
proportion of CD206
positive macrophages (M2like subtype, antiinflammatory) in relation to
the overall density of
macrophages
(CD206/CD68 ratio) is
associated with poor
disease-free & overall
survival rates.
• A higher proportion of
anti-inflammatory M2-like
macrophages (higher
CD206/CD68 ratio) is
associated with beneficial
effects on survival in stage
II CC patients that receive
adjuvant chemotherapy
• Mediators released by
macrophages (with
proinflammatory effects,
M1-like subtype) induced
STAT3-mediated IL-10
production by CC cells that
can lead to M2-polarization
of macrophages

2016

Human tissue

• Intra-tumoral & stromal
macrophage density in CRC
• Direct cell contact between
cancer cells (tumor buds) &
macrophages
• Predominant macrophage
phenotype in CRC

Malesci et al. (80)

2017

Human tissue/
human cell
lines

• Macrophage density at the
invasive front of the primary
tumors & metastatic lymph
nodes
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Koelzer et al. (79)

and IFNα stimulated IL-10
secretion in CC cell lines
• IL-10 gene regulation was
mediated by STAT3. This
mechanism was regulated by
IL-6
• A higher density of
intraepithelial macrophages
correlated with less tumor
budding
• A higher density of stromal
macrophages correlated with
larger tumor diameter & less
lymph node metastasis
• Frequent contact between
tumor buds & macrophages
was present in tumors with:
higher grade, lymph node
metastasis, mismatch repair
deficiency & BRAF mutation
as well as in patients without
adjuvant therapy,
• 40% of macrophages
(CD68 positive) were also
CD163 positive, 60% were
iNOS positive
• High counts of CD163
positive macrophages were
associated with lower tumor
grade, less lymph node
metastasis, less advanced Tstage, absence of lymphatic
invasion, KRAS wild type
genotype & a non-significant
survival benefit
• High macrophage densities
in primary tumors & lymph
nodes were associated with a
lower risk of tumor recurrence
after resection as well as with

• Macrophage phenotypes,
classified by cell surface
markers, show an
association with survival. A
high CD163 positive
macrophage count (M2-like
subtype, anti-inflammatory)
was associated with a nonsignificant survival benefit.
Proinflammatory iNOS
positive macrophages (M1like subtype) showed no
association with survival

• Proinflammatory
macrophages (M1-like
subtype) & 5-fluorouracil
showed a synergistic effect
on cancer cell death

• Prognostic/predictive value
of macrophages & neutrophils
& interactions with 5fluorouracil adjuvant therapy

25

Nandi et al. (81)

2016

Murine

• Effects of CCR6 knockout
on growth of a syngeneic
transplanted CC in mice
• Macrophage density in
syngeneic transplanted CC in
CCR6 deficient mice
• Effect of CCL20 on
macrophage accumulation in
vivo
• Effect of macrophage
accumulation on tumor
growth in CCR6 deficient
mice
• Correlations between
CCR6 expression with that of
the macrophage marker
CD163 & with CCL2, IL-1α,
IL-6 & TNF-α

better disease-free survival in
5-fluorouracil treated patients
• Patients with stage III CRC
& high macrophage density in
tumors (particularly
metastatic lymph nodes)
show significantly better 5year-disease-free survival
than patients with low
macrophage density
• Cancer cell death was not
increased by 5-fluorouracil
exposure after coculturing
with unpolarized
macrophages
• Coculturing cancer cells
with M1-like macrophages
nearly doubled the cell death
rate. This was even further
increased by exposure to 5fluorouracil
• Macrophage density was
lower & tumor growth was
delayed in CCR6 deficient
mice compared to wild type
mice
• Macrophage accumulation
was greater in response to
CCL20 than to CCL2
• Macrophage depletion led
to reduced tumor growth
• Higher macrophage
density in wild type mice
accompanied by increased
expression of CCL2, IL-1, IL6,
but not TNF-α, compared to
CCR6 deficient mice
• Expression of CCR6
correlated with CD163, CCL2,
IL-1α & TNF-α

• Macrophages
accumulating in response
to CCL20 and CCR6
interaction secrete
proinflammatory factors
(M1-like subtype)
• Expression of CCR6
correlates with the
expression of cell surface
marker CD163 (M2-like
subtype, anti-inflammatory)

2006

Murine

• Comparison of mRNA
expression profiles, tumor
load & survival between
animals with macrophagedepleted tumors & controls
• Identification of
macrophage phenotypes
within tumor tissue

Pinto et al. (76)

2019

Human tissue

• Identification of
macrophage phenotypes in
different stages of CRC
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Oosterling et al.
(82)

• Macrophage-depleted
tumors showed higher
differentiation & reduced
inflammatory tumor infiltrates
• Higher tumor load in the
peritoneal cavity & liver
observed in macrophagedepleted animals
• Augmented tumor
development in macrophagedepleted rats correlated with
decreased survival of these
animals, supporting the
significance of macrophage
tumoricidal effector functions.
• General macrophage
density higher throughout
control tumors compared to
macrophage-depleted tumors
• CD163 positive
macrophages confined to the
tumor periphery in control
tumors & no CD163 positive
cells found in macrophagedepleted tumors
• The amount of
macrophages, especially
CD163 positive
macrophages, was high in
stage II CRC
• The amount of CD80
positive macrophages was
higher in less invasive T1
tumors & is associated with
lower risk of cancer
recurrence
• Higher macrophage
density and lower
CD80/CD163 ratio were

• Macrophage depletion
leads to higher tumor load,
reduced inflammatory
tumor infiltrates & to loss of
the anti-inflammatory
macrophage population
present in control tumors
(M2-like subtype)

• CD163 positive
macrophages (M2-like
subtype, anti-inflammatory)
predominated in higher
tumor stages and were
associated with worse
overall survival
• CD80 positive
macrophages (M1-like,
proinflammatory) were
associated with lower tumor
stage & lower risk of
recurrence

Umemura et al.
(83)

2008

Murine/
murine cell
line

Zhou et al. (74)

2010

Human tissue

• Macrophage phenotype
identification in murine colon
adenocarcinoma
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• Association between
CD68 hotspots (small areas
with infiltration of CD68
positive cells above the
average level of CD68
positive cell infiltration) and
other clinicopathologic
parameters, potential of
hepatic metastasis, & 5-year
survival
• Macrophage phenotypes
within tumor tissue

associated with impaired
overall survival
• Tumor-infiltrating
monocytes/macrophages had
CCR2 positive & CX3CR1
positive inflammatory
monocyte characteristics
• Tumor-infiltrating
monocytes/macrophages
were shown to produce TGFβ1, which led to upregulation
of CD206 expression

• CD68 hotspots were
prognostic for survival & were
associated with the potential
of hepatic metastasis & the
interval between colon
resection & the occurrence of
hepatic metastasis
• Patients with stage IIIB
cancer & higher macrophage
density in the invasive front of
the tumor had a higher 5-year
survival rate after resection
• Staining for identification of
macrophage phenotypes
showed a large proportion of
HLA-DR, IL-10 & IL-12
positive macrophages, a
smaller proportion of TGF-β1
positive macrophages &
absence of IL-12 positive
macrophages.

• Tumor-infiltrating
monocytes/macrophages
cannot be classified into M1
and M2 categories since
they bear overlapping
characteristics
• CD206 expression (M2like subtype, antiinflammatory) in tumorinfiltrating
monocytes/macrophages is
regulated by an autocrine
mechanism using TGF-β1
• Macrophage density at
the invasive front of a tumor
is associated with lower
potential of hepatic
metastasis & worse overall
survival in CC
• Macrophages within
tumors predominantly
expressed HLA-DR (M1like subtype,
proinflammatory) & IL-10
(M2-like subtype, antiinflammatory). Fewer cells
were TGF-β1 positive (M2like subtype, antiinflammatory). Clear
conclusions on an M1-like
or M2-like overall subtype
by analyzing cell surface
markers could not be drawn

Legend to Table 3.

CCR6 = C-C Motif Chemokine Receptor 6; CCL = CC-chemokine ligand; CD = cluster of differentiation; IL = interleukin;
TNF = tumor-necrosis factor; CRC = colorectal cancer; BRAF = B-Raf proto-oncogene; iNOS = inducible nitric oxide
synthase; KRAS = Kirsten rat sarcoma viral oncogene homolog gene; HLA-DR = human leukocyte antigen-DR = MHC II =
major histocompatibility complex II; TGF-β1 = Transforming growth factor beta 1; CCR = C-C Motif Chemokine Receptor;
CXCL = chemokine (C-X-C motif) ligand; LLC = Lewis Lung Carcinoma; VEGF = vascular endothelial growth factor; HIF =
hypoxia-inducible factor; FIZZ1 = found in inflammatory zone 1 = RELM α; MGL = macrophage galactose-type lectin-1;
STAT3 = Signal transducer and activator of transcription 3.
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d.

Perspectives for targeting tumor-associated macrophages in clinical
practice
i.

Tumor-associated macrophages as diagnostic markers

TAMs have the potential to be used as diagnostic and prognostic markers in
CRC and possibly as therapeutic targets. Previous studies have shown that
circulating TAMs and the chemokines that they produce could serve as markers
in cancer diagnosis (84-86). Current research has focused on the identification of
circulating TAMs in blood samples by profiling their cell surface markers in
different types of cancer as a basis for developing a noninvasive screening tool.
Relevant markers are cluster of differentiation (CD) 14, CD163, CD68 or hypoxiainducible factor 2α (HIF-2α) (84-86). A combination of analyzes of cell surface
markers, cytokines secreted by TAMs and soluble factors produced by other cells
within the TME could be useful to determine specific cell expression profiles in
CRC. Serum levels of neutrophil elastase within the TME have been shown to
play a potential role as a diagnostic biomarker in CRC (87). While serum matrix
metalloproteinase-9 (MMP-9) was not considered to be an appropriate screening
parameter for CRC (88), tissue inhibitor of metalloproteinase-1 (TIMP-1) seems
to have a potential diagnostic value (89). Targeting related factors that are
expressed by TAMs or neighboring cells within the tumor microenvironment and
circulatory markers may further contribute to the overall diagnostic capacity.
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ii.

Tumor-associated macrophages as prognostic markers

Evidence for prognostic utility of markers in CRC, with a particular role of TAM
phenotypes in different tumor stages, is currently evolving. The findings with
respect to the association between specific TAM phenotypes and prognosis are
inconclusive, suggesting a different role of TAMs during tumor progression. This
could also be caused by the fact, that not only the total cell count of either M1 or
M2 macrophages seems to be relevant for tumor progression, but also the
distribution of these cells within the tumor environment (72). A low density of
TAMs in general, as investigated by CD68+ cell infiltration in tumor tissue, was
associated with worse outcome in patients with different stages of CRC (90). A
high proportion of CD163+ macrophages was associated with lower tumor grade
and less lymph node metastasis (79). Other studies report advanced tumor
stages and worse prognosis positively correlating with high TAM density (76). An
investigation of the prognostic effect of TAMs in patients with CRC undergoing
postoperative chemotherapy recently revealed, that the CD206/CD68 ratio of
TAMs can predict high risk of recurrence in patients with stage II CC (78). As
adjuvant chemotherapy is not routinely recommended in these patients,
identifying those patients with poor prognosis is leading to targeted and more
accurate administration of chemotherapy. The presence of a high density of
TAMs in primary tumor tissue and metastatic lymph nodes of stage III CRC can
identify patients that benefit from 5-fluorouracil (80). In-vitro results indicating
synergistic effects of TAMs and fluoropyrimidines have, however, yet to be
proven in an in-vivo setting (80).
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Since different TAM phenotypes are associated with tumor behavior, the
metabolic reprogramming of TAMs to an ‘antitumor’ phenotype is a major aim of
ongoing research. In TAMs, the NF-κB pathway is the main pathway for
polarization into an antitumor phenotype. This pathway is affected by Toll-like
receptors, Dectin-1 receptors and specific intercellular adhesion moleculegrabbing nonintegrin (SIGN)-related 1 receptors (91, 92). Activation of these
receptors causes an adaptive immune response enhancing phagocytosis and the
release of inflammatory cytokines, such as tumor-necrosis factor-α (TNF-α), IL-2,
IL-10 and IL-12 (92). The yeast-derived polysaccharide β-glucan can act on
these membrane receptors, thereby inducing macrophage polarization into a
proinflammatory anticancer phenotype (92). Apart from NF-κB, other transcription
factors can also be regulated to induce M1-like polarization or to inhibit M2
polarization in macrophages, such as interferon-regulatory factor (IRF), STAT
protein, HIFα and several microRNAs (53).
Pathways that are known to be involved in macrophage activation and
reprogramming in the acute immune response could also play a role in a chronic
inflammatory setting, consequently affecting the onset and development of CRC.
Identifying inflammatory mediators in obesity that support the polarization of
tumor-promoting macrophages could not only help identify patients at high risk of
CRC due to metabolic dysfunction, but also serve as a basis for targeting these
mediators in patients with obesity or type 2 diabetes mellitus. The effects of
obesity and its associated inflammatory stressors on macrophage polarization,
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TAM metabolism and therefore tumor behavior in patients with CRC, need further
elucidation.

e.

Conclusions

Tumor-promoting inflammation is one of the hallmarks of cancer and TAMs are
able to orchestrate these mechanisms based on their cellular metabolism.
Interactions between TAMs, tumor cells and other components within the TME
regulate cancer establishment, tumor growth and metastasis. CRC is closely
related to chronic tissue inflammation. Metabolic dysfunction in patients with
obesity has the potential to induce reprogramming in TAMs through inflammatory
mechanisms. The macrophage metabolite itaconate is produced during TAM
polarization and it is known to have tumor promoting effects. Investigating the
role of itaconate and other metabolites in TAMs can elucidate processes specific
for the onset and progression of CRC on the basis of inflammatory pathways,
particularly in EOCRC. There is a potential to detect new diagnostic and
prognostic targets for the improvement of neoadjuvant and/or adjuvant therapies
in CRC.
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CHAPTER III

INFLAMMATORY PATHWAYS LINKING OBESITY AND EARLY-ONSET
COLON CANCER

a.

Background

The pathogenesis of EOCRC and the role of obesity and metabolic dysfunction
are poorly understood. A systemic low-grade proinflammatory state due to the
dysregulation of obesity-related hormones and low dietary quality in obesity and
diabetes have been postulated to increase CRC risk (93, 94). Inflammatory
mechanisms are mediated by immune cells, with macrophages and their
phenotypical changes playing a central role in CRC (94, 95). M1-like adipose
tissue macrophages contribute to a systemic proinflammatory state in obesity,
thereby increasing cancer risk. Tumors having a high proportion of antiinflammatory M2-like TAMs in CRC are associated with poor overall survival (95).
Obesity-related hormones, such as leptin and adiponectin, are secreted by white
adipose tissue and affect macrophage polarization and cytokine expression (96,
97). These hormones thereby regulate inflammation, insulin resistance and
energy homeostasis (98). Altered hormone levels induce phosphoinositide
kinase-3 (PI3K)/AKT activation in CC, causing increased cell survival,
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hyperplasia and proliferation (94, 99). Inflammatory mechanisms mediated by
this pathway include cytokines such as interleukin 6 (IL-6), TNF-α or IL-1β and
link obesity and inflammation to CRC carcinogenesis through TAM-mediated
CRC cell progression (94, 95).
Central molecules for the control of cell proliferation, differentiation and
tumorigenesis within the gastrointestinal tract include downstream targets of the
PI3K/AKT pathway, such as Neurogenic locus notch homolog 4 (Notch4) and
GATA binding proteins (GATA) (100).
This chapter will introduce the NOTCH4-GATA4-IRG1 axis as a link
between inflammation and sporadic CRC, and will discuss this pathway as a new
potential immunotherapeutic target in individuals affected with obesity and
EOCRC. The genes described as part of the NOTCH4-GATA4-IRG1 axis are
based on an RNA sequencing (RNA-seq) analysis using Ingenuity software,
which is further described in Chapter IV (methods). Genes and their functions are
listed in Table 4.
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Table 4
Genes and their functions as part of the NOTCH4-GATA4-IRG1 axis
Gene

Encoded protein

Function

LEP

Leptin

•

Obesity-related
hormone produced
by adipocytes
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ADIPOQ

PI3K/AKT

Adiponectin

Phosphatidylinositol3-kinase/Protein
kinase B

Obesity-related
hormone produced by
adipocytes

Intracellular lipid
kinase

Cancer-related role of genes in
macrophages
• Leptin induces tumor promoting
anti-inflammatory IL-8 expression
in macrophages;
• It regulates monocyte and
macrophage recruitment and
promotes angiogenesis through
their expression of VEGF and IL-6,
which enhances tumor progression
in breast cancer;
• Induces T-cell apoptosis via INF-γ
in immune suppressive myeloidderived suppressor cells;
• In monocytes, leptin promotes
proinflammatory M1-like marker
expression (IL-1β, IL-6, and TNF,
and resistin)
• Adiponectin promotes antiinflammatory M2-like macrophage
polarization (CD206, AMAC-1);
• It activates PPARα and
suppresses NFκB signaling in M2like macrophages, promoting antiinflammatory cytokine expression;

Role of genes in cancer

•

•

•

PI3Kγ induces tumor promoting
cytokine expression in M1- and
M2-like macrophages;
It decreases the number of TAM in
CC and promotes their polarization

•

•

•

•

Increased leptin expression in
CRC is associated with
advanced tumor stage and
poor prognosis;
Leptin acts as a potent
mitogen and inhibits apoptosis
in CC cells;

Adiponectin inhibits the
PI3K/AKT pathway and
activates the AMPK/mTOR
axis, inhibiting carcinogenesis,
tumor cell adhesion and
migration in CRC;
Adiponectin inhibits tumor
growth
and survival in CRC by
preventing fatty acid synthesis
through AMPK;
The PI3K/AKT pathway
promotes cell growth and
survival through inhibition of
proapoptotic proteins,
degradation of p53 and by

into an immunosuppressive M2like phenotype
•

NFKB

Nuclear Factor
Kappa B

Transcription factor

•
•

•

SERPINE1
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Plasminogen
activator inhibitor-1
(PAI-1)

Serine proteinase
inhibitor

•

NFκB promotes an M2-like
phenotype in macrophages with
protumorigenic characteristics;
Decreases mononuclear cell
infiltrates in tumors and inhibits
anti-tumor cytokine expression
involved in M1-like macrophage
activity and Th1-skewed immune
response (IL-12, CCL-2, TNF-α,
IL1-β) and iNOS;
Induces M2-like protumorigenic
cytokine expression (IL-10,
Arginase);
PAI-1 induces recruitment and M2like phenotype polarization in
monocytes/macrophages (IL-6,
CD163); PAI-1 expression strongly
correlates with M2-like CD163
expression in CC

•
•

•

•

PPARA

PPARα

Transcription factor

•

PPARα inhibits NFκB-related
proinflammatory gene transcription
(iNOS, MMPs, TNF-α)

•
•

PPARG

PPARγ

Transcription factor

•

PPARγ is frequently inactivated by
hypermethylation in peripheral
blood monocytes in patients with
CRC;

•

promoting antiapoptotic gene
transcription through NFκB;
Increased activity is associated
with decreased disease-free
and overall survival in CRC;
Promotes peritoneal
metastasis; Inhibits TNF-α
induced cancer cell apoptosis;
Induces tumor vascularization
in the presence of
macrophages;

Elevated plasma PAI-1 levels
are associated with increased
risk for CRC and correlate with
liver metastasis, tumor size,
differentiation, serosa
infiltration, Duke's stage, and
lymphatic metastasis;
PAI-1 expression is associated
with decreased overall
survival, increased metastasis
and invasion in rectal cancer;
Reduced expression in CC
compared to normal colon
tissue;
Prevents neoplastic
transformation of colon
epithelial cells and CC growth;
PPARγ functions as a cancer
suppressor in CRC, inhibiting
tumor promoting NFκBinduced gene transcription;

IRG1

Aconitate
Decarboxylase 1
(ACOD1)

Dicarboxylic acid with
anti-inflammatory and
carcinogenic effects

•

Itaconate produced by the enzyme
encoded by IRG1 decreases
PPARG expression in M2-like
macrophages;

•

•

ACOD1 is part of the citric acid
cylce and typically expressed in
M1-like macrophages;
IRG1 can be expressed in M2-like
macrophages and is associated
with tumor progression;

•

•

•

•

GATA1/2/3/4/5/6

GATA binding
protein1/2/3/4/5/6

Transcription factor

•
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•

GATA2 expression is associated
with an M1-like phentoype,
regulating LPS-induced IL-1β
expression in macrophages;
GATA3 is highly expressed in M2like macrophages;

•
•

•

•
•
•

It induces cancer cell
apoptosis, inhibits proliferation,
angiogenesis and promotes an
anti-inflammatory tumor
microenvironment in CRC;
IRG1 is expressed in CC, but
carcinogenic mechanisms are
barely understood;
It is associated with growth,
invasion, tumorigenesis and
advanced tumor stage in
gliomas;
It is highly expressed in
monocytes isolated from
ovarian carcinoma patient's
ascites
GATA1 promotes cell
proliferation, migration and
invasion in CRC;
GATA2 is highly expressed in
CRC, which is associated with
an increased risk of disease
recurrence and decreased
disease-free survival;
GATA3 is downregulated in
CRC, which is associated with
poor differentiation, lymph
node metastasis, increased
resistance to chemotherapy
and poor prognosis;
GATA4 is upregulated in CC
cells adapted to an acidic
microenvironment;
GATA4 and GATA5 are
inactivated by
hypermethylation in CRC;
GATA 6 enhances cell
migration and invasion in CC

NOTCH1/2/3/4

Notch
receptor1/2/3/4

Transmembrane
receptors

•

•

•

NOTCH1, NOTCH2 and NOTCH3
are upregulated in M1-like
macrophages compared to M0 and
M2-like phenotypes;
NOTCH1 promotes M1-like
polarization direct metabolic
reprogramming in macrophages,
shifting cellular metabolism to
glycolysis;
NOTCH4 promotes an antiinflammatory macrophage
phenotype by decreasing M1-like
gene expression (IL-6, IL-12,
CD80, CD86);

•

DLL4 is associated with an M1-like
macrophage phenotype;

•

•
•

•
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DLL4

Delta Like Canonical
Notch Ligand 4

NOTCH ligand

•

•
HES1/HEY1

MMP2

Hairy and Enhancer
of split 1/Hairy and
Enhancer of splitrelated with YRPW
motif protein 1
Matrix
Metalloproteinase-2

Notch target genes

•

HES1/HEY1 decrease expression
of a subset of proinflammatory
cytokines (CXCL1, IL-6, IL-12);

•

Metalloproteinase

•

MMP2 excerts anti-inflammatory
effects in macrophages, limiting
proinflammatory tissue responses;
It stimulates vascular permeability
to recruit peripheral blood
monocytes from vessels to the
tissue;
VEGFA expression is induced by
inflammatory stimuli, such as

•

MMP2 expression correlates
with lymph node metastasis
and worse outcome in CRC;

•

VEGFα is an essential factor in
tumor growth and metastasis

•

VEGFA

Vascular Endothelial
Growth Factor A

Increased expression of
NOTCH1 and its downstream
gene HES1 is associated with
advanced colon tumor stage
and poor overall survival in
CRC;
NOTCH2 expression is
associated with increased
overall survival in CRC;
High NOTCH3 expression is
found in poorly differentiated
CRC and associated with poor
prognosis;
High NOTCH4 expression is
associated with advanced
tumor stage, decreased
disease-free survival and
overall survival; Increased
expression was found in liver
metastases compared to
primary cancer tissue;
DLL4 enhances tumor growth
and stem cell frequency in CC;
It is associated with decreased
overall survival in CRC;
Enhances tumorigenicity of
stem-like cancer cells in CC;

Growth factor

•

NFκB in macrophages; it mediates
tumor neovascularization and
growth;
•

ABCG5/ABCG8

TNFA

ATP Binding
Cassette Subfamily
G Member 5/ATP
Binding Cassette
Subfamily G
Member 8

Sterol transporter
(consisting of an
obligate heterodimer
encoded by these two
genes)

•

Tumor Necrosis
Factor α (TNF-α)

Proinflammatory
cytokine

•

ABCG5/ABCG8 is involved in lipid
uptake and metabolism. It is
expressed in macrophages and
upregulated by PPARA;

•

Induced by NFκB, TNF-α is a
master regulator of
proinflammatory cytokine
responses and is predominantly
expressed in M1-like
macrophages;

•

IL-1β is associated with NFKB
expression, and enhances tumor
growth and angiogenesis,
promoting infiltration and activation
of macrophages in tumors
(VEGFA, MCP-1, IL-8);
IL-6 plays a central role in obesityrelated inflammation and can exert
both pro- and anti-inflammatory
effects; it promotes an antiinflammatory M2-like phenotype in
macrophages (Arginase, CD206);

•

•

•
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IL1B

Interleukin 1β (IL1β)

Proinflammatory
cytokine

•

IL6

Interleukin 6 (IL-6)

Cytokine with pro- and
anti-inflammatory
effects

•

•

•

in CRC; its expression levels
are associated with cancer
risk;
High VEGFα expression levels
are associated with high-grade
tumors and increasing tumor
size;
ABCG5/ABCG8 expression is
associated with poor survival in
node-negative CRC;
The expression levels are
dependent on tumor location
and decrease from colon to
rectum;
TNF-α promotes cancer cell
proliferation, survival, and
migration, probably through
facilitating epithelial–
mesenchymal transition in CC;
Serum TNF-α levels are
elevated in patients with CRC
compared to healthy controls
and are associated with
advanced tumor stage and
poor survival;
IL-1β enhances CC cell
proliferation and survival and
promotes cancer progression;

IL-6 promotes cancer cell
proliferation and inhibits
apoptosis in CRC through
JAKs and STAT3;
Increased IL-6 expression is
associated with advanced
tumor stage and decreased
survival in CRC;

Legend to Table 4.

Genes, encoded proteins, and their functions in cancer-related macrophage polarization and function and cancer.

CD = cluster of differentiation; AMAC-1 = human alternative macrophage activation-associated CC chemokine-1; AMPK =
AMP-activated protein kinase; mTOR = mammalian target of rapamycin; p53 = tumor protein p53; CCL = C-C motif
chemokine; iNOS = inducible nitric oxide synthase; LPS = lipopolysaccharide; CXCL = chemokine (C-X-C motif) ligand;
MCP-1 = monocyte chemoattractant protein-1; STAT3 = Signal Transducer And Activator Of Transcription 3
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b.

Leptin, adiponectin and the PI3K/AKT pathway in colorectal cancer –
an overview

Phosphoinositide 3-kinase/Protein kinase B (PI3K/AKT) signaling induces
immune suppression, which further promotes inflammation and tumor
progression (101) (Table 4). PI3Kγ is an isoform of PI3K that is highly expressed
in TAM, but not in cancer cells (95). This lipid kinase has been demonstrated to
be a master regulator of cancer - inhibition of its gene PI3CG stimulates Nuclear
Factor kappa B (NFKB) activation, one of the key pathways for intestinal
carcinogenesis mediating both proinflammatory and anti-inflammatory cytokine
expression (102) (Figure 3). Dysregulation of NFκB is a hallmark of chronic
inflammation. Investigating NFκB-related cytokine responses in cancer cells and
surrounding associated cells is crucial for defining inflammatory carcinogenic
mechanisms. PI3Kγ-associated anti-inflammatory gene expression predicts
patient survival and is therefore an appealing immunotherapeutic target in CRC
(101). Silencing PI3CG in TAM leads to death of CC cells in vitro (95).
The obesity-related hormones leptin and adiponectin both alter gene expression
within this pathway, thereby affecting TAM-mediated CRC progression (103, 104)
(Table 4, Figure 3). Both leptin and adiponectin can mediate protumor effects by
activating PI3K (103, 104). Within the tumor microenvironment, PI3K activation
suppresses proinflammatory M1-like polarization of TAMs, creating an antiinflammatory, tumor promoting environment (101).
The family of Akt proteins consists of the three different serine/threonine
protein kinases Akt1, Akt2 and Akt 3. These kinases regulate cellular functions
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relevant in cancer progression, such as cell metabolism, proliferation and survival
(105). Furthermore, Akt kinases play a crucial role in macrophage polarization,
with AKT1 ablation initiating M1-like polarization and AKT2 ablation leading to a
more M2-like macrophage phenotype (105). Macrophage metabolism and
therefore polarization directly affects tumor progression and survival in patients
with CRC. Investigating the effects of obesity-related mechanisms on PI3K/Akt
signaling can provide new insights on targeting mechanisms in EOCRC and
obesity among the young. Leptin activates Akt by phosphorylation, thereby
affecting macrophage polarization and inducing TAM-mediated tumor
progression (94, 106, 107) (Figure 3). Adiponectin mediates anti-tumorigenic
effects directly in CC cells in vitro and reduces the growth of intestinal polyps (94,
108), while on the other hand, it can induce a more M2-like macrophage
polarization potentially favoring CRC progression (109). The definitive role of
obesity-related hormones in TAM-mediated CRC progression and their effects in
EOCRC are yet to be fully understood.
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Figure 3. Structure of the NOTCH4-GATA4-IRG1 axis.

Legend to Figure 3.

Pathway network showing gene interactions of the NOTCH4-GATA4-IRG1 axis (shaded in red) and their relation to the
obesity-related hormones leptin and adiponectin (yellow hexagons). Red arrows demonstrate activation, while blue dotted
arrows show inhibitory effects. Major gene interactions are shown in bold.
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c.

GATA transcription factors – two sides of a coin

The GATA family of zinc finger transcription factors regulate gene expression during
embryogenesis and the growth of several organs derived from the mesoderm or
endoderm, such as the gastrointestinal tract (110, 111). During embryonic development,
GATA expression is associated with cell proliferation and differentiation(110) (Table 4).
These mechanisms have been shown to play a key role in several types of cancers,
with GATA transcription factors functioning as tumor suppressors (110, 112). Recent
studies, however, have shown that GATA expression is involved in carcinogenic
mechanisms leading to progression of pancreatic ductal adenocarcinoma, suggesting a
cancer-promoting role of the GATA protein family (113).
All GATA transcription factors bind to a canonical GATA motif in the promoters of
various genes (114). GATA proteins are expressed in gastrointestinal tissue and altered
gene expression is associated with several malignancies (114, 115) (Table 4). The
function of members of the GATA family as either oncogenes or tumor suppressor
genes, however, is poorly understood.
In CRC and gastric cancer, GATA4 and GATA5 have been reported to mediate
tumor suppressing effects and are frequently silenced by promoter hypermethylation
(116). Recent data suggests that cancer cells of solid tumors that are adapted to
extracellular acidosis, however, show increased GATA4 expression (117). GATA4
enhances activity of the crucial inflammatory regulator NFκB, which in turn leads to
tumor-promoting effects, such as inhibition of apoptosis (117) (Table 4, Figure 3).
Expression levels of GATA4 are positively associated with the proportion of
proinflammatory macrophages in cancer tissue, which points towards inflammation-
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driven effects in cancer development (113). In CRC, a cancer with an inflammatory
etiology and macrophage-dependent development, GATA4 is expressed in around 64%
of cancers (111).
GATA proteins are involved in macrophage-specific pro- and anti-inflammatory
responses as part of the immune-responsive gene 1 (IRG1) pathway.

d.

Itaconate – a macrophage specific metabolite promoting
colon cancer

IRG1 expression is associated with several types of cancers, such as glioma, ovarian
cancer and CC (18). The gene encodes for the protein aconitate decarboxylase 1, an
enzyme of the tricarboxylic acid (TCA) cycle that produces itaconate from cis-aconitate
(54) (Table 4). Itaconate mediates anti-inflammatory effects by inducing antiinflammatory transcription factors such as NRF2 and oxidative stress reduction (118,
119). In vitro experiments commonly use the two esterified derivatives of itaconate,
dimethyl itaconate (DI) and 4-octyl itaconate (OI), to investigate its effects on different
types of cells in culture. While itaconate itself is polar and cannot easily cross the cell
membrane, its derivatives show increased cell permeability (120). Non-specific
esterases are able to release the physiological polar form of itaconate intracellularly by
hydrolyzing ester groups (120).
IRG1 upregulation is associated with an M1-like macrophage phenotype,
suggesting that it functions as a compensator to regulate proinflammatory cell
responses (54) (Table 4). In anti-inflammatory M2-like macrophages, however, IRG1
upregulation can also be demonstrated under certain circumstances (96). This shows
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that M2-like macrophages have the potential to contribute to an anti-inflammatory
environment favoring CRC progression through itaconate.
The obesity-related hormones leptin and adiponectin can affect macrophage
metabolism and polarization, thereby altering IRG1 expression (121, 122) (Table 4,
Figure 3). The cancer promoting role of obesity-related hormones through itaconate
should be clarified.

e.

Notch receptors – a metabolic target in EOCRC?

The functional role of Notch signaling among different target organs and cancer types
has many facets. Notch receptors are transmembrane proteins regulating tissue
homeostasis (123) (Figure 4). Neighboring cells express transmembrane ligands that
induce Notch signaling within a cell and receptor activation induces proteolytic cleavage
(123). As part of these processes, the notch intracellular domain (NICD) of the receptor
is released (124). After translocation of the NICD to the nucleus, it forms a
transcriptional complex with transcription factor CBF1, suppressor of hairless, lag-1
(CSL) and several coactivators, modifying gene expression (124).
In CRC, Notch receptors have been shown to be involved in colon adenoma
formation, and Notch expression in CRC differs among the four known Notch receptor
subtypes (100, 125) (Table 4). Notch1 receptor expression in cancer tissue is
associated with decreased overall survival in patients with CRC (126). Higher Notch1
expression levels are found in poorly differentiated CRC and in CRC with advanced
tumor stage (127). The opposite role was reported for expression of NOTCH2 in CRC,
showing anti-tumorigenic characteristics with increased overall survival (128). Higher
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NOTCH2 expression is reported to be higher among well-differentiated tumors
compared to poorly differentiated CRC, as well as in early-stage tumors compared to
advanced disease (128). The third subtype NOTCH3 has oncogenic effects in CRC.
Akt-dependent upregulation of NOTCH3 is associated with tumor progression and
worse overall survival (129). In consensus molecular subtype 4 (CMS4) cancers, the
CMS subtype of CRC with the poorest overall patient survival, NOTCH1 and NOTCH3
expression was associated with advanced tumor stage and lymph node and distant
metastasis (129-131). Current data on associations of NOTCH4 expression in patient
CRC tissue with clinical outcome shows inconsistent results (100, 124). Zhang et al.
demonstrated that low NOTCH4 expression in cancer tissue is associated with poor
differentiation, advanced tumor stage, deep wall invasion, lymph node metastasis and
reduced disease-free survival (100). Furthermore, patients who are overweight and
obese had a tendency to have CRC with lower NOTCH4 expression, suggesting a role
of this receptor in obesity-related CRC (100). In contrast, another study by Shaik et al.
showed that NOTCH3 and NOTCH4 overexpression were associated with worse overall
survival (124).
In classically activated M1-like macrophages, Notch4 signaling suppresses
interferon-γ (IFN-γ) and lipopolysaccharide (LPS) induced pathways leading to a more
anti-inflammatory environment (132). These effects suggest Notch4 as an
immunotherapeutic target in anti-inflammatory TAM-mediated CRC progression. A
potential association of Notch4 with obesity has the potential to link proinflammatory
mechanisms in metabolic dysfunction with anti-inflammatory, tumor promoting effects in
CRC through macrophages.
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Anti-inflammatory responses regulating classic activation in M1-like macrophages are
an emerging subject in cancer research. Since sporadic CRC is strongly associated with
dysregulation of inflammation and cellular metabolism within the tumor
microenvironment, these regulatory mediators are of high importance. Currently it is
assumed that anti-inflammatory mediators in M1-like macrophages function as a ‘brake
pedal’, to control proinflammatory responses and prevent excessive oxidative stress
and cell damage (54). Dysregulation of this immunomodulatory function can promote an
anti-inflammatory environment facilitating cancer development.
Despite the complexity of Notch signaling, the transcription factors Hairy and
Enhancer of split (HES) and Hairy and Enhancer of split-related with YRPW motif
protein (HEY) have been identified as direct targets of Notch (100) (Table 4, Figure 3).
In IFN-γ-activated macrophages, NOTCH4 diminishes proinflammatory IFN-γ-related
cell responses by activating Signal transducer and Activator of Transcription 3 (STAT3)
through HES1 (132). Furthermore, Notch signaling had an impact on cytokine profiles in
macrophages through NFKB expression (132). Recent data revealed that NOTCH4
inhibits proinflammatory responses in macrophages, reducing cytokine expression of
interleukin 6 (IL-6) and IL-12 and also M1-like cell surface receptors, such as CD80 and
CD86 (132). While NOTCH1 and NOTCH3 increase NFκB activity in macrophages,
NOTCH4 acts as a negative regulator of NFκB-dependent macrophage cytokine
transcription (132) (Figure 3).
The ultimate role of NOTCH4 as either a tumor suppressor or enhancer in sporadic
CRC has yet to be defined.
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Figure 4. Cellular mechanisms of Notch signaling between cells within the TME.

Legend to Figure 4.

The Notch receptor (red and green) of a signaling cell is modified undergoing two proteolytic cleavages (S2, S3-4) after
binding to its ligands on an adjacent cell (purple). The Notch intracellular domain (NICD, green) is released, transferred to
the nucleus, binds to the DNA-binding CSL (CBF1, Su(H) and LAG-1) protein and induces gene transcription.

- Cleavage at Site-1 (S1): Step during Notch maturation. A furin-like convertase creates a heterodimeric Notch receptor
with an extracellular domain non-covalently bound to the transmembrane/intracellular fragment.
- Cleavage at Site-2 (S2): Ligand binding of the mature Notch receptor induces a conformational change that enables a
membrane bound disintegrin and metalloproteinase (ADAM) to cleave the extracellular receptor domain. Rate-limiting
step and obligatory for S3 to occur.
- Cleavage at Site-3 and Site-4 (S3-4): Cleavage at the Notch transmembrane domain at Site-3 and Site-4 by γ-secretase.
Initiating Notch signaling by releasing the intracellular domain.
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NOTCH = Neurogenic locus notch homolog 4; ECD = extracellular domain; ICD = intracellular domain; MAML =
mastermind-like protein 1; CoA = coenzyme A; CSL protein = CBF1, Su(H) and LAG-1 protein; HEY = Hairy and
Enhancer of split-related with YRPW motif protein; HES = Hairy and Enhancer of split

f.

Conclusion

Sporadic CRC is strongly associated with proinflammatory mechanisms that are
chronically enhanced in patients with obesity. The increasing incidence of
EOCRC and rising rates of obesity worldwide suggest a link through
inflammatory mechanisms. The obesity-related hormones leptin and adiponectin
mediate pro- and anti-inflammatory effects in CRC, respectively. In tumor
development and progression, anti-inflammatory cytokines within the tumor
microenvironment secreted by TAM play a crucial role. TAM-mediated cell
responses due to leptin and adiponectin stimuli in CRC are yet to be
investigated. The NOTCH4-GATA4-IRG1 axis provides a gene network that has
an impact on cancer progression and patient survival through the PI3K/AKT
pathway, NFκB- and PPARγ-related mechanisms. Furthermore, the NOTCH4GATA4-IRG1 axis takes part in processes regulating tissue remodeling and EMT
as critical steps for tumor progression and metastasis. Genes involved are tightly
associated with proinflammatory cytokine expression, including IL-1β, IL-6 and
TNF-α. Leptin and adiponectin affect these mechanisms, providing a potential
link between obesity and EOCRC. The effects on the anti-inflammatory pathway
signaling, involving NOTCH4, GATA4 and IRG1, however, still need to be
elucidated. Anti-inflammatory mediator production in M1-like macrophages is
physiological and functions as a ‘brake pedal’ to prevent excessive
proinflammatory stress responses. A dysfunction of these mechanisms favoring
tumor development by overly enhanced activation of the anti-inflammatory
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NOTCH4-GATA4-IRG1 axis in TAM provides a new potential carcinogenic
mechanism in TAM-mediated CRC progression.
Investigating obesity-related hormonal effects on TAM-mediated pro- and
anti-inflammatory cytokine expression in CRC is important and may provide new
immunotherapeutic targets for the treatment of TAM-mediated EOCRC.
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CHAPTER IV

HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN

a.

Key objective

To develop an in-vitro coculture model of human TAM and CC cells and to study
the cellular responses to the obesity-related hormones leptin and adiponectin
and the macrophage-specific carcinogenic metabolite itaconate, which may
promote CC progression.

b.

Hypothesis

Leptin induces metabolic reprogramming in tumor-associated M2-like
macrophages towards a tumor-promoting phenotype by regulating gene
expression of the NOTCH4-GATA4-IRG1 axis.

c.

Specific aims

Aim 1:
Determine the effects of obesity-related hormones (leptin and adiponectin) on
CC-related gene expression of anti-inflammatory tumor promoting macrophages
and CC cells by establishing a cell line coculture model.
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Aim 2:
Assess whether itaconate is produced in CC and determine the effects of
itaconate on CC-related gene expression profiles of anti-inflammatory
macrophages and CC cells.

Aim 3:
Determine age-related and obesity-related gene expression in samples of
patients with CC, their relation to leptin and adiponectin and their impact on
patient survival.

d.

Experimental plan

The purpose of this project was to develop an in-vitro model of anti-inflammatory
M2-like macrophages similar to TAM and CC cells. We anticipated that created
TAM-like macrophages would show an anti-inflammatory cytokine and cancerrelated gene expression profile that would mimic TAM function in human CC.
This macrophage phenotype is associated with cancer progression, more
advanced tumor stage and decreased overall survival in patients with sporadic
CC.
After characterizing created macrophages to confirm their phenotype and after
obtaining baseline expression values, we treated cells with leptin and itaconate
derivatives. Since cell membranes are not permeable for itaconate, two wellestablished cell membrane permeable itaconate derivatives (OI and DI) were
used in this model.
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Pro- and anti-inflammatory gene expression as well as regulatory changes of
associated transcription factors (PPARγ), which were reported to be associated
with cancer progression in sporadic CC were assessed.
The results from our in-vitro studies were combined with RNA-seq data that were
obtained from several databases that were either publicly available or primary
sources from University studies. Age- and obesity-related genes of the NOTCH4GATA4-IRG1 axis were identified and a gene network was created using
functional annotation analysis (Ingenuity software; Figure 3). The effects of
obesity-related hormones and itaconate on these target genes were studied invitro. Finally, survival analyses were performed to determine genes that are
associated with decreased overall survival in patients with sporadic CC.

e.

Cell culture
The human leukemia cell line THP-1 (TIB202, RRID: CVCL_0006) was

purchased from the American Type Culture Collection (ATCC, Manassas, USA
(catalog no. ) and authenticated using short tandem repeat analysis (133). Cells
were incubated in RPMI-1640 medium (ATCC, Manassas, USA) supplemented
with 10% fetal bovine serum (FBS) (ATCC, Manassas, USA), 10,000 units/mL
penicillin, 10 mg/mL streptomycin, 25 μg/mL amphotericin B and maintained at
37 °C with 5% CO2. THP-1 cells were seeded at 3x105 cells/ml into 24-well cell
culture plates and transformed into an M2-like macrophage phenotype within 14
days. Cells were differentiated into “young M0” macrophages using 100ng/ml
phorbol 12-myristate-13-acetate (PMA) (Sigma-Aldrich) for 72 hours. After 48
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hours of rest in medium without PMA, the cells were polarized into an M2-like
anti-inflammatory phenotype by treatment with 20ng/ml IL-4 (R&D Systems,
Minnesota, USA) and 20ng/ml IL-13 (R&D Systems, Minnesota, USA) for 96
hours. In order to compare macrophages that were actively polarized into an M2like phenotype with M0 macrophages that rested without polarization treatment,
an alternative “aged M0” macrophage type was created by allowing differentiated
macrophages to rest in growth medium alone for 5 days after PMA treatment
rather than polarizing them with interleukins. Our protocol for creating an M2-like
macrophage subtype has been published (134) (Figure 6, Appendix). Doseresponse experiments were performed for each treatment by incubating cells
with either leptin (n=20), OI (n=20) or DI (n=20) (Sigma-Aldrich, St. Louis, USA).
Cellular cytokine expression after treatment with four different doses of each
compound (n=5) was determined at four time points including 3, 6, 18 and 24
hours of cell treatment (96).
HT-29 CC cells were seeded at a cell density of 2x105/ml/well into 24-well
cell culture plates, followed by a 24-hour resting period. Cells were then treated
with a dose of either leptin (n=10), adiponectin (n=10), OI (n=10) or DI (n=10) for
3, 6, 18 and 24 hours, respectively.
In coculture, THP-1-derived macrophages and HT-29 CC cells were
combined for 24 hours before cell treatment with either one dose of leptin (n=10)
or adiponectin (n=10).
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f.

Patient samples

All patients signed written informed consent. This study was approved by the
University of Louisville Institutional Review Board and adheres to the
requirements of the Declaration of Helsinki. Twenty consecutive colon cancer
patients aged 40-81 years were included with primary surgery and curative
resection. Inclusion criteria were diagnosis of sporadic colon adenocarcinoma
without evidence of familial adenomatous polyposis (FAP) or Lynch-syndrome,
and a minimum BMI of 18.5 kg/m2 with no limitations on gender or age. Exclusion
criteria were a history of inflammatory bowel disease, and neoadjuvant treatment
for cancer including chemotherapy and/or radiation.
Paired tissue samples of CC tissue and adjacent normal colon tissue were
collected from each patient. Normal colon tissue was harvested at >5cm distance
from the tumor. Furthermore, 10 ml blood samples were collected immediately
prior to surgery. All samples were processed for storage immediately after
collection and kept at -80°C.
RNA sequencing (RNA-seq) data was obtained from The Cancer Genome
Atlas (TCGA) (n=40), the European Genome-Phenome Archive (EGA) (n=69)
(135, 136) and the ColoCare study from the University of Utah (n=12) (137).
(EGA data is hosted by the European Bioinformatics Institut (EBI) and the Centre
for Genomic Regulation (CRG), under accession number EGAD00001000215.)
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g.

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from cells using the RNeasy purification kit (Qiagen,
Maryland, USA). RNA was quantified with spectrophotometry (NanoDrop 1000,
Thermo Scientific, Massachusetts, USA) and 20ng of total RNA was used to
perform reverse transcription to cDNA according to the manufacturer’s protocol.
TaqMan Gene Expression Assays (Applied Biosystems, California, USA) and
Fast Advanced Master Mix (Applied Biosystems, California, USA) were used for
quantitative real-time PCR (qRT-PCR) using StepOne Real-Time PCR systems
(Applied Biosystems, California, USA). Results for each target gene were
normalized to 18S as the housekeeping gene and are given as mean ΔCT
values.

h.

Cell supernatant preparation and Enzyme-linked Immunosorbent
Assays

Cell supernatants of cells in culture were collected and spun down at 1600 rpm
for 7 minutes and separated from remaining cells. IL-10 and IL-8 concentrations
were measured in the supernatants of THP-1 monocytes, “young M0”, “aged M0”
and M2-like macrophages according to the manufacturer’s protocol using Human
IL-10 and Human IL-8 ELISA Kits (Invitrogen, California, USA).
The enzyme ACOD1, encoded by Human Immune-Responsive
Gene 1 (IRG1), was measured in colon cancer and normal colon patient tissue
samples using ELISA (IRG1-ELISA Kit, MyBioSource, Inc., San Diego, CA, USA)
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as per manufacturer’s protocol. Protein concentrations are given per ug of total
protein of the respective sample.

i.

Flow cytometry

Macrophages were lifted from 24-well plates using the cold shock method by
incubating cells with ice-cold PBS/5% FBS and placing them on ice for 45
minutes. Following this step, cells were mechanically detached using cell
scrapers and washed with cold PBS/5% FBS.
THP-1 cells (n=5), young M0 (n=5) and M2 macrophage-like cells (n=5)
were investigated. Non-specific binding of staining antibodies was inhibited by
incubation with Fcγ-receptor block (BD Pharmingen, San Diego, USA) at room
temperature for 10 minutes. Cells were then stained according to the
manufacturer’s instructions (BD Parmingen, San Diego, USA) with FITCconjugated mouse anti-human CD14 and CD80 antibodies, with PE-conjugated
mouse anti-human CD11b antibodies and with PE-Cy5-conjugated mouse antihuman CD206 antibodies and their isotype-matched IgG for 30 minutes at 4 °C.
Cells were then fixed with 1% formaldehyde. 20,000 cells were acquired for each
measurement.
Four-color flow cytometric analysis was performed and fluorescence
quantitated using a BD FACSCalibur flow cytometer with CellQuest software (BD
Biosciences, San Diego, USA). Gating of cells was carried out to exclude cell
debris according to forward and side scatter. Cell viability after processing cells
for flow cytometry with detachment of macrophages from cell culture plates was
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determined in a representative set of samples (n=6) after incubating the cells with
7-aminoactinomycin-D (7-AAD) for 5 minutes.

j.

Liquid Chromatography with tandem mass spectrometry itaconate
level analysis of patient serum and colon tissue

Itaconate levels in colon cancer and normal colon patient tissue and in patient
plasma samples were analyzed using liquid chromatography with tandem mass
spectrometry (LC-MS/MS). An AB SCIEX API 4000TM tandem mass
spectrometer (Concord, ON, Canada) was coupled to Waters Acquity UPLC®
BEH C18 columns (2.1×100 mm, 1.7 μm), coupled with VanGuard T3
precolumns (2.1×5 mm, 1.7 μm) (Waters, Milford, MA, USA). The column
temperature was held at 40°C, the injection volume was 5 μl, and the flow rate
0.25 mL/min. The mobile phase (buffer A) consisted of 0.1% formic acid-water
and buffer B was comprised of acetonitrile. Mass spectrometry conditions were:
500°C, ion spray voltage (IS): -4500V, curtain gas (CUR): 25psi, gas 1 (GS1):
50psi, gas 2 (GS2): 60psi.

k.

Statistical analysis

The descriptive statistics for ΔCt values were compared among the treatment
dose groups for each respective gene by treatment and time point. The mean
ΔCt values with either 95% confidence intervals or standard error of the mean
(SEM) were presented (138). Significant maximum fold changes (FC) over all
doses at various time points are reported.
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A one-way Analysis of Variance (ANOVA) test was performed for each
respective gene, treatment and time point. The p-values were reported for the
comparisons between dose groups, with a treatment confirmed as significant in
the case of at least 2 significant changes in gene expression at 2 consecutive
doses and 2 different time points (139).
All calculations were performed using SAS System V9 statistical software (SAS
Institute Inc., North Carolina, USA) (140).

i.

Differential gene expression analysis

RNA-seq data from forty CC cases with matching normal tissue were
downloaded from The Cancer Genome Atlas (TCGA), each with raw gene counts
for 60,483 gene locations (Table 5) (135). Data in sixty-nine additional CC cases
with matching normal tissue were obtained from the European Genomephenome Archive (EGA) as pair-end raw sequencing files (fastq) (136, 141). The
EGA sequencing files averaged 33 million reads per sample. The quality of the
reads was assessed using FastQC (v.0.10.1), which indicated that no sequence
trimming was necessary (142). The sequences were aligned to the human
reference genome assembly (hg38) using Star (v.2.6) with an average alignment
rate of 97% across the samples (143). Read counts for gene regions were
obtained with HTSeq (v.0.10.0) using Gencode (v22) annotations, the same
annotations used to derive gene counts for TCGA samples (144, 145). This
produced raw counts for the same 60,483 gene locations. The TCGA and EGA
files were merged and filtered to remove low expressed genes, resulting in
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46,634 gene locations. The combined raw read counts were normalized using
the relative log expression (RLE) method and input to a principal component
analysis (PCA) which showed a good separation between the tumor and normal
tissue samples (Figure 5). Differential gene expression for tumors relative to
normal tissue was performed using DESeq2 which utilizes a negative binomial
regression model (146). Patient number was added as a covariate to the
regression model to account for sample pairing.
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Figure 5. Principal component analysis (PCA) on tumor and normal samples.

Legend to Figure 5

Three PCA biplots with samples plotted in two dimensions according to their projections onto principal component 1 and 2
(A), principal component 1 and 3 (B) and principal component 2 and 3 (C).
Normal colon tissue samples are shown in orange, cancer (tumor) colon tissue samples are shown in blue. The percent
variance associated with each particular principal component is shown in parentheses on the x- and y-axes. 7.6% of the
variability across samples (PC3) is largely due to differences in tissue type, separating tumor and normal colon samples
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(B, C).

ii.

Patient survival analysis

There was information regarding patient survival for one hundred eighty-five
colon tumor samples retrieved from TCGA (Table 5). Twelve additional tumor
samples with survival information were available from the University of Utah
(ColoCare study) as paired-end raw sequencing files (fastq).
The Utah sequencing files averaged 28 million reads per sample. FastQC
(v.0.10.1) indicated reads were of good quality and no trimming was necessary.
The sequences were aligned to the human reference assembly (hg38) using the
Star (v.2.6) aligner with an average alignment rate of 93%. Read counts for gene
regions were obtained with HTSeq (v.0.10.0) using Gencode (v22) annotations.
The TCGA and Utah samples were merged and filtered to exclude low expressed
genes, and raw read counts normalized using the RLE method. Kaplan-Meier
curves and significance levels were generated using the survival package
(v3.2.7) in R to determine whether there was an association between IRG1
expression and patient survival (147, 148).
Prism 9 (GraphPad Software, Inc., La Jolla, CA, USA) was used for
statistical analysis, and data are shown as mean ± standard deviation or mean
and 95% confidence intervals.
A McNemar analysis of binominal gene expression data of patient samples was
performed. Paired samples were compared using the Wilcoxon signed rank test,
and unpaired samples compared using the Mann-Whitney U test with a
significance level set at 5% (2-tailed).
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Furthermore, a Spearman correlation analysis was performed and graphs were
created using Microsoft Excel Version 2107.
RNA-seq data analyses for differential gene expression and survival
analyses were conducted using R (R Foundation for Statistical Computing,
Vienna, Austria) (148).

Table 5
Sample sizes (n) for RNA sequencing data and respective analysis (differential
gene expression and survival analysis)

Dataset

TCGA
EGA
ColoCare
study
Total

RNA-seq data

RNA-seq data

Differential gene
expression
(paired samples)
40
69

Survival
(metadata on survival
available)
185
-

-

12

109

197

TCGA = The Cancer Genome Atlas; EGA = European Genome-Phenome
Archive
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CHAPTER V

A CELL CULTURE MODEL OF M2-MACROPHAGE MARKER EXPRESSION IN
COLON CANCER

INTRODUCTION

Macrophages have various roles in the control of infections, wounds and cancer
development, including inflammation, proliferation and tissue remodeling (149,
150). Tissue macrophages induce responses that can have either local or
systemic effects, ranging from the regulation of wound healing to the induction of
acute phase protein synthesis through hepatocytes, thereby affecting systemic
inflammation and metabolism (150, 151).
Macrophages are divided into two major subtypes depending on their
origin. Contrary to the erroneous assumption that tissue macrophages mostly
originate from circulating bone marrow monocytes that invade tissues, most local
macrophage populations are derived from embryonic progenitors that are seeded
before birth (149, 152, 153). These fetal macrophages initially evolve from the
yolk sac blood islands that develop during the first two weeks of gestation and in
adults they are believed to maintain their population by self-renewal (154).
Whether they can actually persist through adulthood and to which extent they
replenish their populations is currently still discussed (155).
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In contrast, bone marrow derived tissue macrophages are part of the wellestablished mononuclear phagocytic system (MPS) and evolve from circulating
peripheral monocytes (152). Among the mononuclear phagocytic lineage,
macrophages represent the final cell type after differentiation of monocytes that
originate in the bone marrow (152). The monocyte-like THP-1 cell line was
derived from peripheral monocytes of a one-year-old infant with acute monocytic
leukemia and has been widely used as an in vitro model for demonstrating
mechanisms in human monocytes and macrophages (133, 156). THP-1 cells can
be differentiated into macrophage-like cells and then polarized into either
proinflammatory M1 or anti-inflammatory M2 phenotypes. Due to their high
plasticity macrophages can continuously switch between a predominantly
proinflammatory or mostly anti-inflammatory state (157). Numerous methods
have been described for differentiating THP-1 monocytes and for polarizing them
into either M1 or M2 macrophages (158-162). Depending on the desired outcome
of a study, different reagents are used to induce differentiation and polarization
(160, 161, 163). While differentiation of primary monocytes is induced using
granulocyte macrophage colony-stimulating factor (GM-CSF) or macrophage
colony-stimulating factor (M-CSF), THP-1 cells require protein kinase C
activators, such as PMA or byrostatin for differentiation into macrophages (164).
IL-4 or a combination of IL-4 and IL-13, TGF-β1 or IL-10 can be used for
polarization of THP-1 monocyte-derived macrophages (162, 165). Comparison of
studies using a variety of methods, however, is problematic due to the lack of
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standardized and established procedures, that use well-defined macrophage
subtypes.
Macrophages are characterized by their high plasticity, changing their cellular
metabolism to switch between M1- and M2-like phenotypes (166). This
dichotomous model cannot fully describe their characteristics, since
macrophages, specifically TAM, do not exclusively express either M1- or M2-like
markers. Macrophage characterization based on this paradigm is, however,
widely-used and the fundamental basis for further functional analyses (167, 168).
Proinflammatory M1-like markers, such as CD80, TNF-α, CXCL10, tend to be
associated with an anti-tumor immune response, while macrophages expressing
other proinflammatory cytokines (IL-1β, IL-6) can mediate tumor cell migration
and cancer progression (169, 170). Predominantly anti-inflammatory markers,
such as CD206, IL-10, IL-8, CCL8, and CCL22 are known to be associated with
advanced tumor stage and poor survival (171).
Furthermore, TAM express tumor-promoting mediators that are involved in tumor
neovascularization, such as matrix metalloproteinases (MMP) and ADAM
metallopeptidase with thrombospondin type 1 motif 1 (ADAMTS1) (172, 173).
AP-1 is closely related to cell proliferation differentiation and apoptosis and
mediates proinflammatory cytokine expression in macrophages (174).
Alpha/beta-hydrolase domain containing 5 (ABHD5), a key enzyme in lipolysis
regulating tumor biology (175) and toll like receptor 4 (TLR4), induced by fatty
acids and mediating NFκB pathways, both also play an important role in TAMmediated tumor progression (176). Another cancer-related gene involved in lipid

70

metabolism and macrophage activation is monoacylglycerol lipase (MGLL)
contributing to lipid accumulation in macrophages and regulating tumor
progression (176).
In the tumor microenvironment, TAM predominately have anti-inflammatory M2like attributes that are particularly associated with tumor progression and poor
overall patient survival (18, 59, 177). In order to investigate the mechanisms
mediated by anti-inflammatory TAMs in a cell culture model, a distinct M2-like
macrophage subtype is required. Therefore, in vitro inflammatory stimuli must be
overcome, including the mechanical stress to the cells as a consequence of
media changes, and/or cell treatment with proinflammatory compounds, such as
PMA to induce monocyte differentiation (178, 179).
The aim is to create and characterize THP-1 monocyte-derived macrophages
after differentiation and polarization into a distinct M2-like subtype within 14 days.
In order to compare macrophages that were actively polarized into an M2-like
phenotype with M0 macrophages that rested without polarization treatment, an
alternative “aged M0” macrophage type was created by allowing differentiated
macrophages to rest in growth medium alone for 5 days after PMA treatment
rather than polarizing them with interleukins. An overview of the created cell
types that were compared to one another is shown in Figure 6. Herein cytokine
and tumor-associated marker gene expression, protein secretion and cell surface
marker expression of cells were investigated using quantitative real-time
polymerase chain reaction (qRT-PCR), enzyme-linked immunoassay (ELISA)
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and flow cytometry. Detailed methods are described in Chapter IV and
Appendix.
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Figure 6. Model for differentiation and polarization of THP-1 monocytes into a distinct M2-like macrophage phenotype.
THP-1 monocytes are incubated in growth medium with PMA (“young M0” macrophage). Differentiated macrophages are
then polarized using IL-4 and IL-13 (M2 macrophage).
Alternatively, young M0 macrophage-like cells were incubated in growth medium alone (“aged M0” macrophages).

PMA = phorbol 12-myristate-13-acetate; IL = interleukin

RESULTS

i.

Expression of pro- and anti-inflammatory markers in THP-1
monocytes, M0 and M2 macrophages

Cells were differentiated into “young M0” macrophages using 100ng/ml PMA
(Sigma-Aldrich) for 72 hours. After 48 hours of rest in medium without PMA, the
cells were polarized into an M2-like anti-inflammatory phenotype by treatment
with 20ng/ml IL-4 (R&D Systems, Minnesota, USA) and 20ng/ml IL-13 (R&D
Systems, Minnesota, USA) for 96 hours. In order to compare macrophages that
were actively polarized into an M2-like phenotype with M0 macrophages that
rested without polarization treatment, an alternative “aged M0” macrophage type
was created by allowing differentiated macrophages to rest in growth medium
alone for 5 days after PMA treatment rather than polarizing them with
interleukins.
Pro- and anti-inflammatory marker expression was significantly different among
all cell types for CD80, TNF-α, IL-1β, CXCL10, CD206, IL-10, IL-8/CXCL8,
CCL18, CCL22; each with p=<0.001, and for IL-6 p=0.033 (Table 6 and 7). The
p-values of pairwise comparisons are provided in Table 8. Expression patterns
(mean ΔCT values) of all markers for the respective cell types are shown as a
heat map in Figure 7.
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Table 6
Expression patterns (ΔCT values) of proinflammatory markers among cell types

CD80

THP-1
(ΔCT)
N=16
26.27 ± 1.55

Young M0
(ΔCT)
N=32
24.36 ±3.37

Aged M0
(ΔCT)
N=40
22.87 ± 0.58

M2
(ΔCT)
N=80
20.79 ± 0.54

TNF-α

17.88 ± 1.47 18.53 ± 0.91

18.57 ± 0.45

17.97 ± 0.73

<.001

IL-1β

21.96 ± 0.51 14.78 ± 3.54

20.18 ± 0.72

21.84 ± 0.55

<.001

IL-6
28.59 ± 1.22 27.26 ± 1.74
CXCL10 25.75 ± 1.24 21.20 ± 0.89

26.92 ± 6.41
20.21 ± 1.52

26.04 ± 1.53
22.34 ± 0.76

0.033
<.001

Marker
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p-value

Significant pairwise differences

<.001

All
THP-1 – young M0;
THP-1 – Aged M0;
Young M0 – M2;
Aged M0 – M2
THP-1 – Young M0
THP-1 – Aged M0
Young M0 – Aged M0
Young M0 – M2
Aged M0 – M2
THP-1 – M2;
All

Marker expression was investigated using quantitative real-time PCR. Results are shown as mean ΔCT values and
standard deviations (SD) for all cell types. N-numbers represent the number of wells of the respective cell type created.
To compare all groups, a one-way ANOVA model with a post hoc Benjamini-Hochburg correction was used.
Significant results of pairwise comparisons between cell types are listed.
CD = cluster of differentiation; TNF-α = tumor necrosis factor α; IL = interleukin; CXCL = C-X-C Motif Chemokine Ligand;
CCL = C-C Motif Chemokine Ligand

Table 7
Expression patterns (ΔCT values) of anti-inflammatory markers among cell types

CD206
IL-10

THP-1
(ΔCT)
N=16
28.15 ± 1.14
28.22 ± 1.55

Young M0
(ΔCT)
N=32
23.99 ± 0.71
22.88 ± 0.67

Aged M0
M2
(ΔCT)
(ΔCT)
p-value
N=40
N=80
19.73 ±0.50 18.80 ± 0.47 <.001
19.38 ± 0.44 18.70 ± 0.47 <.001

IL-8

19.41 ± 1.39

14.93 ± 2.21

20.69 ± 0.82 19.45 ± 0.43

<.001

CCL18

28.95 ± 0.91

28.06 ± 0.95

23.80 ± 0.42 17.23 ± 0.34

<.001

CCL22

17.96 ± 0.55

19.45 ± 1.10

19.03 ± 0.46 19.03 ± 0.40

<.001

Marker

Significant pairwise
differences
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All
All
THP-1 – Young M0;
THP-1 – Aged M0;
Young M0 – Aged M0;
Young M0 – M2;
Aged M0 – M2
All
THP-1 – Young M0;
THP-1 – Aged M0;
THP-1 – M2;
Young M0 – Aged M0;
Young M0 – M2;

Legend to Table 7
Marker expression was investigated using quantitative real-time PCR. Results are shown as mean ΔCT values and
standard deviations (SD) for all cell types.
N-numbers represent the number of wells of the respective cell type created.
To compare all groups, a one-way ANOVA model with a post hoc Benjamini-Hochburg correction was used.
Significant results of pairwise comparisons between cell types are listed.

CD = cluster of differentiation; IL = interleukin; CXCL = C-X-C Motif Chemokine Ligand; CCL = C-C Motif Chemokine
Ligand
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Table 8

Corrected p-values for all pairwise comparisons of pro- and anti-inflammatory gene expression between cell
Types

Marker
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CD80
TNF-α
IL-1β
IL-6
CXCL10
CD206
IL-10
IL-8
CCL18
CCL22

THP-1
vs
Young M0
0.000
0.016
0.000
0.245
0.000
0.000
0.000
0.000
0.000
0.000

THP-1
vs
Old M0
0.000
0.015
0.000
0.201
0.000
0.000
0.000
0.001
0.000
0.000

THP-1
vs
M2
0.000
0.851
0.796
0.042
0.000
0.000
0.000
0.923
0.000
0.000

Young M0
vs
Old M0
0.000
0.879
0.000
0.679
0.000
0.000
0.000
0.000
0.000
0.005

Young M0
vs
M2
0.000
0.004
0.000
0.201
0.000
0.000
0.000
0.000
0.000
0.002

Old M0
vs
M2
0.000
0.004
0.000
0.245
0.000
0.000
0.000
0.000
0.000
0.990

p<0.05 indicates a significant pairwise comparison (paired t-test). Non-significant comparisons are bold.
CD = cluster of differentiation; TNF-α = tumor necrosis factor α; IL = interleukin; CXCL = C-X-C Motif Chemokine Ligand;
CCL = C-C Motif Chemokine Ligand

Figure 7. Marker gene expression using qRT-PCR among cell types.

Heat map of marker gene expression (ΔCT values) of pro- and anti-inflammatory
markers among all cell types. Lowest gene expression is depicted by a red color,
highest expression by green.

Proinflammatory macrophage markers: CD80, TNFα, IL-1β, IL-6, CXCL10.
Anti-inflammatory macrophage markers: CD206, IL-10, IL-8, CCL18, CCL22
CD = cluster of differentiation; TNF-α = tumor necrosis factor α; IL = interleukin;
CXCL = C-X-C Motif Chemokine Ligand; CCL = C-C Motif Chemokine Ligand
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1.

M1-associated marker expression

Overall p-values with means and standard deviations of PCR ΔCT values for all
cell types are shown in Table 6.
Pairwise comparisons between groups demonstrated a significant
difference of M1-associated CD80 between cell types due to upregulation of
CD80 in “young M0”, “aged M0” and M2 macrophages compared to THP-1
monocytes (Figure 7, Table 6). The pro-inflammatory marker TNF-α was
significantly downregulated in “young M0” and “old M0” compared to M2
macrophages and compared to THP-1 monocytes. The difference between M2macrophages and THP-1 cells at baseline was not statistically significant (Figure
7, Table 6). The M1-associated marker IL-1β was significantly upregulated in
“young M0” and “aged M0” macrophages compared to THP-1 cells as well as
compared to M2 subtype macrophages. “Young M0” macrophages showed the
highest level of IL-1β expression (Figure 7, Table 6). IL-6 was significantly
upregulated in “young M0”, “aged M0” and M2 macrophages compared to THP-1
cells (Figure 7, Table 6). CXCL10 showed a significantly higher expression in
“young M0”, “aged M0” and M2 macrophages compared to THP-1 monocytes.
The highest level of CXCL10 expression was demonstrated in both M0 cell
groups (Figure 7, Table 6).

2.

M2-associated marker expression

Means, standard deviations and overall p-values of PCR ΔCT values for all cell
types are shown in Table 7.
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CD206 was most highly expressed in M2 macrophages, with “young M0”,
“aged M0” and M2 cells showing significant upregulation compared to THP-1
monocytes (Figure 7, Table 7). The M2-associated marker IL-10 showed the
same expression pattern as CD206, with the highest expression in M2
macrophages. “Aged M0” macrophages showed significantly higher CD206
expression compared to “young M0” macrophages or THP-1 cells, (Figure 7,
Table 7). IL-8/CXCL8 was significantly upregulated in “young M0” macrophages
compared to “aged M0”, M2, and THP-1 cells. The highest M2-associated CCL18
expression was seen in M2 macrophages with significant upregulation compared
to all other cell types. “Aged M0” cells showed a significantly higher expression
compared to “young M0” and THP-1 cells (Figure 7, Table 7). CCL22 was
significantly downregulated in all cell types compared to THP-1 cells. (Figure 7,
Table 7).

ii.

Expression of tumor-associated markers in THP-1 monocytes, M0
and M2 macrophages

Tumor-associated marker expression was significantly different among all cell
types for MMP2, MMP7, MMP9, MMP12, ABHD5, ADAMTS1, AP-1, MGLL
each with p=<0.001 (Table 9). TLR4 expression showed no significant difference
among cell types. The corresponding p-values of pairwise comparisons are
shown in Table 10.
All investigated tumor-promoting MMPs were significantly increased in
M2-like macrophages, with MMP2 showing the lowest upregulation in M2-like
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macrophages compared to THP-1 monocytes (Table 9, Table 10). The
metallopeptidase ADAMTS1 was significantly downregulated in M2-like, “young
M0” and “aged M0” macrophages compared to THP-1 cells (Table 9, Table 10).
ABHD5, a lipolytic factor either potentiating tumor growth or functioning as a
tumor suppressor in certain types of cancer, was significantly downregulated in
M2-like macrophages compared to all other cell types (Table 9, Table 10).
Upregulation of MGLL, a key enzyme in lipid metabolism that also has both
tumor promoting and suppressing effects, was most evident in both M0
phenotypes compared to THP-1 monocytes, but also significant in M2-like
macrophages (Table 9, Table 10).
Expression of the immune-response receptor TLR4 did not differ between cell
types. The transcription factor AP-1, which exerts a dual role among different
types of cancers, showed slight upregulation in “young M0” macrophages
compared to THP-1 cells, but no difference was found comparing M2-like
macrophages versus THP-1 monocytes (Table 9, Table 10).
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Table 9
Expression patterns (ΔCT values) of tumor-associated markers among cell types

MMP2
MMP7
MMP9

THP-1
(ΔCT)
N=16
19.59 ± 0.27
28.33 ± 3.21
16.55 ± 0.63

Young M0
(ΔCT)
N=32
19.13 ± 1.10
18.29 ± 0.68
10.02 ± 0.48

Aged M0
(ΔCT)
N=40
16.72 ± 0.36
25.30 ± 0.92
11.15 ± 0.38

M2
(ΔCT)
N=80
17.87 ± 0.34
22.92 ± 0.61
10.59 ± 0.42

MMP12

27.31 ± 1.80

19.62 ± 2.41

22.80 ± 0.66

19.04 ± 0.64

<.001

ADAMTS1

19.39 ± 0.32

20.40 ± 1.54

20.29 ± 0.71

21.61 ± 1.13

<.001

ABHD5

18.47 ± 0.32

18.29 ± 0.63

18.78 ± 1.03

19.68 ± 1.54

<.001

MGLL

21.96 ± 0.46

16.74 ± 1.51

16.94 ± 0.46

18.25 ± 0.37

<.001

TLR4

20.24 ± 0.25

18.27 ± 0.71

19.18 ± 3.43

18.77 ± 2.50

0.056

AP-1

25.80 ± 1.20

25.05 ± 2.90

27.00 ± 0.89

26.25 ± 1.48

<.001

Marker

p-value
<.001
<.001
<.001

Significant pairwise
differences
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All
All
All
THP-1 – Young M0;
THP-1 – Aged M0
THP-1 – M2;
Young M0 – Aged M0;
Aged M0 – M2;
THP-1 – Young M0;
THP-1 – Aged M0;
THP-1 – M2;
Young M0 – M2;
Aged M0 – M2;
THP-1 – M2;
Young M0 – M2;
Aged M0 – M2;
THP-1 – Young M0;
THP-1 – Aged M0;
THP-1 – M2;
Young M0 – M2;
Aged M0 – M2;
THP-1 – Young M0;
Young M0 – M2;
Aged M0 – M2;

Legend to Table 9.

Marker expression was investigated using quantitative real-time PCR. Results are shown as mean ΔCT values and
standard deviations (SD) for all cell types. N-numbers represent the number of wells of the respective cell type created.
To compare all groups, a one-way ANOVA model with a post hoc Benjamini-Hochburg correction was used.
Significant results of pairwise comparisons between cell types are listed.

MMP = matrix metalloproteinase; ADAMTS1 = ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1; ABHD5 =
alpha/beta-hydrolase domain containing 5; MGLL = monoglyceride lipase; TLR4 = toll like receptor 4; AP-1 = activator
protein 1
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Table 10

Corrected p-values for all pairwise comparisons of tumor-associated gene expression between cell types

Marker
ABHD5
ADAMTS1
AP-1
MGLL
MMP2
MMP7
MMP9
MMP12
TLR4

THP-1
vs
Young M0
0.624
0.004
0.046
0.000
0.013
0.000
0.000
0.000
0.052

THP-1
vs
Old M0
0.448
0.006
0.335
0.000
0.000
0.000
0.000
0.000
0.210

THP-1
vs
M2
0.001
0.000
0.120
0.000
0.000
0.000
0.000
0.000
0.103

Young M0
vs
Old M0
0.124
0.662
0.120
0.268
0.000
0.000
0.000
0.000
0.210

Young M0
vs
M2
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.061
0.418

Old M0
vs
M2
0.001
0.000
0.002
0.000
0.000
0.000
0.000
0.000
0.418
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p<0.05 indicates a significant pairwise comparison (paired t-test). Non-significant comparisons are bold.

ABHD5 = alpha-beta hydrolase domain-containing 5; ADAMTS1 = ADAM Metallopeptidase With Thrombospondin Type 1
Motif 1; AP-1 = activator protein 1; MGLL = monoacylglycerol lipase; MMP = matrix metalloproteinase; TLR4 = toll like
receptor 4

iii.

Anti-inflammatory interleukin-8 and interleukin-10 protein expression
in M0 macrophages and M2 macrophages compared to THP-1
monocytes

Protein expression of the anti-inflammatory cytokine IL-8/CXCL8 was significantly
different among cell types (p=<0.001) (Figure 8A). IL-8/CXCL8 protein
expression did not significantly differ between THP-1 cells, “aged M0” cells and
M2 macrophages. “Young M0” cells showed a variable, but significantly
increased IL-8/CXCL8 protein expression (19989.56 [95% CI 12930.32,
27048.80] pg/ml) compared to the other cell types.
Protein expression of the M2-like cytokine IL-10 differed significantly among cell
types (p=<0.001) (Figure 8B). IL-10 was not detectable in THP-1 cells. There
was no significant IL-10 protein expression in “young M0” macrophages. IL-10
protein was significantly expressed in “aged M0” (15.43 [95% CI 9.82, 20.98]
pg/ml) and in M2 macrophages (13.29 [95% CI 8.75, 17.82] pg/ml), with no
significant difference between these two cell types.
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Figure 8. Pirate Plots of protein expression of anti-inflammatory markers among cell types (A) interleukin 8 (IL-8), (B)
interleukin 10 (IL-10).

IL = interleukin; CXCL = C-X-C motif chemokine ligand

iv.

Pro- and anti-inflammatory cell surface markers

Cell viability of differentiated macrophages after incubating cells with 7-AAD was
>95% throughout all samples.
The myeloid marker CD14 was expressed in 2.06%±0.46% of THP-1 cells.
“Young M0” macrophages showed low CD14 expression (3.87%±1.81% of cells).
There was, however, a distinct upregulation of CD14, which was demonstrated in
69.18%±3.48% of M2 macrophages (Figure 9).
THP-1 monocytes exhibited low CD11b expression (4.39%±1.36% of cells). A
significant upregulation of CD11b could be demonstrated in M2 macrophages
(76.37%±4.68%) (Figure 9), with a lower expression in “young M0” macrophages
(11.47%±2.65%).
The M1-like marker CD80 was not markedly expressed in any cell type
(0.11%±0.07% of THP-1 cells; 0.36%±0.17% of M0 cells and 0.05%±0.01% of
M2 macrophage-like cells) (Figure 9).
Expression of the M2-like marker CD206 was low among THP-1 cells
(0.22%±0.07%) and “young M0” macrophages (0.98%±0.64%), with a significant
upregulation in M2 macrophages (58.08%±2.74%) (Figure 9).
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Figure 9. Flow cytometry fluorescence analysis for surface marker expression in M2 macrophages.

Representative density plots of cell surface marker expression of (A) the myeloid markers CD14 (FITC, FL1-H) and
CD11b (PE, FL2-H) and of (B) the proinflammatory marker CD80 (FITC, FL1-H) and the anti-inflammatory marker CD206
(PE-tandem conjugate, FL3-H) in M2 macrophage-like cells after the 14-day cell treatment. Total percentages of cells are
shown in each quadrant.

CD = cluster of differentiation; FITC = Fluorescein isothiocyanate; PE = phycoerythrin; FL = fluorescence channel

DISCUSSION

Macrophages mediate central mechanisms in wound healing, fibrosis and cancer
growth. Specifically, the proportion of anti-inflammatory M2-like macrophages is
associated with advanced tumor stage and decreased overall survival in certain
types of cancers (18, 180, 181). Currently there is no distinct M2-like
macrophage subtype based on an established reproducible protocol, that makes
studies investigating functional analyses in cancer research comparable. Various
techniques for differentiating and polarizing macrophages are available, but
experimental models are rarely characterized and lack reproducibility (158-162).
We have provided a protocol of a cell line model for differentiating and polarizing
THP-1 monocytes within 14 days and herein characterize the distinct M2-like
macrophage subtype that is thereby created (182). This provides the basis for
investigating mechanisms mediated by anti-inflammatory macrophages in vitro.
One of the limitations of this study is the use of a human cell line model
rather than primary cells as a basis to investigate human macrophage
mechanisms in vivo. In contrast, primary macrophages are characterized by
great variation in marker expression patterns and have different functional roles
according to their source of origin (183). Previous data showed that PMA-treated
THP-1 macrophages did not completely mimic the complexity of primary MDM
activation (184). The use of a cell line, however, can provide a reproducible and
standardized model to recreate functional responses in vitro. Furthermore,
characteristics of THP-1 derived cells used for mimicking macrophage
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mechanisms in vivo can be altered to achieve similar marker profiles to primary
macrophages. Another limitation is the complexity of myeloid cell characterization
due to cell plasticity and the wide variety of functional abilities of these cells. This
leads to limited characterization of M2 macrophage-like cells created by this
protocol. The cell treatment scheme of this study, however, demonstrates the
reproducible creation of a distinct M2-like phenotype of macrophages, that can
be further characterized depending on the intended experimental setting (134).
Cytokine mRNA and protein expression and flow cytometry used in this study
demonstrated a clear anti-inflammatory shift of differentiated macrophages and
differences between resting cells versus cells receiving polarization treatment.
Further analyses concerning pro- and anti-inflammatory cytokine expression,
protein production, cell surface marker expression as well as functional analyses
of these M2-like macrophages should follow on the basis of the underlying
treatment protocol.
The differentiation of THP-1 monocytes is widely performed by incubating
cells with the proinflammatory compound PMA (160, 178, 179, 185). This method
of differentiation is especially suitable for mimicking primary human monocytederived macrophages (MDM), showing similar characteristics concerning cell
morphology, macrophage surface markers and cytokine profiles (186). Proinflammatory responses of the macrophages that are created by this approach
must decrease in order to obtain non-polarized M0 macrophages and to assure
an adequate M2-like polarization process. For this reason, cells are reported to
rest in medium only after PMA treatment for various periods of time (158, 161,
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185). This model is based on a five-day rest period after PMA incubation,
creating macrophages that mimic primary human MDM in terms of cytoplasmatic
volume and cell surface adherence (185, 187).
The cytokine profile of young M0 macrophages that are described in this
study demonstrated significantly increased expression of the proinflammatory
markers CD80, IL-1β, IL-6 and CXCL10 compared to THP-1 monocytes, while no
difference in TNFα expression was shown. Even though the term “M0
macrophages” defines differentiated macrophages in a resting state,
characteristics of cellular activation (M1-like state) are usually identified in the
real-world setting (188). Therefore, the standardized model presented herein
clearly describes cytokine expression as a baseline threshold for future
experiments. The anti-inflammatory marker IL-8, however, is most highly
expressed in young M0 macrophages, and significantly upregulated compared to
all the other cell types. This was confirmed by protein expression analysis,
showing high variability of IL-8/CXCL8 concentrations among “young M0”
macrophages. Variation in expression levels of IL-8/CXCL8 is a previously
described characteristic of this cytokine in several different cell types, such as
pulmonary epithelial cells or cervical cancer cells (189). THP-1-derived
macrophages have also been reported to show highly variable IL-8/CXCL8
protein expression after treatment with proinflammatory stimuli (187, 189). This
observation is partially understood to result from the functional role of IL8/CXCL8, that involves synchronization of several regulatory pathways, including
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NFκ-B, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase
(p38 MAPK) (187).
The M2-like macrophages created by this model demonstrate a significant
upregulation of the anti-inflammatory markers CD206, IL-10 and CCL18
compared to both “young M0” and “aged M0” macrophage-like cells, with CCL18
upregulation showing the greatest difference in M2-like cells as compared to
either type of M0 cells. This demonstrates that the cell line model of this study is
mimicking primary human MDM, as CCL18 is also abundantly produced by these
cells following M2-like polarization (190). This cytokine induces macrophage
maturation into an M2-like phenotype itself and is known to be produced by TAM
in several different types of cancers (191-193). Both groups of M0 macrophages
did not differ from M2-like cells with respect to CCL22 expression. Production of
IL-10 in M2-like macrophages was confirmed by a significantly increased IL-10
protein expression in these cells compared to that observed in THP-1 monocytes
and young M0 macrophages. IL-10 production in “aged M0” macrophages did not
differ from M2 macrophages on the protein level, however, the variability in IL-10
production was high among “aged M0” cells. IL-10 is reported to be upregulated
in polarized primary human MDM as well, mostly as part of an autocrine
mechanism using the Signal Transducer And Activator Of Transcription 3
(STAT3) pathway (194).
Flow cytometry analysis for cell surface expression markers revealed that
the distinct M2-like subtype that is created by this protocol not only shows high
expression of the anti-inflammatory marker CD206, but also of both myeloid
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markers CD14 and CD11b. The macrophage differentiation marker CD14 is also
highly expressed by primary human MDM as a response to IL-10 and
distinguishes THP-1-derived macrophages from THP-1 cells that are
differentiated into a dendritic cell type with low CD14 expression (195, 196). Coexpression of the myeloid CD11b has been reported in primary human muscle
tissue macrophages (197). Furthermore, the anti-inflammatory M2-like markers
CD206 and IL-10 are expressed by resident macrophages of the colon lamina
propria (198).
The tumor-associated attributes of created macrophages were assessed
focusing on marker genes that play a role in neovascularization as well as
cellular metabolism and therefore macrophage polarization.
MMPs are important cancer-related targets promoting vascularization and
tumor development (172, 173). All investigated subtypes of MMPs were
upregulated in the M2-like macrophage phenotype. The metallopeptidase
ADAMTS1 was significantly downregulated in all cell types compared to THP-1
cells and showed the most evident decrease in M2-like macrophages.
Expression of this protumorigenic gene in M2-like macrophages, however, could
be demonstrated. This suggests that ADAMTS1-related pathways can be
investigated using the distinct M2-like macrophage phentotype presented
herein.In general, many markers regulating tumor development can be
expressed in macrophages and have a dual role depending on the type of cancer
they have been investigated in – such a ABHD5, MGLL, TLR4 or AP-1 (199202). All of these markers are expressed in the M2-like macrophages created by
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this model with AP-1 showing the lowest level of gene expression in M2-like
macrophages. This suggests that changes in gene expression due to cell
treatment or cell signaling can be assessed. The demonstrated tumor-associated
gene expression patterns are the basis for expression changes in different
experimental settings.
A clear similarity of cells created by this model to primary human
macrophages and tumor-associated characteristics of the M2-like phenotype are
to be confirmed by further functional experiments comparing THP-1 derived
macrophages versus primary cells.
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CHAPTER VI
THE ROLE OF ITACONATE IN COLON CANCER PATIENTS

INTRODUCTION

Metabolic overload and chronic inflammation in obese patients leads to
increased oxidative stress and altered cellular metabolism, both of which are
associated with colorectal carcinogenesis (203-205). These mechanisms are
regulated by itaconate, an anti-inflammatory metabolite of the citric acid cycle,
which is specifically produced in macrophages (54). The dicarboxylic acid
itaconate is produced by the mitochondrial matrix enzyme cis-aconitate
decarboxylase 1 (ACOD1). Recent studies demonstrated that itaconate mediates
tumor promoting mechanisms in several types of cancer, such as melanoma,
ovarian cancer, and glioma (35, 206, 207). The role of itaconate in human CC,
however, is currently still unknown (18).
Cancer cells must adapt their cellular metabolism to proliferate rapidly.
Metabolic reprogramming is a hallmark of cancer and various metabolic gene
expression subtypes in CC have been identified. A CC subtype that exhibits
downregulation of lipid metabolic gene expression patterns is associated with
decreased patient survival (208, 209). Lipid metabolism also plays a key role in
the functional subtypes of TAMs that, in turn, regulate inflammation and oxidative
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stress within the tumor microenvironment (210). Macrophage function is
characterized by cell polarization in a dynamic setting, determining either a more
proinflammatory M1-like or an anti-inflammatory M2-like phenotype (211). Both
functional macrophage subtypes use lipid and mitochondrial oxidative
metabolism as their source of energy to a variable extent, and itaconate is
typically produced in classically activated M1-like macrophages (54). Itaconate
production has, however, also been demonstrated in the more anti-inflammatory
M2-like subtype, as part of M2-like macrophage activation via glutamine
metabolism (212). In patients with obesity, a chronic proinflammatory state due to
metabolic dysfunction may cause reprogramming of the cellular metabolism in
tissue-resident macrophages and TAMs, leading to cancer onset and promoting
tumor growth (18).
Within the tumor microenvironment in CC, M2-like macrophages provide
an anti-inflammatory environment and thereby promote cancer progression. A
higher M2/M1-like ratio within the TAM population is associated with advanced
tumor stage and poor patient survival in CC (72, 213). Whether anti-inflammatory
itaconate released by TAMs contributes to this tumor environment, cancer onset
or tumor progression in CC and the association with metabolic dysfunction in
patients with obesity is poorly understood. The aim is to evaluate IRG1 gene
expression, the role of the enzyme ACOD1, and the dicarboxylic acid itaconate in
patients with sporadic colon adenocarcinoma using qRT-PCR, ELISA and mass
spectrometry (LC-MS/MS). Detailed methods are described in Chapter IV.
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RESULTS

i.

Patient demographics

Clinical patient characteristics are shown in Table 11.
Eleven out of 20 patients (55%) were men. The mean age at diagnosis was 65.9
± 14.9 years, with five patients (20%) diagnosed with EOCC at ≤50 years of age.
Mean BMI was 29.0 kg/m2 (range 21.6 – 40.4 kg/m2); with eight patients (40%)
normal weight, three patients (15%) overweight, and nine patients (45%) obese
according to the World Health Organization (WHO) classification (214). Four of
20 patients (20%) presented with cancers with regional or distant metastases,
classified as stage III or IV according to the American Joint Committee on Cancer
(AJCC) classification.
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Table 11

Clinical characteristics of patients (n=20) providing paired CC and normal colon
samples for qRT-PCR, ELISA and mass spectrometry

Gender [% men]
Age [years]
(mean ± SDa)
Tumor stageb [N]
Mean body mass
index (BMI)c [kg/m2]
(mean ± SDa)
Normal weight [N]
Overweight [N]
Obesity class 1 [N]
Obesity class 2 [N]
Obesity class 3 [N]
a

Total
Group
n=20
55

≤50 years of
age
n=5
40

>50 years of
age
n=15
60

65.9 ± 14.9

45.6 ± 4.2

72.6 ± 9.9

-

I (7)
II (9)
III (3)
IV (1)

-

I (2)
II (3)

-

I (5)
II (6)
III (3)
IV (1)

29.0 ± 6.3

32.9 ± 7.7

27.8 ± 5.5

8
3
5
2
2

1
1
1
0
2

7
2
4
2
0

Standard deviation

b American
c Body

Joint Committee on Cancer (AJCC) staging

mass index [kg/m2] according to class of obesity (WHO

classification) (214):
Normal weight: BMI 18.5-24.9
Overweight: BMI 25-30
Obesity class 1: BMI 30-35
Obesity class 2: BMI 35-40
Obesity class 3: BMI >40
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ii.

IRG1 Gene expression, ACOD1 protein analysis and itaconate levels

The role of itaconate in patient samples was analyzed on three different levels,
including IRG1 gene expression, ACOD1 protein expression and by measuring
the dicarboxylic acid itaconate (Figure 10).
The mean delta CT for IRG1 gene expression in CC tissue samples was
27.4 [95% CI (26.0, 28.7)]. IRG1 gene expression was demonstrated in 65% of
CC samples, while only 5% of normal colon samples expressed IRG1 with a ΔCT
of 20.4 (chi-square: 10.083, p=0.002).
On the protein expression level, ACOD1 in CC tissue was significantly
higher compared to normal colon (11.8 ng/ug [95% CI (3.4, 20.2 ng/ug)] versus
3.7 ng/ug [95% CI (0.7, 6.7 ng/ug)]; p=0.002). In young patients, the mean
ACOD1 protein concentration was higher in cancer and normal colon compared
to old patients, however, this did not reach statistical significance (Table 12).
The presence of the macrophage metabolite itaconate could be
demonstrated in both CC and normal colon samples. CC tissue samples showed
a higher mean itaconate level compared to normal colon tissue with a high
variability of levels in both tissue types and no observed significant difference
(216.1 [95% CI (107.8, 324.4)] versus 153.2 [95% CI (103.4, 203.0)]; p=0.294)
(Table 12). In young patients (≤50 years of age); however, tissue itaconate levels
in normal colon were significantly higher compared to old patients (231.2 [95% CI
(124.4, 338.1)] versus 125.3 [95% CI 69.6, 181.1)]; p=0.026) (Table 12).
The distribution of itaconate levels in paired colon tissue and plasma
samples is shown in Figure 11. Plasma levels did not correlate with itaconate
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tissue levels either in cancer samples (rs= -0.20; p=0.414) or normal colon
samples (rs= 0.19; p=0.433). There was, however, a significant positive
correlation between overall plasma itaconate levels and BMI (rs= 0.51; p=0.021)
(Figure 12).

Figure 10. Overview of the evaluation of itaconate on the gene expression,
protein and metabolite level.

IRG1 = immune-responsive gene 1; ACOD1 = aconitate decarboxylase 1
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Table 12
Colon tissue IRG1 gene expression, ACOD1 protein expression and itaconate tissue levels by patient group
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Type of
tissue

Total group
n=20

≤50 years of age
n=5

>50 years of age
n=15

IRG1 gene expression
[ΔCT]

cancer

N=13
27.4 [95% CI (26.0, 28.7)]

N=4
28.1 [95% CI (24.3; 31.9)]

N=9
27.1 [95% CI (25.4, 28.8)]

IRG1 gene expression
[ΔCT]

normal
colon

N=1
20.4

N=1
20.4

-

ACOD1 protein
[ng/ug total protein]

cancer

11.8 [95% CI (3.4, 20.2)]

18.4 [95% CI (0, 57.9)]

9.4 [95% CI (4.1, 14.8)]

ACOD1 protein
[ng/ug total protein]

normal
colon

3.7 [95% CI (0.7, 6.7)]

7.4 [95% CI (0, 20.0)]

2.5 [95% CI (0.1, 4.9)]

Itaconate
[ng/mg]

cancer

216.1 [95% CI (107.8,
324.4)]

214.1 [95% CI (0, 454.9)]

216.9 [95% CI (77.4,
356.3)]

Itaconate
[ng/mg]

normal
colon

153.2 [95% CI (103.4,
203.0)]

231.2 [95% CI (124.4,
338.1)]

125.3 [95% CI 69.6, 181.1)]

IRG1 = Immune-Responsive Gene 1; ACOD1= cis-aconitate decarboxylase 1

Figure 11. Distribution of itaconate levels with mean values (red) among patient
tissue and plasma samples.
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Figure 12. Correlation between plasma itaconate level and Body Mass Index
(BMI) among patients.
Levels of patients >50 years of age are shown in blue, patients ≤50 years of age
are represented in orange.

BMI = body mass index
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iii.

Differential gene expression and survival among RNA sequencing
data

The TCGA cohort (n=40) involved 48% men and patients with a mean age of 71
(range 40-90). Tumor stage was available for 39 out of 40 patients. Stage I was
found in five patients, stage II in 22 patients, stage III in five individuals and stage
IV in seven patients. Metadata such as patient age, gender and tumor stage
were not available for the EGA dataset (n=69).
Out of 109 patients, IRG1 was expressed in 53% of cancer samples
compared to 25% of normal colon tissues (z = 4.68, p=<0.001). Differential
expression analysis showed upregulation of IRG1 in CC tissue relative to paired
normal colon samples (log2 FC = 1.41, corrected p = 0.03).
Survival analysis on IRG1 expression (measured as expressed/not
expressed) showed to have no effect on survival across 197 CC patients at
different stages of tumor progression (Χ2 = 0, p = 0.9). Table 13 displays the
number of events at each stage. No deaths occurred at stage I, and no effect on
survival was found for stage II and III (stage II Χ2 = 1.4, p = 0.2; stage III Χ2 = 1.7,
p = 0.2). However, for the subset of patients with tumors at stage IV, the risk of
death was increased for IRG1 gene expression relative to no expression (Χ2 =
6.3, p = 0.01). Kaplan-Meier curves showing survival rates are shown in Figure
13.
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Table 13
Number of events at different tumor stages
Stage

Deceased

Living

I

0

31

II

11

67

III

14

51

IV

9

14
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Figure 13. Kaplan-Meier curves for patients with stage IV colon.

IRG1 gene expression (blue, dotted line) versus no IRG1 gene expression (red,
solid line).
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DISCUSSION

The macrophage-specific metabolite itaconate is a product of the citric acid cycle
and serves as an anti-inflammatory mediator decreasing oxidative stress (54,
118, 210). Furthermore, its carcinogenic effects in different types of cancers have
previously been described (35, 206, 207). Itaconate therefore has the potential to
provide a link between metabolic dysfunction, obesity and cancer.
To the best of our knowledge, data is lacking with respect to IRG1-related
expression and itaconate levels in human sporadic CC. The findings of this study
demonstrate that itaconate may play a role in patients with sporadic CC and
obesity and that it has the potential to play a major role in young patients with the
increasing trends in obesity and the increasing incidence of EOCC.
The gene expression of IRG1 encoding the enzyme producing itaconate
was detectable in a significantly higher number of cancer samples (65%)
compared to paired normal colon tissue (5%). This was confirmed by RNA-seq
data showing expression in 53% of cancers versus 25% of paired normal colon
samples. Protein expression of ACOD1 confirmed these results demonstrating a
significantly higher amount of ACOD1 protein in cancer samples compared to
normal colon. These findings indicate that IRG1 is amplified in sporadic colon
adenocarcinoma and may serve as an oncogene target in CC. In other types of
cancers, such as human glioma, similar expression patterns of ACOD1 protein
have been described, correlating with tumor stages and recurrence-free survival
(207). As protein expression in these previous reports was classified as either
high or low, quantitative levels of ACOD1 protein in glioma tissue were not
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reported (207). Monocytes derived from ascites fluid of patients with ovarian
carcinoma showed a significantly elevated IRG1 gene expression, enhancing
peritoneal tumor progression (35). Furthermore, increased IRG1 mRNA
expression has been described in the murine cell lines B16 (melanoma), 3LL
(Lewis lung carcinoma) and MC38 (colon adenocarcinoma) (35). These findings
suggest that IRG1-related mechanisms mediate tumor-promoting effects and
may not be specific for patients with CC. The pivotal role of inflammation and
macrophage metabolism in CC, however, points out the particular importance of
the immunosuppressive effects of IRG1, and the metabolic mediator itaconate in
CC (175, 215). Itaconate directly modifies oxidative phosphorylation and
therefore cellular metabolism in TAMs, which is associated with macrophage
polarization and induces reactive oxygen production (ROS) (35). ROS can
mediate tumor-promoting mechanisms through several transcription factors, such
as Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) and
mitogen-activated protein kinases (MAPKs) (216). Furthermore, M2-polarized
TAMs are associated with precancerous dysplasia in colon polyps and poor
patient survival in CC (49, 78). The relationship between itaconate production
and an M2-like macrophage phenotype in CC remains to be further investigated.
The metabolic profile of IRG1-related mechanisms and itaconate may
provide a link between metabolic dysfunction and obesity and EOCC in young
patients. In this study, an association of systemic itaconate and obesity was
demonstrated by showing a positive correlation between preoperative plasma
itaconate levels and BMI (rs=0.51; p=0.020). The chronic inflammatory metabolic
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state in patients with obesity and CC may be associated with a certain phenotype
of peripheral monocytes producing itaconate. A proinflammatory phenotypic
switch of adipose tissue-infiltrating macrophages is described, contributing to
insulin resistance and diabetes in obesity (217, 218). This mechanism could also
be associated with systemic itaconate levels and an increased risk of CC. The
demonstrated correlation analysis cannot confirm a causal relationship between
these variables, and the size of the studied patient cohort is not sufficient to
reveal an empirical correlation. Finding this significant association despite these
limitations, however, suggests systemic itaconate levels to be a target of interest
in patients with higher BMI and CC.
Further investigating the disparities between patients with sporadic CC
>50 years old and young patients with EOCC, a significantly higher level of
itaconate was identified in normal colonic tissue of young patients. Cancer tissue
itaconate levels did not differ between the two age groups. This finding has not
been previously described; however, conclusions are limited due to the small
sample size. A significant difference was shown despite the high variability of
measured itaconate levels among samples. These findings illustrate that in
addition to a general role of itaconate in CC, a specific mechanism in canceronset may be related to itaconate in young patients and should be further
investigated.
Tumor metabolism and clinical outcome is affected by microsatelliteinstability (MSI) and associated with tumor location within the colon in CC (219221). Furthermore, MSI cancers are more likely to cause an immune response
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due to abnormal protein translation (222). This points out another limitation of this
study, since patients could not be sorted according to these criteria due to a lack
of the relevant data. In addition, measured ACOD1 and itaconate levels could not
be correlated with tumor stage due to small sample size.
Differential gene expression analysis for IRG1 revealed a significantly
higher expression in cancers compared to normal colon tissue, suggesting a role
of IRG1 in tumor growth and development. A significant impact of IRG1 gene
expression in cancer tissue on patient survival was only found in stage IV CC. An
effect in earlier cancer stages may be masked due to limited sample size and a
generally low expression of IRG1 that is detected depending on the sensitivity of
the respective sequencing technique. Standardized tissue quality and
sequencing methods suggest a feasibly comparable pool of data; however,
differences in the resolution of gene expression between samples may be
impaired.
Itaconate and its related carcinogenic mechanisms could serve as a new
target in obese patients with CC and in EOCC. This suggests that TAM
metabolism may affect cancer progression through anti-inflammatory
mechanisms mediated by itaconate in EOCC.
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CHAPTER VII

LEPTIN AND ITACONATE AFFECTING PPARγ IN M2-LIKE MACROPHAGES –
A POTENTIAL LINK TO EARLY-ONSET COLON CANCER

INTRODUCTION

The obesity-related hormone leptin circulates systemically as a 146-amino acid
glycoprotein that is primarily produced and released by adipocytes (223) (Figure
14A). Its role in central appetite and energy regulation is only one facet of this
hormone’s functions and does not describe its complexity due to the numerous
effects of leptin in obesity-related complications, such as type 2 diabetes,
cardiovascular disease and hypertension (224). In CRC, leptin has a metabolic
impact, affecting cytokine expression in CRC, as well as macrophage
polarization (121, 225). Leptin acts as a central mediator of inflammation in CRC
inducing proinflammatory cytokine production of TNF-α and/or Interleukin 6 (IL-6)
in macrophages and lymphocytes (226). In mouse models, leptin treatment
results in reduced CC growth, an increased proportion of proinflammatory M1like macrophages in CC and increased proinflammatory cytokine production
(121, 227). An indirect relationship between obesity and CRC has been reported
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due to the association of the function of leptin with several known risk factors of
CRC, such as energy intake, sex hormone levels, stress, and inflammatory
immune responses (224). A causal link between obesity and CRC through leptin,
however, has never been demonstrated (224).
Acting through the JAK2-STAT3 pathway, a key pathway in tumorigenesis
and metastasis, leptin increases cell survival and cell growth in CC cells,
therefore promoting CC progression (94, 225, 226) (Figure 15). The MAPK and
the AMPK pathways are also regulated by leptin, both altering gene transcription
and inflammatory responses of cells. All three of these pathways affect NFκB
activity. An excessive activation of NFκB plays a key role in colorectal
carcinogenesis (228).
NFκB is a ubiquitous transcription factor that regulates cytokine, cytokine
receptor and adhesion molecule expression in an inflammatory setting, affecting
both cancer cells and TAMs (228). The anti-apoptotic effect of leptin on cancer
cells is also mediated through NFκB, inducing proliferation, differentiation,
metastasis, angiogenesis and chemoradiotherapy resistance in cancer cells
(229). PPARγ is an established target in metabolic dysfunction and insulin
resistance, also known as the glitazone receptor (230). This protein is a potent
inhibitor of NFκB. Low PPARγ expression in CRC is associated with worse
clinical outcomes (231, 232). Leptin slightly downregulates PPARγ expression in
human macrophages thereby contributing to this expression pattern (233).
As immune responses and inflammation play an increasingly important
role in CRC research, macrophages and their metabolic states are coming into
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focus of carcinogenic mechanisms and clinical outcomes. The macrophagespecific metabolite itaconate is a dicarboxylic acid derived from cis-aconitate in
the Krebs cycle in macrophages (54) (Figure 14B). Macrophage activation with
lipopolysaccharide (LPS) or other cytokines, such as interferons, can induce
itaconate production by the enzyme ACOD1 in the mitochondrial matrix (54).
Itaconate is highly polar and is therefore not able to cross cell membranes easily
(234). Due to this limitation, membrane-permeable itaconate derivatives, such as
OI and DI, are commonly used for in vitro experiments (119, 235). In addition to
the effects of leptin, itaconate can enhance NF-κB activity by inducing succinate
accumulation and thereby increasing mitochondrial production of ROS (35, 236).
The association between leptin, itaconate production and PPARγ expression in
macrophages and CRC cells are widely unknown.
The aim is to investigate the effect of the obesity hormone leptin and the
membrane-permeable itaconate derivatives OI and DI on M2-like macrophages,
their cytokine expression profiles and on PPARγ expression in vitro using qRTPCR. Dose-response experiments were performed for each treatment by
incubating cells with either leptin (n=20), OI (n=20) or DI (n=20) (Sigma-Aldrich,
St. Louis, USA). Cellular cytokine expression after treatment with four different
doses of each compound (n=5) was determined at four time points including 3, 6,
18 and 24 hours of cell treatment. Detailed methods are described in Chapter IV.
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Figure 14. Molecular structures of the macrophage-specific metabolite itaconate, its derivatives and the obesity-related
hormone leptin (237).

(A) Quaternary structure of the protein leptin-E 100 that is circulating systemically, affecting organs and tissues (237).
(B) Fischer projection of itaconate and its derivatives 4-octyl itaconate and dimethyl itaconate with chemical formula and
molecular weight. Altered structures between itaconate and its derivatives are shown in red.

MW = molecular weight; kD = kilodalton
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Figure 15. Effects of leptin and itaconate on cellular pathways altering gene transcription, including the MAPK, the
JAK/STAT and the AMPK pathway

Legend to Figure 15.

The three molecular pathways MAPK (purple), JAK/STAT (pink) and AMPK (green) and their regulation through leptin
and its receptor. Molecules in the cytoplasm (light blue) and the nucleus (grey) are shown.
All three of these pathways alter gene transcription affecting inflammatory responses induced by the NFκB system. MAPK
and STAT3 initiate induction of NFκB mediated gene expression, enhancing pro-proliferative and anti-apoptotic
mechanisms. On the other hand, AMPK signaling can indirectly inhibit NFκB activity by induction of several downstream
factors, such as p53. Furthermore, AMPK plays a key role in macrophage polarization by regulating mitochondrial
oxidative phosphorylation and glycolysis.
Itaconate can enhance mechanisms mediated by leptin through activation of the JAK/STAT pathway and downregulation
of PPARγ (red arrows).
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MAPK = mitogen-activated protein kinase; JAK/STAT = Janus kinase-signal transducer and activator of transcription;
AMPK = AMP-activated protein kinase; NFκB = Nuclear factor kappa light chain enhancer of activated B cells; p53 =
tumor protein p53; PPARγ = peroxisome proliferator activated receptor gamma; SHP2 = SH2 containing protein tyrosine
phosphatase-2; GRB2 = Growth Factor Receptor Bound Protein 2; RAS/RAF = Rapidly Accelerated Fibrosarcoma-Rat
sarcoma protein; MEK = MAPK/extracellular signal–regulated kinase kinase; PGC1α = peroxisome proliferator-activated
receptor gamma coactivator 1-alpha; RXR = retinoid X receptor; IL = interleukin; TNF-α = Tumor Necrosis Factor Alpha

RESULTS

For detailed methods see Chapter IV.
i.

Gene expression in M2-like macrophages

Raw gene expression data, expressed as normalized PCR cycles (ΔCT values),
is shown in Table 14. Mean ΔCT values for all doses (D1, D2, D3, D4) for
treatments with leptin, OI and DI and for each respective gene at all four time
points are shown in Figure 16.
PPARγ gene expression was not altered in M2-like macrophages treated
with either leptin or DI. In contrast, OI treatment resulted in significant
downregulation of PPARγ at the highest dose (D4) at 6h (FC -3.78, p=<0.001),
18h (FC -32.67, p=<0.001) and 24h (FC -12.55, p=<0.001) (Figure 16a).
Leptin and DI had no significant effect on anti-inflammatory IL-10
expression at all doses and at all time points. OI treatment induced a clear
downregulation of IL-10 using the two highest doses (D3 and D4) at all time
points (at 3h [FC -54.57 at D3, p=<0.001], at 6h [FC -80.45 at D3, p=<0.001], at
18h [FC -101.13 at D4, p=<0.001] and at 24h [FC -28.84 at D4, p=<0.001])
(Figure 16b).
Treatment of cells with leptin consistently upregulated IL-8 expression at
all doses with a maximum fold change using the highest dose at 6h (FC 26.35 at
D4, p=<0.001) and 18h (FC 12.82 at D4, p=0.006) (Figure 16c). DI showed this
effect as an early response at 3h (FC 4.44 at D4, p=<0.001) and at 6h (FC 23.26
at D3, p=0.006) (Figure 16d). OI had no significant effect on IL-8 expression.
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There was no significant effect on CCL18 expression at any dose or time
point for leptin, DI or OI treatments.
Proinflammatory IL-1β and IL-6 expression also were not affected in a time- or
dose-dependent manner by leptin, DI or OI.
A significant downregulation of proinflammatory TNF-α gene expression
was demonstrated following OI treatment at 6h (FC -9.06 at D3, p=<0.001), 18h
(FC -103.25 at D4, p=<0.001) and at 24h (FC 36.00 at D3, p=<0.001) (Figure
16e).
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Table 14

Maximum fold changes (FC) and associated mean ΔCT values in M2-like macrophages for the respective treatment and
gene
Gene

PPARG

IL8

120

CCL18

Treatment

Time
[hours]

leptin

18

4-octyl
itaconate
dimethyl
itaconate

IL1B

24

leptin

6

dimethyl
itaconate

6

leptin

18

4-octyl
itaconate
dimethyl
itaconate
leptin

IL10

18

4-octyl
itaconate
dimethyl
itaconate

18
6
3
18
18

leptin

6

4-octyl
itaconate

3

Control
[mean ΔCT
(95% CI)]
18.25 (17.85
- 18.64)
18.92 (18.50
- 19.34)
18.66 (18.28
- 19.04)
18.45 (18.31
- 18.58)
17.80 (16.66
- 18.95)
18.15 (17.86
- 18.44)
16.61 (10.33
- 22.88)
18.85 (18.04
- 19.66)
19.05 (18.16
- 19.94)
19.06 (16.94
- 21.19)
19.19 (17.18
- 21.19)
21.28 (20.74
- 21.82)
18.58 (15.99
- 21.16)

D1
[mean ΔCT
(95% CI)]
18.84 (18.48
- 19.20)
18.75 (18.40
- 19.11)
18.60 (18.36
- 18.83)
17.00 (16.68
- 17.32)
16.13 (14.62
- 17.64)
18.54 (17.60
- 19.48)
16.19 (10.21
- 22.18)
17.12 (15.97
- 18.26)
14.09 (13.71
- 14.47)
19.58 (17.92
- 21.24)
18.16 (17.00
- 19.32)
20.61 (19.88
- 21.35)
20.41 (20.17
- 20.65)

D2
[mean ΔCT
(95% CI)]
18.08 (17.40
- 18.77)
19.60 (18.75
- 20.46)
18.31 (18.02
- 18.60)
15.58 (14.31
- 16.84)
15.37 (13.73
- 17.01)
19.22 (18.28
- 20.16)
18.60 (10.88
- 26.33)
17.09 (15.81
- 18.37)
16.10 (13.86
- 18.33)
21.72 (19.42
- 24.02)
17.76 (16.29
- 19.24)
20.20 (19.34
- 21.05)
22.80 (22.46
- 23.14)

D3
[mean ΔCT
(95% CI)]
18.11 (17.76
- 18.46)
20.77 (19.80
- 21.74)
18.11 (17.76
- 18.46)
14.97 (13.86
- 16.07)
13.26 (11.01
- 15.50)
18.20 (17.74
- 18.65)
16.67 (10.38
- 22.95)
17.19 (16.23
- 18.15)
19.71 (19.37
- 20.05)
24.12 (22.58
- 25.65)
17.78 (16.25
- 19.30)
19.41 (18.10
- 20.73)
22.47 (22.07
- 22.88)

D4
[mean ΔCT
(95% CI)]
18.64 (18.28
- 19.00)
23.95 (23.72
- 24.17)
17.89 (17.49
- 18.29)
13.73 (12.62
- 14.84)
13.71 (12.44
- 14.97)
18.07 (17.73
- 18.42)
21.14 (14.25
- 28.04)
17.32 (16.48
- 18.17)
14.64 (12.28
- 17.01)
25.72 (23.42
- 28.03)
18.43 (17.62
- 19.23)
18.04 (16.74
- 19.33)
21.18 (20.08
- 22.27)

max. FC
(dose)
-1.51
(D1)
-32.67
(D4)
1.71
(D4)
26.35
(D4)
23.26
(D3)
-2.10
(D2)
-21.10
(D4)
3.39
(D2)
31.12
(D1)
-101.13
(D4)
2.69
(D2)
9.45
(D4)
-18.64
(D2)

p-value
ns
<0.001
ns
<0.001
0.006
ns
ns
ns
ns
<0.001
ns
ns
ns

IL6

dimethyl
itaconate

24

leptin

3

4-octyl
itaconate
dimethyl
itaconate
leptin

TNFA

4-octyl
itaconate
dimethyl
itaconate

24
18
6
18
24

22.01 (21.75
- 22.27)
24.23 (20.46
- 28.00)
27.56 (26.59
- 28.53)
24.99 (20.99
- 29.00)
18.38 (18.15
- 18.60)
18.25 (17.15
- 19.36)
19.17 (18.59
- 19.76)

21.70 (20.71
- 22.70)
22.64 (19.11
- 26.17)
28.65 (28.02
- 29.29)
27.86 (26.86
- 28.87)
18.15 (17.99
- 18.30)
19.36 (18.80
- 19.93)
18.45 (17.48
- 19.43)

21.08 (20.85
- 21.30)
21.51 (16.84
- 26.18)
28.50 (27.60
- 29.40)
28.72 (27.93
- 29.51)
17.77 (17.53
- 18.01)
20.56 (19.49
- 21.62)
18.40 (17.88
- 18.93)

20.48 (19.90
- 21.06)
21.39 (18.55
- 24.24)
27.01 (24.66
- 29.36)
28.27 (27.52
- 29.03)
17.27 (16.73
- 17.80)
22.28 (21.17
- 23.40)
16.76 (16.49
- 17.03)

17.84 (17.46
- 18.21)
22.19 (19.26
- 25.12)
23.31 (18.97
- 27.66)
29.03 (28.25
- 29.80)
16.72 (16.01
- 17.43)
24.94 (23.05
- 26.83)
17.78 (17.56
- 18.00)

18.00
(D4)
7.16
(D3)
19.03
(D4)
-16.45
(D4)
3.16
(D4)
-103.25
(D4)
5.31
(D3)

<0.001
ns
ns
ns
ns
<0.001
ns
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Legend to Table 14.

Leptin treatment [ng/ml]:
D1: 100
D2: 300
D3: 500
D4: 1000
4-octyl itaconate [μg/ml]:
D1: 10
D2: 30
D3: 50
D4: 100
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Dimethyl itaconate [μg/ml]
D1: 20
D2: 50
D3: 100
D4: 200

LEP = leptin; OI = 4-octyl itaconate; DI = dimethyl itaconate; IL = interleukin; PPARG = peroxisome proliferator
activated receptor gamma; TNFA = tumor necrosis factor alpha;
ns = not significant
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Figure 16. Dose and time response after cell treatment with leptin, 4-octyl itaconate (OI) and dimethyl itaconate (DI)
Mean PCR gene expression values (ΔCT values) for each cell treatment and for each respective gene, including four
different doses (see legend within figure) and four time points (3h, 6h, 18h, 24h). Red highlighting indicates a significant
effect (a,b,c,d,e).
LEP = leptin; OI = 4-octyl itaconate; DI = dimethyl itaconate; IL = interleukin; TNFα = tumor necrosis factor alpha; PPARγ
= peroxisome proliferator activated receptor gamma

ii.

Gene expression in M0 macrophages

M0 macrophages were treated with either leptin, OI or DI. Since maximum
effects were observed at 18 hours in M2 macrophages, expression levels in M0
macrophages were investigated for this time point specifically. Results are shown
in Table 15.
Leptin induced an upregulation of IL-8 (p=0.001), TNF-α (p=0.026), IL-1β
(p=0.001), CCL18 (p=0.002) and PPARγ (p=0.030) (Table 15). Compared to M2macrophages, only a slight upregulation of IL-8 could be found in M0
macrophages after leptin treatment. Upregulation of TNF-α, IL-1β, CCL18 and
PPARγ was significant in M0 macrophages, which could not be demonstrated on
M2-like cells (Table 14, Table 15).
OI treatment of M0 macrophages led to a downregulation of IL-10 (p=<0.001),
TNF-α (p=0.002), IL-1β (p=0.032) and a downregulation of PPARγ (p=0.003)
(Table 15). Compared to M2-like macrophages, IL-10, TNF-α and PPARγ were
downregulated to a lesser extent in M0 macrophages (Table 14, Table 15).
While no significant changes for IL-1β expression were demonstrated in M2-like
macrophages, M0 cells showed a significant downregulation of IL-1β (Table 14,
Table 15).
DI induced upregulation of IL-8 (p=<0.001), IL-10 (p=0.002), TNF-α (p=<0.001)
and IL-1β (<0.001) (Table 15). IL-8 upregulation was shown to be higher in M0
macrophages compared to M2-like cells, while IL-1β upregulation was lower in
M0 cells (Table 14, Table 15). A slight upregulation of IL-10 and TNF-α was
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found in M0 with no significant changes among treatment doses in M2-like
macrophages (Table 14, Table 15).

Table 15
Maximum fold changes (FC) and associated mean ΔCT values in M0
macrophages for the respective treatment and gene

Gene
IL8
IL10
TNFA

IL1B
CCL18
PPARG

Treatment
Leptin
DI
OI
DI
Leptin
OI
DI
Leptin
OI
DI
Leptin
Leptin
OI

Control
18 hours
mean
[mean ΔCT] [mean ΔCT (95% CI)]
FC
19.8
18.6
19.7
19.6
20.0
19.7
19.4
19.5
19.1
18.5
24.6
18.0
17.3

18.2 (17.7 - 18.8)
13.4 (12.9 - 13.9)
24.2 (23.2 - 25.3)
18.9 (18.6 - 19.1)
19.4 (18.9 - 19.9)
22.6 (21.5 - 23.6)
17.5 (17.3 - 17.8)
18.5 (18.2 - 18.8)
20.7 (19.3 - 22.1)
16.3 (15.9 - 16.6)
23.7 (23.4 - 24.1)
17.3 (16.8 - 17.9)
20.2 (19.0 - 21.3)

3.2
36.8
-20.0
1.7
1.5
-6.5
3.8
1.9
-2.5
4.8
1.9
1.6
-6.0

pvalue
0.001
<0.001
<0.001
0.002
0.026
0.002
<0.001
0.001
0.032
<0.001
0.002
0.030
0.003

LEP = leptin; OI = 4-octyl itaconate; DI = dimethyl itaconate; IL = interleukin;
PPARG = peroxisome proliferator activated receptor gamma; TNFA = tumor
necrosis factor alpha
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DISCUSSION

The expression of the metabolic nuclear transcription factor PPARγ in
CRC has a key role in cellular lipid and glucose metabolism and mediates
several antineoplastic mechanisms in CRC (231, 238). PPARγ is understood to
function as a tumor suppressor, that can serve as a marker of an indolent subset
of CRC (232). Itaconate is a metabolic product of the Krebs cycle in TAMs and
can alter macrophage cytokine expression as well as their polarization state (54).
In metabolic dysfunction and obesity, itaconate can provide a link to EOCRC by
enhancing carcinogenic mechanisms that are regulated by obesity-related
hormones such as leptin. Identifying this link is the basis for developing new
immunotherapeutic targets in CRC. In this study, we provide evidence that
itaconate promotes significant downregulation of the tumor suppressor PPARγ in
anti-inflammatory M2-like macrophages and upregulation of M2-like macrophage
cytokines. In this manner, itaconate promotes carcinogenic mechanisms in
EOCRC and obesity-affected pathways through PPARγ.
The itaconate derivatives that have been used in this study demonstrated
disparate effects on gene expression in M2-like macrophages. While DI did not
seem to alter PPARγ expression, OI resulted in significant downregulation.
Furthermore, OI induced a clear downregulation of anti-inflammatory IL-10
expression as well as of proinflammatory TNFα expression. In contrast, DI had a
clear impact on IL-8 expression, while OI showed no significant effects. The
membrane-permeable derivatives of itaconate that are established in in vitro
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investigation, have been reported to not necessarily show similar effects (118,
235). OI and DI are the most commonly used forms of this macrophagemetabolite that are used to provide itaconate intracellularly (118). Mechanisms of
intracellular modification of these derivatives, which alter their function and the
transmembrane transport mechanisms of itaconate itself are, however, not well
understood and are therefore important subjects of current research (119, 235).
Treatment of cells with either leptin, OI or DI led to significant effects on
gene expression at different doses over time. Variation of PCR cycle values
between plate replicates was shown depending on the respective gene analyzed
and upon the compound added for cell treatment. The variability of cellular
responses of M2-like polarized macrophages in cell culture demonstrates the
high plasticity of this cell type with dynamic and continuous switching between
either a more M1-like or more M2-like marker expression. Characterization of the
distinct anti-inflammatory M2-like macrophage subtype that was used in this
study, however, revealed a clear M2-like polarization state. Despite variability of
PCR cycle values between cell plates, a clear pattern of cellular responses could
be demonstrated for each respective treatment. The comparison of responses
between M2-like TAMs and M0 macrophages demonstrated that the antiinflammatory phenotype showed a much more pronounced gene expression
response to cell treatment than the non-polarized M0 cell type. An exception was
found in case of IL-8 expression, which is highly expressed even in untreated M0
macrophages, and which increases following DI treatment of these cells (Figure
6). This suggests that leptin and itaconate mediate tumor-promoting cytokine and
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marker expression mainly through M2-like TAM responses rather than shifting
M0 macrophages into a more anti-inflammatory TAM-like cell type.
A limitation of this study is the focus on TAMs and therefore on only one
cell type within the TME. On the other hand, the investigation of individual
responses of the macrophage population is important to define their individual
contribution to gene expression patterns in CRC. Cell line co-culture models or
human CRC organoid cultures are necessary to analyze intercellular
mechanisms and paracrine signaling following treatment with leptin and
itaconate. Furthermore, this study is limited to the gene expression levels of
pathway-related cytokines and PPARγ. After investigating dose- and timedependent effects in detail, protein expression and further macrophage subtype
markers should be determined to identify protein activation and TAM polarization
due to leptin and itaconate. In addition, the effects of leptin and itaconate on
TAMs should be analyzed using macrophages in different polarization states.
Anti-inflammatory M2-like macrophages are the most common subtype of
macrophage in more advanced tumor stages and have been shown to be
associated with worse clinical outcomes in CRC, such as reduced overall or
progression free survival (239). This study limited to TAMs of this M2-like
subtype, but the effects on macrophages of other metabolic polarization states,
such as M0 or proinflammatory M1-like macrophages, should be evaluated in
future experiments.
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CHAPTER VIII
LEPTIN, ADIPONECTIN AND ITACONATE AFFECTING GENE EXPRESSION
IN COLON CANCER CELLS

INTRODUCTION

Tumor immunology plays an essential role particularly in CRC, since tumor
development and progression of this type of cancer are directly linked to
inflammatory mediators (240). Cytokine networks can promote cell proliferation,
migration and resistance to apoptosis in CRC and are affected by systemic
mediators as well as cellular signaling within the TME (94, 240). As part of innate
and adaptive immune cells regulating pro- and anti-inflammatory gene
expression in tumors, cancer cells are interacting with these cells within the TME
and modify their gene expression profile to promote their own growth (240, 241).
The obesity-related hormones leptin and adiponectin can affect cytokine
profiles in cancer cells and thereby either inhibit or promote carcinogenic
mechanisms (94). A protective function of adiponectin has been postulated for
several types of cancers, inhibiting genes that promote apoptosis and cell
migration (94, 242). Opposite effects have been found for leptin, affecting the
STAT3-NFκB axis, which is critical in CRC (94, 240). The macrophage-specific
metabolite itaconate and its cell-permeable derivatives 4-octyl itaconate and
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dimethyl-itaconate are strong inflammatory mediators with a potential role
in different types of cancers, but their effects on cytokine expression profiles in
CRC are poorly understood (54). The acute inflammatory response is critical for
the host defense and mediates antitumorigenic effects. In contrast, chronic
proinflammatory stress leads to an immunosuppressive environment, exerting
predominately anti-inflammatory features (243). Chronic inflammation is a key
feature of obesity and a hallmark in CRC that is linked to a high M2/M1
macrophage phenotype ratio and secretion of immunosuppressive cytokines and
chemokines by cells within the TME, such as IL-10 and CCL22 (243). This leads
to recruitment of T helper cells and regulatory T cells and decreased cytotoxic T
cell activity, inhibiting cancer cell apoptosis (243).
CC cells were demonstrated to secrete mediators that modify TAM
polarization and cytokine expression, further enhancing tumor growth and
progression through IL-6 (18, 243). Leptin, adiponectin and itaconate affect
cellular metabolism and marker expression of cancer cells. The two isotypes of
adiponectin receptors, adiponectin receptor 1 and 2 (AdipoR1 and AdipoR2), are
both expressed in CC cells and are associated with decreased epithelial cell
proliferation (244). Leptin receptor expression as well as expression of the actual
hormone leptin is increased in CC versus normal colon cells and promotes tumor
growth (245, 246). Furthermore, leptin can reduce cytotoxic effects of the
common chemotherapeutic agent 5-fluorouracil in CC (247). A tumor inhibiting
role of leptin under certain circumstances, however, is still discussed (248).
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The aim is to define cytokine and gene expression profiles in CC cells as a
response to treatment with the obesity-related hormones leptin and adiponectin
and the two derivatives of the macrophage-specific mediator itaconate, OI and DI
using qRT-PCR. Detailed methods are described in Chapter IV.
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RESULTS

HT-29 CC cells were incubated with either leptin, adiponectin, OI or DI for four
different time periods (3, 6, 18, 24 hours). Cells were then harvested, qRT-PCR
was performed, and delta CT values were compared to a negative control.
Results are shown in Table 16.
Leptin induced upregulation of anti-inflammatory IL-8 expression with a maximum
fold change (FC) after 6 hours (FC 7.3, p=<0.001). Proinflammatory TNF-α was
also upregulated with a maximum FC after 18 hours (FC 5.8, p=0.027) following
leptin treatment (Table 16).
CC cells treated with adiponectin also showed an upregulation of antiinflammatory IL-8 with a maximum effect after 3 hours (FC 68.1, p=<0.001).
Proinflammatory CXCL10 and TNF-α were upregulated following adiponectin
treatment with a maximum fold change after 6 hours, respectively (FC 3.0,
p=0.025 and FC 110.7, p=<0.001). The chemokine CCL22 also was significantly
upregulated with a maximum after 18 hours (FC 16.3, p=<0.001) (Table 16).
OI treatment induced downregulation of anti-inflammatory IL-8 with a maximum
FC after 24 hours (FC -4.7, p=<0.001). Proinflammatory CXCL10 was
downregulated due to OI treatment and the maximum effect was demonstrated
after 24 hours (FC -16.8, p=<0.001). The transcription factor PPARγ showed a
maximum downregulation after 24 hours (FC -9.8, p=0.031) (Table 16).
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DI led to downregulation of proinflammatory CXCL10 with a maximum FC after
24 hours (FC -18.3, p=<0.001). A maximum downregulation of transcription
factor PPARγ was shown at 18 hours (FC -1.7, p=0.033) (Table 16).
Other genes expressing IL-1β, CCL18, IL-6, IL-10, CD80, IRG1 and NFκB
showed no significant changes due to any treatment.
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Table 16 (part 1)
Gene expression in HT-29 CC cells (ΔCT) after 3, 6, 18 and hours of treatment
Gene

Treatment

3h
control
ΔCT
[mean ± SEM]

3h
treated
ΔCT
[mean ± SEM]

CCL22

23.9 ± 0.8

24.8 ± 0.9

CXCL10

24.4 ± 0.4

IL1B
IL8

Leptin

3h

6h
treated
ΔCT
[mean ± SEM]

6h

Overall
effect

p-value

6h
control
ΔCT
[mean ± SEM]

p-value

p-value

0.638

26.3 ± 0.8

28.1 ± 0.8

0.178

0.168

24.3 ± 0.5

0.817

22.0 ± 0.4

22.6 ± 0.4

0.421

0.492

27.3 ± 0.7

26.4 ± 0.7

0.292

24.2 ± 0.7

22.7 ± 0.6

0.292

0.133

19.6 ± 0.3

18.9 ± 0.3

0.052

21.3 ± 0.3

18.5 ± 0.3

<0.001

<0.001

PPARG

16.0 ± 0.3

16.3 ± 0.3

0.854

16.3 ± 0.3

16.2 ± 0.2

0.854

0.720

TNF

29.1 ± 0.7

27.7 ± 0.7

0.218

25.2 ± 0.7

25.2 ± 0.7

0.986

0.024

CCL22

21.6 ± 0.5

21.5 ± 0.5

0.819

24.3 ± 0.5

21.5 ± 0.4

<0.001

<0.001

CXCL10

23.6 ± 0.4

22.4 ± 0.4

0.044

22.8 ± 0.4

21.2 ± 0.4

0.025

0.001

IL1B

25.2 ± 0.4

21.8 ± 0.4

<0.001

23.2 ± 0.5

21.6 ± 0.5

0.058

<0.001

20.0 ± 0.4

13.9 ± 0.4

<0.001

18.9 ± 0.4

14.6 ± 0.4

<0.001

<0.001

PPARG

16.2 ± 0.2

16.0 ± 0.2

0.877

16.1 ± 0.2

16.0 ± 0.2

0.877

0.621

IL8

Adiponectin
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TNF

25.6 ± 0.5

19.9 ± 0.6

<0.001

27.5 ± 0.5

20.7 ± 0.6

<0.001

<0.001

CCL22

22.8 ± 1.2

26.9 ± 1.2

0.063

25.8 ± 1.5

25.3 ± 1.3

0.947

0.171

CXCL10

24.4 ± 0.5

26.0 ± 0.5

0.045

25.0 ± 0.6

25.9 ± 0.5

0.241

<0.001

25.8 ± 0.6

26.0 ± 0.6

0.776

27.6 ± 0.6

28.2 ± 0.6

0.673

0.335

IL1B
IL8

OI

21.1 ± 0.4

20.8 ± 0.4

0.677

19.5 ± 0.3

20.9 ± 0.4

0.004

<0.001

PPARG

16.8 ± 1.0

13.5 ± 1.0

0.031

16.2 ± 0.9

18.5 ± 0.9

0.058

<0.001

TNF

28.2 ± 1.2

21.7 ± 1.2

0.001

27.2 ± 1.0

26.0 ± 1.0

0.748

0.003

CCL22

24.4 ± 0.5

23.8 ± 0.7

0.732

27.6 ± 0.6

25.4 ± 0.7

0.092

0.176

CXCL10

23.2 ± 0.4

23.4 ±

0.702

22.2 ± 0.4

23.3 ± 0.4

0.076

<0.001

IL1B

25.2 ± 0.4

24.8 ±

0.647

25.1 ± 0.4

25.8 ± 0.4

0.357

<0.001

19.3 ± 0.3

19.5 ±

0.796

21.3 ± 0.3

20.9 ± 0.2

0.590

0.312

PPARG

15.8 ± 0.2

16.3 ±

0.233

16.5 ± 0.2

16.5 ± 0.2

0.899

0.025

TNF

28.3 ± 0.5

29.6

0.314

27.8 ± 0.5

28.4 ± 0.5

0.371

0.152

IL8

DI

Table 16 (part 2)
Gene expression in HT-29 CC cells (ΔCT) after 3, 6, 18 and hours of treatment
Gene

Treatment

18 h
control
ΔCT
[mean ± SEM]

18 h
treated
ΔCT
[mean ± SEM]

CCL22

26.5 ± 0.7

26.4 ± 0.7

CXCL10

25.2 ± 0.4

IL1B
IL8

Leptin

18 h

24 h
control
ΔCT
[mean ± SEM]

24 h
treated
ΔCT
[mean ± SEM]

p-value

Overall
effect
p-value

0.893

26.1 ± 0.8

27.9 ± 0.7

0.178

0.168

24.5 ± 0.4

0.421

25.0 ± 0.5

24.9 ± 0.5

0.817

0.492

26.3 ± 0.6

25.4 ± 0.5

0.292

27.8 ± 0.7

26.5 ± 0.7

0.292

0.133

p-value

24 h

21.2 ± 0.3

18.6 ± 0.3

<0.001

20.2 ± 0.3

19.2 ± 0.3

0.008

<0.001

PPARG

16.6 ± 0.2

16.9 ± 0.2

0.854

16.1 ± 0.3

16.1 ± 0.3

0.961

0.720

TNF

28.0 ± 0.7

25.5 ± 0.7

0.027

29.4 ± 0.7

28.1 ± 0.7

0.218

0.024

CCL22

28.7 ± 0.6

24.7 ± 0.5

<0.001

21.7 ± 0.5

21.6 ± 0.5

0.819

<0.001

CXCL10

21.1 ± 0.6

22.1 ± 0.4

0.155

23.2 ± 0.5

21.9 ± 0.4

0.044

0.001

IL1B

23.5 ± 0.6

24.0 ± 0.4

0.488

24.3 ± 0.6

23.1 ± 0.4

0.160

<0.001

18.6 ± 0.6

18.9 ± 0.4

0.653

19.4 ± 0.5

17.3 ± 0.4

0.002

<0.001

PPARG

14.9 ± 0.3

14.9 ± 0.2

0.877

15.8 ± 0.3

15.3 ± 0.2

0.655

0.621

IL8

Adiponectin

135

TNF

25.3 ± 0.7

26.0 ± 0.5

0.440

26.4 ± 0.6

27.0 ± 0.5

0.440

<0.001

CCL22

25.5 ± 1.3

25.6 ± 1.3

0.947

26.9 ± 1.2

25.6 ± 1.3

0.947

0.171

CXCL10

26.4 ± 0.6

28.2 ± 0.5

0.045

25.4 ± 0.5

29.4 ± 0.5

<0.001

<0.001

25.8 ± 0.7

27.3 ± 0.6

0.360

25.6 ± 0.7

26.9 ± 0.6

0.360

0.335

IL1B
IL8

OI

19.4 ± 0.4

21.6 ± 0.3

<0.001

20.9 ± 0.4

23.1 ± 0.4

<0.001

<0.001

PPARG

16.6 ± 0.9

19.3 ± 0.9

0.040

16.1 ± 0.9

19.4 ± 0.9

0.031

<0.001

TNF

26.8 ± 1.0

27.8 ± 1.2

0.748

28.0 ± 1.2

27.7 ± 1.2

0.890

0.003

CCL22

29.5 ± 0.5

28.9 ±

0.732

26.8 ± 0.5

27.0 ± 0.6

0.771

0.176

CXCL10

24.1 ± 0.4

25.9 ±

0.002

24.6 ± 0.4

28.8 ± 0.4

<0.001

<0.001

IL1B

25.5 ± 0.4

25.2 ±

0.647

25.9 ± 0.4

28.3 ± 0.3

<0.001

<0.001

21.1 ± 0.3

21.0 ±

0.796

19.9 ± 0.3

19.1 ± 0.3

0.264

0.312

PPARG

16.4 ± 0.2

17.1 ±

0.033

15.9 ± 0.2

16.3 ± 0.2

0.234

0.025

TNF

28.3 ± 0.5

28.9

0.371

27.6 ± 0.6

28.7 ± 0.5

0.314

0.152

IL8

DI

Legend to Table 16.

Significant differences in expression and significant overall p-values are marked bold.

SEM = standard error of the mean
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DISCUSSION

Obesity-related hormones and itaconate significantly change the gene
expression patterns in CC cells and can thereby promote tumor growth,
progression and recurrence.
The hormones leptin and adiponectin are reported to have contrary roles in CRC
progression, with leptin inducing cancer progression and adiponectin inhibiting
tumor growth in vitro (94). Investigating cytokine expression profiles that can
affect CC development, however, both cytokines induce pro- and antiinflammatory marker expression to a certain extent. Anti-inflammatory IL-8
production is a key factor in CRC and associated with enhanced tumor growth,
progression and recurrence through autocrine effects on cancer cells (249).
Furthermore, IL-8 promotes angiogenesis in CC and mediates proinflammatory
effects by functioning as a chemoattractant for neutrophils inducing the JAK3
pathway (249, 250). Leptin significantly upregulated IL-8 expression in CC cells,
but adiponectin showed a much higher cellular response with a 68-fold
upregulation following treatment. A similar cellular response was found for TNFα, with adiponectin inducing expression to a much higher extent compared to
leptin (111-fold versus 6-fold). This suggests that adiponectin might have tumor
promoting abilities by upregulating IL-8 expression and inducing proinflammatory
responses through TNF-α in advanced cancer stages.
Both itaconate derivatives downregulated proinflammatory CXCL10 expression,
which is a key factor of the anti-tumor T-cell response in CRC (251). Common
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chemotherapies in CRC upregulate CXCL10 expression through IFN-γ signaling
by DNA damage, which induces cytotoxic T cell recruitment (251, 252). Itaconate
can reduce proinflammatory mechanisms and T cell infiltration and therefore antitumorigenic activity by downregulating CXCL10.
A prognostic factor in CRC that is associated with patient survival is expression
of the tumor suppressor PPARγ. Both derivatives OI and DI can exert tumor
enhancing effects with poor patient survival by downregulating PPARγ, with OI
showing a higher impact (232).
CCL22 directly induces tumor cell migration and is therefore associated with
tumor promoting effects in CC (253). Adiponectin was the only treatment that
significantly affected CCL22 expression by upregulating it 16-fold in CC cells.
This suggests that adiponectin can enhance tumor progression and metastasis in
later stages of the disease.
A major limitation of this work is that effects were only shown in vitro using one
CC cell line derived from Duke’s C stage human colon adenocarcinoma.
Furthermore, cellular responses within the TME are affected by other types of
cells that alter the overall effect on tumor development (254). Investigating the
response of only one cell type, however, is the basis for coculture models and
functional studies using organoid cancers mimicking the TME.
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CHAPTER IX

LEPTIN AND ADIPONECTIN AFFECTING THE NOTCH4-GATA4-IRG1 AXIS
– A COCULTURE MODEL AND GENOMIC ANAYLSIS

INTRODUCTION

The NOTCH4-GATA4-IRG1 axis shares a network of genes involved in CRC,
with the potential to define macrophage metabolism and obesity-related EOCRC.
GATA4 is associated with both anti-inflammatory IRG1 and NOTCH4 expression,
which in turn are affected by the obesity-related hormone leptin (Figure 3). The
role of the NOTCH4-GATA4-IRG1 axis in EOCRC as an immunotherapeutic
target has yet to be investigated.
Expression of the anti-inflammatory metabolite itaconate by the enzyme encoded
by IRG1 in macrophages was shown to be peroxisome proliferator-activated
receptor-γ (PPARγ)-dependent (212) (Figure 3). Downregulation of PPARG led
to increased IRG1 expression in peritoneal mouse macrophages, demonstrating
that PPARγ is a regulator of macrophage metabolism (212). Additionally, PPARγ
plays a pivotal role in epithelial cell differentiation, and decreased levels of
PPARG expression in CRC have been demonstrated to enhance CRC
progression (255, 256) (Table 4). The ability to affect macrophage metabolism
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and CRC progression makes PPARγ a potential key regulator in TAM-mediated
CRC development and EOCRC.GATA4 is another gene affecting IRG1
expression, while its definitive role in CRC has yet to be clarified. In pretreated
mouse embryonic fibroblasts, GATA4 induced a decrease in IRG1 expression
(257) (Figure 3). While there is currently no known direct interaction for GATA4
and PPARG, an interaction of GATA family proteins with (PPAR)-binding protein
(PBP) in murine embryonic development has been demonstrated (258).
Furthermore, GATA4 expression is associated with altered expression of ATPbinding cassette (ABC) transporters, such as the subfamily G member 5 and 8
(ABCG5/ABCG8) (259) (Table 4, Figure 3). In GATA4-deficient murine
enterocytes, ABCG5 expression was decreased, suggesting a positive
association between these two genes (259). ABCG5 expression is common in
tumor buds of patients with node-negative CRC and is associated with poor
prognosis (260). This might also have a potential role in node-positive cancers
requiring chemotherapy, as ABC transporters can regulate chemotherapy
resistance by transporting chemotherapeutic agents out of cancer cells (261).
This mechanism is assumed to promote 5-fluorouracil resistance in CRC with
ABCG5 overexpression (261). Defects in the leptin axis in a murine model
affected ABC transporter expression in the liver, leading to decreased excretion
of biliary cholesterol (262). The effects of leptin on ABCG5/ABCG8 expression in
CRC, however, are poorly understood.
An interplay of GATA4 and Notch signaling was demonstrated in murine Leydig
cells, showing downregulation of GATA4-dependent gene expression involved in
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steroidogenesis through Notch signaling pathways (263) (Figure 3). The impact
of GATA4 on NOTCH4 expression in enterocytes has yet to be investigated.
Expression of Notch-induced transcription factors, such as HEY1, are increased
by Delta-like 4 (DLL4) in human lymphatic endothelial cells (264) (Figure 3).
DDL4 is a membrane-bound ligand in Notch signaling, targeting NOTCH1 and
NOTCH4 (265). DLL4 is of interest in CRC research, since its expression is
enhanced by vascular endothelial growth factor α (VEGFA) and hypoxia, two
factors enhancing tumor progression (265).
In human coronary artery endothelial cells, VEGFA and NOTCH4 expression
showed a positive association (266). In breast cancer, high expression levels of
leptin, IL-1, VEGF and Notch proteins were associated with metastasis and poor
survival (267). Leptin has the potential to enhance these mechanisms by
inducing DLL4 as well as NOTCH4 expression in murine breast cancer cells
(267) (Figure 3). Another tumor promoting gene associated with NOTCH4,
Serine protease inhibitor family E member 1 (SERPINE1), is currently discussed
to function as a novel therapeutic target in CRC (268). In murine epithelial breast
cancer cells, however, NOTCH4 reduced SERPINE1 expression (269) (Figure
3). SERPINE1 is the gene encoding for plasminogen activator inhibitor-1 (PAI-1),
which is involved in cell proliferation and decreased apoptosis. It is upregulated
in CRC tissue and was shown to be associated with relapse in CRC patients
(270) (Table 4).
Tumor growth and metastasis are also promoted by enzymes responsible for
tissue remodeling and cell migration such as MMPs (271) (Table 4, Figure 3).
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Notch signaling was positively associated with MMP2 expression in cardiac
tissue through HEY1 in an embryonic mouse model investigating epithelial to
mesenchymal transition (EMT) (272). In CRC, EMT-associated proteins were
also shown to be regulated by MMP2, with increasing expression during tumor
progression (271). Furthermore, in tissue remodeling mediated by rat cardiac
fibroblasts, it was demonstrated that leptin levels can upregulate MMP2
expression and cell migration (273) (Figure 3). In human breast cancer cells,
leptin induced SERPINE1 and MMP2 expression (274). The effects of obesityrelated hormones on EMT and CRC progression in obese patients, however,
deserve further study.
Both SERPINE1 and MMP2 expression are tightly associated with upregulation
of proinflammatory cytokine expression. As CRC is a cancer type that is tightly
associated with chronic inflammation, inflammatory cytokines that are produced
by either cancer cells or other cells of the tumor microenvironment play a crucial
role in tumor progression (215). IL-1β, IL-6 and TNF-α are central cytokines in
CRC that are associated with the NOTCH4-GATA4-IRG1 axis (Figure 3). IL-1β
is a proinflammatory cytokine that is elevated in cancer tissue of patients with
metastatic CRC and it can induce cancer cell proliferation, promote myeloid cell
invasion, and thereby enhance tumor development (102). IL-1β expression is
induced by activation of NFκB and is predominantly produced by myeloid cells in
the TME (102, 275). This brought IL-1β and associated pathways into focus for
new immunotherapeutic treatment strategies (275). Adiponectin can increase IL1β expression in macrophages, while leptin was demonstrated to induce IL-1β in
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murine colon (276) (Figure 3). IL-6 and TNF-α are other proinflammatory
cytokines induced by leptin, that in turn have been shown to upregulate leptin
production (276, 277). Adiponectin mediates anti-carcinogenic effects by
suppressing CC cell proliferation due to IL-6 or TNF-α (278). Both these
cytokines in turn reduce adiponectin production in breast cancer, while PPARγ
agonists increase adiponectin levels (279).
Anti-inflammatory IRG1 expression is negatively correlated with proinflammatory
cytokines, such as IL-1β, IL-6 and TNF-α (280).
The aim of this work is to determine the effects of obesity-related leptin and
adiponectin on the NOTCH4-GATA4-IRG1 axis using a coculture model of M2like macrophages and HT-29 CC cells. Furthermore, a genomic analysis of this
pathway is performed using human RNA-seq data, and specific gene-related
patient survival is investigated. Detailed methods are described in Chapter IV.

143

RESULTS

i.

Inflammatory marker expression and the NOTCH4-GATA4-IRG1 axis
in an M2-like macrophage / HT-29 colon cancer coculture model
THP-1 monocytes were differentiated and polarized into M2-like macrophages
within 14 days as previously described (182). After combining M2-like
macrophages with HT-29 CC cells, cocultures were treated with either 300
ng/ml of leptin or 20 μg/ml of adiponectin for 6 hours and 18 hours, harvested
and qRT-PCR was performed. Results are shown in Table 17.

1. Leptin in M2-like macrophages and HT-29 CC
cells
Leptin treatment induced a significant upregulation of the M1-like cell surface
marker CD80 in M2 macrophages in coculture with a maximum at 6 hours (FC
11.3, p=<0.001) (Table 17). The M2-like marker CD206 was downregulated at 18
hours of leptin treatment (FC -3.8, p=<0.001).
PPARγ was slightly downregulated in M2-like macrophages and CC cells at 18
hours, respectively (FC -1.3, p=0.011 and FC -0.9, p=0.027). A slight
downregulation of NFκB was demonstrated in CC cells, with a maximum at 6
hours (FC -1.5, p=0.004). In M2-like macrophages, however, NFκB expression
was considerably upregulated with a maximum FC of 7.7 at 6 hours (p=<0.001)
(Table 17).
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Investigating cytokine expression, IL-6 was upregulated 39-fold in M2
macrophages at 6 hours of leptin treatment (FC 39.4, p=<0.001). IL-6 was not
expressed in CC cells at any time. Proinflammatory IL-1β expression in M2
macrophages was maximally upregulated at 6 hours (FC 20.8, p=<0.001), with
no difference of expression due to leptin in CC cells. Proinflammatory CCL22
showed a slight upregulation in macrophages at 6 hours only and no changes in
CC cells (FC 2.0, p=0.002). CCL18 was significantly downregulated at 18 hours
of leptin treatment (FC -2.1, p=0.005).
Anti-inflammatory IL-8 was upregulated in both M2 macrophages and HT-29
cells, with macrophages showing a much higher response compared to CC cells
(FC 51.5, p=<0.001 versus FC 1.2, p=0.023) (Table 17). IL-10 expression was
only demonstrated in M2-like macrophages and showed a slight downregulation
at 18 hours (FC -1.8, p=0.001).
SERPINE1 was significantly downregulated in both cell types at 18 hours
of leptin treatment, with macrophages showing a -2.3-fold and cancer cells a 1.7-fold downregulation (p=0.023 and p=0.011) (Table 17). Macrophage-specific
IRG1 expression was maximally upregulated at 6 hours (FC 14.6, p=<0.001).
GATA5 and ABCG8 were not expressed in M2-like macrophages. Expression of
GATA4 and TNF-α did not change due to leptin treatment (Table 17).
GATA4, ABCG8, IL-6, IL-10, CCL-18 and the macrophage markers CD80,
CD206 and IRG1 were not expressed in HT29 CC cells. TNF-α, IL-1β and
CCL22 showed no significant changes due to leptin treatment (Table 17).
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Table 17
Maximum significant changes of gene expression in M2-like macrophages and HT-29 CC cells following leptin treatment

Leptin

(300 ng/ml)
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Cell type
in coculture

Gene

Control
[mean
ΔCT]

M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
HT-29
HT-29
HT-29
HT-29
HT-29

CD80
CD206
PPARG
NFKB
IL6
IL1B
CCL22
CCL18
IL8
IL10
SERPINE1
IRG1
GATA5
PPARG
NFKB
IL8
SERPINE1

20.3
18.8
18.4
17.7
29.1
18.8
19.4
15.6
17.9
17.9
27.2
25.5
25.5
16.6
16.6
19.9
21.4

max. effect
[mean ΔCT (95% CI)]

max.
effect
[FC]

16.8 (16.7 - 16.9)
20.6 (20.1 - 21.2)
18.8 (18.6 - 19.0)
14.8 (14.5 - 15.0)
23.8 (22.9 - 24.8)
14.4 (14.2 - 14.7)
18.4 (18.1 - 18.7)
16.6 (16.1-17.1)
12.3 (11.8 - 12.8)
18.8 (18.6 - 19.0)
28.3 (27.5 - 29.1)
21.7 (21.1 - 22.2)
27.5 (25.7 - 29.3)
17.0 (16.9 - 17.1)
17.3 (17.0 - 17.5)
19.6 (19.4 - 19.9)
22.2 (21.7 - 22.7)

11.3
-3.8
-1.3
7.7
39.4
20.8
2.0
-2.1
51.5
-1.8
-2.3
14.6
-5.7
-1.3
-1.5
1.2
-1.7

Upregulations are highlighted in green, downregulations in red.
FC = fold change

time point
of max.
effect
[hours]
6
18
18
6
6
6
6
18
6
18
18
6
6
18
6
6
18

p-value
<0.001
<0.001
0.011
<0.001
<0.001
<0.001
0.002
0.005
<0.001
0.001
0.023
<0.001
0.032
0.002
0.004
0.023
0.011

2. Adiponectin in M2-like macrophages and HT-29 colon
cancer cells
Treatment of cells with adiponectin in coculture showed a significant upregulation
of the M1-marker CD80 in macrophages, while the anti-inflammatory M2-like
marker CD206 was slightly upregulated as well (FC 7.2, p=<0.001 and FC 1.9,
p=0.002) (Table 18).
PPARG was downregulated in macrophages following adiponectin treatment,
with no changes in expression in HT-29 CC cells (FC -2.4, p=<0.001) (Table 18).
In M2-like macrophages, adiponectin upregulated NFκB expression (FC 5.8,
p=<0.001) as well as all targeted pro- and anti-inflammatory cytokines, such as
IL6 (FC 14.9, p=<0.001), IL-1β (FC 9.6, p=<0.001), CCL22 (FC 2.6, p=0.002),
CCL18 (FC 2.0, p=<0.001) and IL-10 at 6 hours (FC 2.2, p=0.001) and IL-8 at 18
hours (FC 21.3, p=<0.001). NFκB was maximally upregulated in HT-29 CC cells
at 6 hours (FC 1.5, p=<0.001), while IL-1β and CCL22 were maximally
downregulated in HT-29 following adiponectin at 6 hours (FC -4, p=0.033 and FC
-2.8, p=0.023). SERPINE1 expression was downregulated in macrophages and
upregulated in HT-29 cells (FC -4.4, p=0.010 at 6 hours and FC 1.2, p=0.019 at
18 hours).
Macrophage-specific IRG1 was maximally upregulated (FC 5.3, p=0.032) at 18
hours. GATA5 expression was demonstrated to be downregulated in CC cells
after 6 hours (FC -2.6, p=0.029).
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Table 18
Maximum significant changes of gene expression in M2-like macrophages and HT-29 CC cells following adiponectin
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Adiponectin

treatment (20μg/ml)

Cell type
in coculture
M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
M2
HT-29
HT-29
HT-29
HT-29
HT-29

Gene

Control
[mean ΔCT]

max. effect
[mean ΔCT (95% CI)]

max. effect
[FC]

CD80
CD206
PPARG
NFKB
IL6
IL1B
CCL22
CCL18
IL8
IL10
SERPINE1
IRG1
GATA5
NFKB
IL1B
CCL22
SERPINE1

21.2
20.6
17.9
17.6
28.8
19.6
20.3
17.4
19.5
18.6
23.3
28.2
24.8
17.2
25.1
25.9
22.5

18.5 (17.8 - 19.1)
19.7 (19.3 - 20.0)
19.1 (19.0 - 19.3)
15.1 (14.6 - 15.7)
25.0 (24.3 - 25.7)
16.4 (15.9 - 16.8)
19.0 (18.5 - 19.4)
16.4 (16.2 - 16.6)
15.1 (14.7 - 15.5)
17.5 (17.1 - 17.8)
25.2 (24.0 - 26.3)
26.0 (24.2 - 27.8)
26.1 (25.0 - 27.1)
16.6 (16.4 - 16.8)
26.6 (25.3 - 28.0)
27.3 (26.4 - 28.3)
22.2 (21.9 - 22.4)

7.2
1.9
-2.4
5.8
14.9
9.6
2.6
2.0
21.3
2.2
-4.4
5.3
-2.6
1.5
-4
-2.8
1.2

Upregulations are highlighted in green, downregulations in red.
FC = fold change

time point
of max.
effect
[hours]
6
6
6
6
6
6
6
6
18
6
6
18
6
6
6
6
18

p-value
<0.001
0.002
<0.001
<0.001
<0.001
<0.001
0.002
<0.001
<0.001
0.001
0.010
0.032
0.029
<0.001
0.033
0.023
0.019

ii.

Patient samples and genomic analysis

Leptin and adiponectin protein levels were measured in plasma, CC tissue and
paired normal colon tissue from 20 sporadic CC patients with class I-III obesity.

1. Leptin and adiponectin in patients with sporadic colon
cancer

There was a high variability of leptin tissue levels and no significant difference in
mean leptin levels between normal and cancer tissue (51.9 ± 52.7 pg/mg versus
41.1 ± 54.7 pg/mg; p=0.765). The mean adiponectin level in normal colon tissue
was, however, higher than in CC tissue (32.6 ± 13.3 ng/ug versus 24.2 ± 9.4
ng/ug; p=0.005). The subgroup of patients >50 years of age showed a significant
difference in adiponectin tissue concentration between normal colon and CC
(37.6 ± 10.4 ng/ug versus 26.7 ± 9.7 ng/ug; p=0.003), while no difference could
be demonstrated in young individuals ≤50 years (17.9 ± 5.1 ng/ug versus 19.5 ±
11.4 ng/ug; p=0.625).
There was a positive correlation between plasma leptin levels and BMI
(rs=0.6; p=0.003) was observed, and a negative correlation between plasma
adiponectin levels and BMI (rs=0.7; p=<0.001).
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2. Genomic analysis on gene expression in patients with
colon cancer

RNA-seq data on 157 sporadic CC patients with matched normal colon tissue
was analyzed to include 18,884 genes. Differential gene expression, tissue
interaction and patient survival analysis for target genes were performed.
IRG1 showed the lowest mean overall expression and therefore no significant
changes (Table 19). Differential gene expression demonstrated a 2-fold
upregulation of the transcription factor GATA4 in CC versus normal colon tissue
(p=0.010) (Table 19). A significant age by tissue interaction was found for
GATA4 with a 3-fold increase in GATA4 expression in CC tissue of young
patients with EOCC compared to CC older patients (p=0.045). GATA5 was
differentially expressed showing a 4-fold downregulation in CC versus normal
colon tissue (p=<0.001), SERPINE1 was 1-fold downregulated (p=0.015), and IL1β was 2-fold upregulated (p=0.020) (Table 19).
Six target genes showed significant age by gene interaction (Table 19). All of
these genes were significantly upregulated in EOCC. GATA4 and SERPINE1
demonstrated the highest increase in expression among young CC patient
samples (3-fold and 2-fold, p=0.045 and p=0.001, respectively) (Table 19).
Analyzing BMI by tissue interaction, a significant upregulation of GATA5 was
demonstrated in obese versus normal-weight (p=0.030) patients. Another gene
showing a significant BMI by tissue interaction was ABCG5, showing higher
expression in obese patients (p=0.003) (Table 19).
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Survival analysis of the genes with significant age or obesity by tissue
interactions revealed that high GATA4, GATA5 and HEY1 expression were
associated with decreased overall patient survival, (p=0.039, p=0.015 and
p=0.036, respectively) (Figure 17). ABCG5, DLL4, NOTCH4, SERPINE1 and
VEGFA showed no significant impact on patient survival. SERPINE1 and VEGFA
showed trends towards decreased patient survival in the case of high gene
expression (Figure 17).
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Table 19
Gene expression (normalized read counts), differential gene expression and age and BMI by tissue interaction of genes
within the NOTCH4-GATA4-IRG1 axis
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Gene

Mean
overall reads

ABCG5
ADIPOQ
DLL4
GATA4
GATA5
HEY1
IL1B
IL6
IRG1
LEP
MMP2
NOTCH4
PPARA
PPARG
SERPINE1
VEGFA

39.7
404.6
1014.7
53.6
25.6
355.1
561.7
290.8
1.4
141.4
14653.7
1117.5
2320.5
2175.9
2996.2
6319.9

Significant results are highlighted.
FC = fold change; BMI = body mass index

Differential
expression
(Cancer vs.
Normal)
[log2 FC]
-1.3
-2.1
0.4
1.9
-3.7
-1.3
2.2
-1.2
0.1
-2.2
-0.4
-1.0
0.1
0.8
-1.0
0.8

pvalue

0.005
0.025
0.018
0.010
<0.001
<0.001
<0.001
0.014
0.945
0.005
0.147
<0.001
0.643
0.005
0.015
<0.001

Age by
ptissue
value
interaction

0.2
-1.5
0.8
2.6
0.5
0.8
-0.7
0.5
-0.9
0.6
0.2
1.0
-0.3
-0.1
2.1
0.7

0.927
0.496
0.011
0.045
0.751
0.011
0.501
0.718
0.706
0.803
0.852
0.007
0.275
0.961
0.001
0.017

BMI (>40
kg/m2) by
tissue
interaction

pvalue

2.1
0.5
-0.4
2.2
2.1
-0.1
-0.3
-0.7
-0.1
0.9
-0.4
-0.6
0.0
0.1
-0.4
-0.4

0.003
0.894
0.420
0.149
0.030
0.877
0.893
0.619
0.978
0.718
0.670
0.295
0.981
0.921
0.789
0.450
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Figure 17. Survival analysis for target genes with significant age or BMI by tissue interaction.

Legend to Figure 17.

The top row shows genes with significant impact on patient survival.
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DISCUSSION

Leptin and adiponectin both regulate gene expression of the NOTCH4-GATA4IRG1 axis in anti-inflammatory macrophages and CC cells. The hormones show
distinct differences in affecting gene expression that are associated with tumor
progression and patient outcome. Targeted genes showed significant tissue
interactions for age and BMI.
Low PPARγ expression is a prognostic factor in CC (232). In the
presented coculture model, PPARγ was demonstrated to be downregulated
following leptin treatment, but not following adiponectin treatment. This suggests
a prognostically relevant tumor promoting role of leptin in CC. When comparing
leptin and adiponectin treatment in coculture, diametric cellular responses were
also demonstrated for the transcription factor NFκB. While adiponectin induced
upregulation of NFκB in both macrophages and CC cells, leptin upregulated
NFκB in M2-like macrophages and led to downregulation in CC cells. This
suggests that both leptin and adiponectin affect inflammatory mechanisms
through NFκB and both can potentially exert carcinogenic effects in TAMs by
promoting NFκB overexpression, which regulates CC progression (228, 270).
SERPINE1 expression was slightly upregulated in HT-29 cells following
adiponectin treatment, while leptin induced downregulation of SERPINE1 in both
cell types. SERPINE1 expression has been demonstrated to be elevated in CRC
tissue versus normal colon and associated with disease progression and
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recurrence (270). Both obesity-related hormones affect its expression, with
adiponectin exerting a potential tumor promoting role.
Upregulation of proinflammatory CCL18 enhances recruitment of
regulatory T cells within the colon, which in turn establishes an
immunosuppressive environment promoting cancer progression (281). While
leptin downregulated CCL18 expression in macrophages, adiponectin induced an
upregulation. This could point out another potential carcinogenic role of
adiponectin during later stages in CRC, where an anti-inflammatory environment
promotes tumor progression (18).
The targeted pro- and anti-inflammatory cytokines that potentially mediate tumor
promoting effects were upregulated following adiponectin treatment, except for
CCL22 in CC cells. Both obesity-related hormones induced a profound
upregulation of IL-6 and IL-8 expression, which both play an essential role in
CRC progression (282, 283). IL-6 and IL-1β expression was upregulated by
leptin to a much greater degree than by adiponectin; however, both hormones
induced an upregulation of these tumor promoting proinflammatory cytokines
(275, 283).
RNA-seq analysis revealed significant differential gene expression of 13
target genes between CC and normal colon tissue. Six genes showed significant
age or obesity by tissue interactions. No differences were found for the target
gene IRG1. The low read counts of this gene among all patient samples
suggests that IRG1 has a low expression profile in general. Differences in
expression might be masked dependent on the sensitivity (read depth) of the
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respective RNA-seq method used to obtain data. Therefore, no clear conclusions
concerning IRG1 expression can be drawn.
All target genes of the NOTCH4-GATA4-IRG1 axis that showed a
significant age or obesity by tissue interaction were upregulated in young patients
or in obese patients, respectively. Furthermore, high expression of GATA4,
GATA5 and HEY1 were associated with decreased overall patient survival. This
suggests that these genes are factors for poor overall survival in young and
obese patients, making them a potential treatment target in EOCC.
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CHAPTER X

CONCLUSIONS AND OVERVIEW

Obesity and metabolic dysfunction are strong risk factors of CC and their role in
EOCC requires further study. The rising incidence of EOCC as a common cause
of cancer death among the young requires investigation of underlying
mechanisms and identification of age- and obesity-related target genes for
specific treatment strategies.
The 14-day cell line model for differentiating and polarizing THP-1
monocytes produces a distinct anti-inflammatory macrophage phenotype
mimicking TAMs. The cell treatment protocol is reproducible and creates an M2like macrophage phenotype to be studied for underlying inflammatory
mechanisms in CC. This is confirmed by upregulation of M2-like antiinflammatory and tumor-related macrophage markers, such as CD206 or MMP2.
These markers play a role in tumor progression and metastasis and are also
associated with patient outcome.
This thesis focuses on the obesity-related hormones leptin and
adiponectin and the macrophage-specific metabolite itaconate mediating tumorpromoting mechanisms through macrophages by altering gene expression of the
NOTCH4-GATA4-IGR1 axis. The data presented herein demonstrate that IRG1
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is amplified in sporadic colon adenocarcinoma and that colon tissue
concentrations of the ACOD1 protein and the metabolite itaconate differ between
age groups. These findings have not yet been reported in CC and provide new
insight into its onset and progression. Itaconate may have a particular
immunotherapeutic role in patients with CC and obesity, specifically with EOCC.
Further studies analyzing larger sample sizes are needed to investigate itaconate
in CC and related mechanisms. Itaconate may serve as a potential therapeutic
target in patients with EOCC.
Itaconate affects PPARγ gene expression in M2-like macrophages and
promotes anti-inflammatory cytokine expression in M2-like macrophages. The
obesity-related hormones leptin and adiponectin can induce IRG1 expression
and therefore itaconate production and promote tumor promoting marker
expression in M2-like macrophages and CC cells in vitro. In contrast, M0
macrophages showed a very limited response to treatment with leptin,
adiponectin or itaconate. This suggests that the carcinogenic effects of obesityrelated inflammatory factors may play a role in tumor progression, when M2-like
TAMs are already established, rather than at tumor onset.
The investigated marker expression patterns in macrophages and CC
cells are associated with worse clinical outcomes in patients with CRC.
Upregulation of the IRG1-related transcription factor GATA4 in CC is agedependent, increased in the young and associated with decreased patient
survival. Increased expression of the PPARγ-related transcription factor GATA5
is dependent on BMI and is associated with decreased overall survival in patients
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with CC. GATA5 expression in CC cells in vitro is upregulated due to leptin
treatment in the presence of macrophages. High leptin levels in obese patients
with CC may induce tumor-promoting mechanisms through the PPARγ pathway,
increasing GATA5 expression.
The NOTCH4-GATA4-IRG1 axis may partly explain the increased
incidence in EOCC and may present a new potential therapeutic target in young
patients with EOCC. Its target genes provide a link between metabolic
dysfunction in obese patients and EOCC. The proinflammatory role of leptin and
the anti-inflammatory role of adiponectin that has been postulated in the literature
do not concur with the inflammatory cellular responses observed in our coculture
model. The effects of obesity-related hormones may also change during cancer
development, as this represents a dynamic setting. Further studies are
necessary to demonstrate the pathway mechanisms of itaconate that directly
mediate carcinogenic effects.

Future Directions
Carcinogenic itaconate production plays a role in colon cancer and macrophagespecific IRG1 expression is upregulated by obesity-related hormones. This
suggests a tumor promoting role of leptin and adiponectin through macrophages,
which should be validated by functional in vitro experiments in the future.
Therefore, macrophage-responses using the cell line model introduced in this
thesis should be characterized in more depth. Also proinflammatory M1-like
macrophages should be analyzed in this setting.
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Since the dichotomous model of M1-like and M2-like macrophages does seem to
fully reflect macrophage function, the analysis of gene protein expression, protein
and metabolite levels related to macrophage metabolism are important foci for
future investigations. Multiplex flow cytometry targeting a wider spectrum of
markers can help defining the phenotypic profile of macrophages more
accurately. Mitochondrial respiration and glycolysis of macrophages can be
quantified using Seahorse Real-Time cell metabolic analysis, and Cytometry by
time of flight (CyTOF) measuring multiple metabolites can contribute to a highdimensional phenotypic and functional profile of the macrophage of interest.
Furthermore, the precise definition of the role of itaconate and obesity-related
hormones in CC requires a larger sample size of patients providing cancer and
normal colon tissue as well as blood. A consecutive patient collective evenly
representing different age and BMI groups is of high interest to be able to draw
further conclusions on itaconate and obesity-related mechanisms in CC.
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APPENDIX

Macrophage differentiation and polarization into an M2-like phenotype
using a human monocyte-like THP-1 leukemia cell line

Protocol
An overview of the steps described in this protocol is shown in Figure 18.
The human monocyte-like leukemia cell line THP-1 was purchased from the
American Type Culture Collection (ATCC TIB202). We authenticated the THP-1
cell line using short tandem repeat analysis (ATCC).

All steps should be performed under sterile conditions.
The THP-1 monocytic cell line grows in suspension and does not attach to cell
culture surfaces. Adherence can be induced by differentiating monocytes into
macrophage-like cells through e. g. mechanical stress or specific treatment with
PMA.

1. Culturing and maintenance of THP-1 monocyte-like cells

1.1 Set a timer for 2 minutes and 30 seconds. Remove the frozen vial containing
the THP-1 cell line (Table 20) from the liquid nitrogen and thaw it immediately in
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a clean water bath (37 °C). Start the timer as soon as the vial is put into the water
bath. The cap can be loosened to release pressure that is building up due to the
thawing process, but the tube opening should not get in contact with the water to
avoid contamination. The optimal time period for thawing the cells lies between 2
minutes and 2 minutes and 30 seconds. Continue thawing the cell suspension
until an ice chip of the size of about 4 mm is left within the vial, then proceed to
the next step immediately.

1.2 Transfer the liquid phase of the cell suspension to a 15 ml tube containing 9
ml of warm (37 °C) growth media (Table 20). Then transfer 1 ml of the warm
medium-cell-suspension into the THP-1 vial and back into the 15 ml tube to melt
the remaining ice chip and to flush the vial. This step assures that no cells are left
behind.

1.3 Mix the suspension gently by pipetting up and down with a 1000 μl pipette.
Remove a small sample (approximately 10 μl) to count the cells for viability
(using trypan blue for exclusion) while they are spun. Spin down the warm cell
suspension at 200 x g for 7 minutes at 37 °C.

1.4 Remove the supernatant completely and resuspend with a certain volume of
warm growth medium to achieve a cell density of 5x105/ml. Mix your suspension
gently and transfer 22 ml of volume into T-75 cell culture flasks (Table 20). Store
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flasks upright in an incubator at 37 °C with 5 % carbon dioxide (CO2)
concentration. Exchange growth media every 3-4 days.

2. Seeding of THP-1 cells and differentiation into M0 macrophages

2.1 Prepare the cell containing growth medium with the respective cell density to
seed cells at a density of 3x105/ml/well into 24-well cell culture plates (Table 20).
Mix the medium gently and prepare aliquots of 26 ml, each put into a 50 ml-tube.
Use each 26 ml-aliquot for seeding the cells into a respective plate.

2.2 Transfer 1ml of cell-containing medium into each well of a 24-well plate. Mix
the media gently by pipetting up and down between transfers.

2.3 Prepare a stock solution of PMA (1 mg PMA dissolved in 100 μl of Dimethyl
Sulfoxide (DMSO) = ~16 mM solution of PMA in DMSO) and dilute it with cold
Phosphate Buffered Saline (PBS) to a final working concentration of 10 ng/μl
right before cell treatment (Table 20). Keep the solution on ice and use it
immediately. Do not refreeze.
Add 100 ng of PMA per well. Let each cell plate sit in the incubator without any
further treatment for 72 hours.
2.4 After 72 hours, remove the growth medium and replace it with 1 ml of fresh
growth medium. Do not touch the bottom of the wells with pipette tips. Let cells
rest for another 96 hours in the incubator.
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2.5 After 96 hours, repeat step 2.4 (media change) and let the cells rest for
another 24 hours.

The M0 macrophages are now ready to be used for experiments (Figure 19).
Immediately prior to treating the cells as part of further experiments, consider a
media change with RPMI only (Table 20), since growth media supplements can
cause interference with reagents that are added for cell treatment.
In case M2-like macrophages are needed, proceed with section 3.

3. Polarization of M0 macrophages into M2-like macrophages

3.1 Prepare a stock solution of IL-4 and IL-13 (20 μg IL-4 or IL-13 dissolved in
200 μl nuclease-free water, respectively) and dilute it to a final working
concentration of 2 ng/μl with PBS immediately prior to cell treatment. Keep the
solution on ice and use it immediately. Do not refreeze.
Remove the growth medium and replace it with 1 ml of fresh growth medium.
Add 20 ng interleukin 4 (IL-4) and 20 ng interleukin 13 (IL-13) per well. Let cells
rest for 48 hours in the incubator.

3.2 After 48 hours, repeat step 3.1. Let cells rest for another 48 hours in the
incubator.
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3.3 Remove the growth medium and replace it with 1 ml of fresh growth medium.
Let cells rest for 48 hours in the incubator.

M2-like macrophages are now ready to be used for experiments (Figure 19).
Immediately prior to treating the cells as part of further experiments, consider a
media change with RPMI only (Table 20), since growth media supplements can
cause interference.

4. Detaching and harvesting macrophages for flow cytometry

To detach and harvest polarized macrophages from plates for flow cytometry, a
mechanical method combining cold shocking and cell scraping is used.

4.1 Remove warm cell medium and replace it with a mixture of ice-cold PBS
(without calcium and magnesium) and 5 % fetal bovine serum (FBS), 1 ml per
well. Immediately after this, place the cell plate on ice for 45 minutes. Do not
place the cell plate on ice before the warm cell medium is removed, since this will
decrease cell viability significantly. Keep cells on ice only once a cold shock with
ice-cold PBS/5 % FBS mixture is induced.

4.2 After 45 minutes on ice, scrape off cells using mini cell scrapers (Table 20).
Gently transfer the detached macrophages in cold PBS/5 % FBS into a 15 ml
tube. Keep the tube on ice at all times until cells are stained.
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Note: To reach adequate cell counts for staining, we recommend pooling eight
wells of cells together

Table 20.

Table of materials.

Name of Material/ Equipment

Company

Catalog
Number

0.4% trypan blue
1.5ml microcentrifuge tube
1000μl TipOne pipet tips

VWR
USA Scientific
USA Scientific

152-5061
1615-5510
1111-2821

10ml serological pipet
15ml Centrifuge tube
200μl TipOne pipet tips
20μl TipOne pipet tips
25ml serological pipet
50ml Centrifuge tube
5ml serological pipet
Antibiotic Antimycotic Solution (100x), stabilized
Binder CO2 Incubator
CytoOne T-75cm flask with filter cap
Dulbecco’s Phosphate Buffered Saline (PBS)
Eppendorf Centrifuge 5804 R (refrigerated)
Ethyl alcohol (70%)
FACSCalibur flow cytometer
Falcon 24-well plate
Fetal Bovine Serum (FBS)
FITC Mouse Anti-Human CD14
FITC Mouse Anti-Human CD80
FITC Mouse IgG1 κ Isotype Control
FITC Mouse IgG2a, κ Isotype Control
Human BD Fc Block
Human interleukin 13 (IL-13)
Human interleukin 4 (IL-4)

VWR
VWR
USA Scientific
USA Scientific
VWR
VWR
VWR
Sigma
VWR
USA Scientific
Sigma
Eppendorf
BD Biosciences
VWR
ATCC
BD Biosciences
BD Pharmingen
BD Pharmingen
BD Biosciences
BD Biosciences
R&D
R&D

Labconco Biosafety Cabinet (Delta Series 36212/36213)
L-Glutamine Solution, 200 mM
Lipopolysaccharide (LPS) from E. coli 0111:B4
Mini Cell Scrapers

Labconco
ATCC
Sigma
Biotium

89130-898
89039-664
1120-8810
1120-1810
89130-900
89039-662
89130-896
A5955-100ml
C170-ULE3
CC7682-4875
D8537-500ml
353504
30-2020
555397
557226
555748
553456
564220
IL-771-10ug
SRP309320ug
30-2214
L2630-100mg
22003
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Neubauer hemocytometer
Nikon Eclipse inverted microscope TS100
Nuclease-free water
Olympus Light Microscope RH-2
P10 variable pipet- Gilson
P1000 variable pipet-Gilson
P200 variable pipet- Gilson
PE Mouse Anti-Human CD11b
PE Mouse IgG1, κ Isotype Control
PE-Cy 5 Mouse Anti-Human CD206
PE-Cy 5 Mouse IgG1 κ Isotype Control
Phorbol 12-myristate 13-acetate (PMA)
Powerpette Plus pipettor
Precision Water bath (model 183)
RPMI-1640 Medium
THP-1 cell line, American Type Culture Collection
(ATCC)
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Fisher Scientific
Nikon
Invitrogen
Microscope
Central
VWR
VWR
VWR
BD Biosciences
BD Biosciences
BD Pharmingen
BD Pharmingen
Sigma
VWR
Precision Scientific
ATCC
ATCC

02-671-5
AM9937
40888
76180-014
76177-990
76177-988
555388
555749
551136
555750
P8139
75856-448
66551
30-2001
TIB-202
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Figure 18. Protocol overview of the M2-like macrophage cell line model.

Legend to Figure 18.

On day 0, cells are seeded into plates with a growth
medium and incubated with PMA for 72 h. On day 3 and day 7 cell medium is changed, which lets the cells rest
without
PMA for a total of 120 h. On day 8, the growth medium is changed once more, and cells are incubated with IL-4
and
IL-13 to induce M2-like polarization. This step is repeated after 2 days, on day 10. On day 12, the last medium
change is
performed, and M2-like cells rest in the growth medium for another 48 h before being used for experiments (PMA =
phorbol 12-myristate-13-acetate; IL = interleukin).
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Figure 19. Cell morphology of THP-1 cells differentiated (M0) macrophages, and
M2-like macrophages using light microscopy.
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Legend to Figure 19.

Cells were seeded at 3 x 105 per well in a 24-well plate. (A,B) THP-1 cells are
shown at baseline. (C,D) The
differentiated M0 macrophages received PMA treatment for 72 h, growth medium
change and a 96-h-resting period. (E,F)
The M2-like macrophages are shown after completed polarization treatment with
IL-4 and Il-13 at day 14 of this cell model
(20x and 40x magnification; scale = 100 μm).
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(S. Galandiuk, M.D.)
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Academic appointments
06/2015

M.D. Thesis: University of Heidelberg, Germany:
“Stellenwert der Galaktographie zur Abklaerung pathologischer
Sekretion in der komplementaeren Mammadiagnostik“
(Mentor: K. Wasser, M.D. / S. O. Schoenberg, M.D., Ph.D.)

05/2022

Ph.D. Thesis: Department of Physiology and Biophysics, School
of Medicine, University of Louisville, Kentucky, United States of
America.
“The Role of Obesity in Macrophage-mediated Mechanisms
promoting early-onset Colon cancer"
(Mentor: Susan Galandiuk, M.D.)

International presentations
2017

German Society of Surgery (DGCH) in Munich, Germany,
oral presentation on “Microvascular complications in patients with type 2
diabetes mellitus – metabolic surgery vs. medical treatment: a systematic
review and meta-analysis”

2017

International Federation Surgery of Obesity and Metabolic Disorders
(IFSO) in London, United Kingdom,
poster presentation on “Metabolic surgery improves diabetic nephropathy
independent of weight loss: a systematic review with meta-analysis”

2018

International Federation for the Surgery of Obesity and Metabolic
Disorders – European Chapter (IFSO-EC) in Athens, Greece,
oral presentation on “Serum uromodulin in diabetic nephropathy - early
diagnosis using serum markers”

2021

Central Surgical Association (CSA) in Chicago, USA,
oral presentation on “Early-onset colorectal cancer – new insights on
macrophage function, itaconate and obesity”

Grants/Funding
03/2017

Heidelberg Surgery Foundation: 12.000€

03/2018

Heidelberg Surgery Foundation: 10.000€
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05/2018

Mentorship program Research Talent Academy, European
Association for Endoscopic Surgery (EAES), Chairman Dr. Sheraz
Markar, London

03/2019

Heidelberg Surgery Foundation: 10.000€

Reviewer activities
-

Diseases of the Colon and Rectum

-

Langenbeck’s Archives of Surgery

Supervisory and Teaching Activity
-

Instructor for surgical nurses and medical students at the University of
Heidelberg

Societies
-

Member of the American Society of Colon and Rectal Surgeons (ASCRS)

Research
•

Scheurlen KM, Schnitzer A, Krammer J, Kaiser C, Schonberg SO, Wasser K. Value
of galactography for the diagnostic work-up of pathological nipple discharge in
multimodal breast diagnostics. Part 1: An online survey among German breast care
centers. Radiologe. 2014;54:63–67.

•

Scheurlen KM, Schnitzer A, Krammer J, Kaiser C, Schonberg SO, Wasser K. Value
of galactography for the diagnostic work-up of pathological nipple discharge in
multimodal breast diagnostics. Part 2: a systematic review of the literature.
Radiologe. 2014;54(2):160-6.

•

Billeter AT, Kopf S, Zeier M, Scheurlen KM, Fischer L, Schulte TM, Kenngott HG,
Israel B, Knefeli P, Büchler MW, Nawroth PP, Müller-Stich BP. Renal function in type
2 diabetes following gastric bypass. Dtsch Arztebl Int. 2016 Dec 9;113(49):827-833.

•

Billeter AT, Vittas S, Israel B, Scheurlen KM, Hidmark A, Fleming TH, Kopf S,
Büchler MW, Müller-Stich BP. Gastric bypass simultaneously improves adipose
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tissue function and insulin-dependent type 2 diabetes mellitus. Langenbecks Arch
Surg. 2017;402(6):901-10.
•

Billeter AT and Scheurlen KM, Probst P, Eichel S, Nickel F, Kopf S, Fischer L,
Diener MK, Müller-Stich BP. Meta-analysis of metabolic surgery versus medical
treatment for microvascular complications in patients with type 2 diabetes mellitus. Br
J Surg. 2018 Feb;105(3):168-181. Review.

•

Schwarz AC, Billeter AT, Scheurlen KM, Bluher M, Muller-Stich BP. Comorbidities
as an Indication for Metabolic Surgery. Visc Med. 2018;34(5):381-7.

•

Billeter AT, de la Garza Herrera JR, Scheurlen KM, Nickel F, Billmann F, MullerStich BP. Management of Endokrine Disease: Which metabolic procedure?
Comparing outcomes in sleeve gastrectomy and Roux-en Y gastric bypass. Eur J
Endocrinol. 2018;179(2):R77-R93.

•

Scheurlen KM, Billeter AT, Müller-Stich BP. Metabolische Chirurgie: Diabetiker
profitieren – unabhängig vom Gewicht. Dtsch Arztebl. 2018;115(41):[12].

•

Scheurlen KM, Probst P, Kopf S, Nawroth PP, Billeter AT and Müller-Stich BP.
Metabolic surgery improves renal injury independent of weight loss: a meta-analysis.
Surg Obes Relat Dis. 2019;15(8):1319-1325.

•

Scheurlen KM, Billeter AT, Kopf S, Herbst V, Block M, Nawroth PP, Zeier M,
Scherberich JE and Müller-Stich BP. Serum uromodulin and Roux-en-Y gastric
bypass – improvement of a marker reflecting nephron mass. Surg Obes Relat Dis.
2019;15(6):1006-1020.

•

Billeter AT, Eichel S, Scheurlen KM, Probst P, Kopf S, Müller-Stich BP. Metaanalysis of metabolic surgery versus medical treatment for macrovascular
complications and mortality in patients with type 2 diabetes. Surg Obes Relat Dis.
2019;15(7):1197-1210.

•

Billeter AT, Scheurlen KM, Probst P, Müller-Stich BP. Response to the letter to the
editor: Different effect on improvement of renal injury in urinary albumin-creatinine
ratio at different follow-up time and metabolic surgery. Surg Obes Relat Dis. 2020
May;16(5):706-708.

•

•
•

O'Brien SJ, Bishop C, Hallion J, Fiechter C, Scheurlen KM, Paas M, Burton J,
Galandiuk S. Long non-coding RNA (lncRNA) and epithelial-mesenchymal transition
(EMT) in colorectal cancer: a systematic review. Cancer Biol Ther. 2020 Sep
1;21(9):769-781.
Scheurlen KM, Billeter AT, O'Brien SJ, Galandiuk S. Metabolic dysfunction and
early-onset colorectal cancer - how macrophages build the bridge. Cancer Med.
2020 Sep;9(18):6679-6693.
O'Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Patel A, Rochet A,
Scheurlen KM, Gardner S, Eichenberger M, Sarojini H, Srivastava S, Rai S,
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Kalbfleisch T, Polk HC Jr, Galandiuk S. Long non-coding RNA ZFAS1 is a major
regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin,
vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021 Mar
26;7(1):61.
•

Scheurlen KM, Snook DL, Gardner SA, Eichenberger MR, Galandiuk S.
Macrophage Differentiation and Polarization into an M2-Like Phenotype using a
Human Monocyte-Like THP-1 Leukemia Cell Line. J Vis Exp. 2021 Aug 2;(174).

•

O'Brien SJ, Hallion J, Scheurlen KM, Fiechter C, Burton J, Paas M, Schmidt M,
Gardner S, Eichenberger MR, Pan J, Rai S, Galandiuk S. Crohn's disease-related
single nucleotide polymorphisms are associated with ileal pouch afferent limb
stenosis.
J Gastrointest Surg. 2021 Sep;25(9):2377-2386

•

Kavalukas SL, Scheurlen KM, Galandiuk S. State-of-the-art surgery for Crohn's
disease: Part I-small intestine/ileal disease. Langenbecks Arch Surg. 2021 Nov 4.
Epub ahead of print.

•

O'Brien SJ, Scheurlen KM, Rochet A, Fiechter C, Paas M, Pan J, Rai SN,
Galandiuk S
Increased Expression of Long Non-coding RNA H19 is Associated With Colon
Cancer Recurrence. J Surg Res. 2022 Jan;269:59-68.

•

Scheurlen KM, Snook DL, Walter MN, Cook CN, Fiechter CR, Pan J, Beal RJ,
Galandiuk S. Itaconate and leptin affecting PPARγ in M2 macrophages: A potential
link to early-onset colorectal cancer. Surgery. 2022 Mar;171(3):650-656.

In progress:
•

Scheurlen KM, Snook DL, Littlefield A, George J, Riggs DW, Beal RJ, Gaskins J,
Galandiuk S. Anti-inflammatory mechanisms in cancer research: a distinct M2-like
macrophage model derived from the THP-1 cell line.
Submitted to PLOS ONE, February 2022

Book Chapter
•

Scheurlen KM, Kavalukas SL, Galandiuk S.
Diverticular Disease of the Colon.
Cameron & Cameron, 14th Edition
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